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Abstract 
Candida spp. are major human pathogens and a major issue in intensive care units around the world. 
Candida infections have a high mortality rate despite the use of antifungal treatments. One cause of 
these therapeutic failures is the acquisition of mutations in the fungus leading to antifungal resistance. 
In the case of the fungistatic azole drug fluconazole (FLC), the mechanisms of resistance have been 
extensively studied in the past. However, some clinical isolates are known to be able to survive at high 
FLC concentrations without acquiring resistance mutations. This phenomenon is attributed to 
antifungal tolerance. Mechanisms behind FLC tolerance are still understudied, mainly due to the lack 
of proper way to identify and quantify tolerance between isolates. In this study, we first attempted to 
better define and characterize antifungal tolerance in Candida albicans by establishing a convenient 
quantification method and proposing thresholds allowing a better discrimination of tolerance between 
isolates. Next, we implemented this method and definition in order to identify mediators of tolerance 
using a collection of approximatively 580 doxycycline-dependent overexpression (OE) C. albicans 
strains, each of which overexpressing a specific C. albicans gene. By pooling the whole collection and 
maintenance under FLC pressure, we were able to enrich the pool in FLC-tolerant strains which were 
further characterized. Among tested strains, three of them, overexpressing either CRZ1, GZF3 or YCK2 
resulted in an increased FLC tolerance in presence of doxycycline. However, only the CRZ1 and GZF3 
OE strains reached the threshold of tolerance. These two genes were further confirmed to be involved 
in FLC tolerance as their deletion in known tolerant clinical isolates resulted in a decrease of tolerance. 
Furthermore, we showed that Gzf3 was likely acting downstream of Crz1 since CRZ1 OE in absence of 
GZF3 resulted in an increased tolerance, which was not the case of GZF3 OE in absence of CRZ1. In 
addition, using a transcriptomic approach, we showed that CRZ1 might play a role in the tolerance of 
clinical isolates as it was overexpressed as compared to the wild type susceptible strain SC5314 in 
presence of FLC. Overall, this study allowed a better definition of tolerance and gave new insights of 
the mechanisms behind this phenomenon. This study established novel approaches for the 
identification of genetic mediators of tolerance as well as a convenient testing of tolerance in large 
strain collections.  
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Résumé  
Les espèces Candida sont des pathogènes humain importants et un problème majeur dans les unités 
de soins intensifs du monde entier. Les infections à Candida possèdent un taux de mortalité élevé 
malgré la présence de traitements antifongiques. L'une des causes de ces échecs thérapeutiques est 
l'acquisition de mutations conduisant à une résistance aux antifongiques. Dans le cas du fluconazole 
(FLC), les mécanismes de résistance ont été largement étudiés dans le passé. Cependant, certains 
isolats cliniques sont capables de survivre à des concentrations élevées de FLC sans acquérir ou 
développer de résistance ; un phénomène connu sous le nom de tolérance. Les mécanismes à l'origine 
de la tolérance au FLC sont encore peu étudiés, principalement en raison de l'absence de méthode 
appropriée pour identifier et quantifier la tolérance. Dans cette étude, nous avons d’abord essayé de 
mieux définir et caractériser la tolérance en proposant une méthode de quantification et des seuils 
appropriés permettant une meilleure discrimination entre isolats. Puis, nous avons utilisé cette 
méthode et définition afin d’identifier de nouveaux médiateurs de la tolérance à l’aide d’une collection 
d’environ 580 souches, chacune surexprimant un gène spécifique en présence de doxycycline (Dox). 
En regroupant la totalité de la collection en une seule population et en maintenant une sélection en 
présence de de FLC, nous avons pu enrichir la population en souches résistantes et/ou tolérantes. 
Après analyse de ces dernières, trois d'entre elles, surexprimant CRZ1, GZF3 et YCK2, respectivement, 
ont montré une tolérance accrue en présence de Dox et de FLC. Cependant, seules les souches 
surexprimant CRZ1 et GZF3 ont atteint notre limite inférieure de tolérance. En délétant ces gènes dans 
des isolats cliniques tolérants, nous avons pu confirmer leurs rôles dans ce phénotype, démontrer par 
la perte de tolérance découlant de ces délétions. Gzf3 fût aussi déterminé comme se trouvant en aval 
de Crz1 dans la réponse au FLC, comme la surexpression de CRZ1 en l'absence de GZF3 entraînait une 
augmentation de la tolérance, ce qui n'était pas le cas de GZF3 en l'absence de CRZ1. Finalement, 
utilisant une approche transcriptomique, nous avons démontré que CRZ1 pouvait jouer un rôle dans 
la tolérance des isolats cliniques, celui-ci étant surexprimé par rapport à la souche sauvage SC5314 en 
présence de FLC. En résumé, cette étude a permis de donner une meilleure définition au phénomène 
de tolérance, tout en proposant de nouveaux médiateurs de cette réponse au FLC. Cette étude a aussi 
permis le développement de nouvelles approches, tant pour l’identification de médiateurs génétiques 
de la tolérance que pour l’identification de souches tolérantes en utilisant de larges collections de 
souches.  
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General introduction 
Candida spp. and their relevance as human pathogens  
Fungal pathogens are challenging organisms that can cause a wide range of diseases, from mild to life-
threatening infections. They are a major issue in hospital, especially in neonates and Intensive Care 
Units (ICUs) and the number of cases of sepsis caused by such pathogens is increasing since the early 
1990s [1]. 
Among all human fungal pathogens, Candida species represent the most common cause of invasive 
infections [1]. It is estimated that, without considering dermatophytes infections, around 300 million 
people are affected by fungal infections worldwide. Among them, invasive candidiasis affects more 
than 250’000 people each year and is the cause of more than 50’000 deaths despites antifungal 
therapy [2].  
It has been estimated that Candida spp. are the 4th most commonly isolated human pathogen causing 
bloodstream infections (BSIs) in ICUs [3]. However, outside of ICUs, candidemia has been established 
as the 7th to 10th most common cause of BSIs [2]. It is important to take in account that the distribution 
of Candida spp. responsible for invasive candidiasis varies depending of the geographical areas, the 
affected population, but also on a prophylaxis-based manner (Figure 1) [1, 2].  
Among the 17 and more Candida spp. responsible for candidemia, it is estimated that five of them (C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei) account for 92 % of all cases of 
candidemia, with C. albicans being responsible for more than 60 % of all the cases worldwide (Figure 
1 A and B) [1, 4]. 
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Figure 1: Candida spp. distribution over the last decades. (A), in European countries and USA (B) and the major non-albicans 
Candida spp. prevalence worldwide (C). Adapted from Guinea [1] and Pappas et al. [5].  
The frequency at which each Candida species occurs varies depending on the geographical area, but, 
globally, C. albicans remains the prominent species (Figure 1 B) [1]. The main diversity in frequencies 
is observed between C. glabrata and C. parapsilosis. Indeed, in Northern Europe and the USA, C. 
glabrata is responsible for 10-30 % of candidemia events, and C. parapsilosis for 5-20 % (Figure 1B and 
C). However, it is reported that C. parapsilosis is more prevalent over C. glabrata in Spain, Brazil and 
Japan, representing 25 % of all cases against 8-14 % for C. glabrata (Figure 1B and C) [1, 5].  
In addition to geographical diversity, it has also been observed that, along the last decades, a global 
shift in Candida spp. distribution is occurring, with an overall decrease in C. albicans frequency in favor 
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of non-albicans species (Figure 1A) [1]. Lately, a newly emerging species C. auris was reported. C. auris 
cases are spreading worldwide since first appearance in Japan in 2009. The C. auris infection rate 
increase is probably to the prophylactic use of FLC and selection of azole-resistant strains. Since its first 
isolation in Japan, C. auris has been isolated and identified in multiple countries on five continents. C. 
auris is a major human-health concern due to its resistance to multiple antifungal classes (Figure 1 C) 
[6].  
Table 1: Known risk factors favoring Candida spp. infections. Adapted from Kullberg and Arendrup [2]. 
. Risk factors Comments 
Critical illness Especially for long-term ICU patients 
Abdominal surgery 
Especially in case of anastomotic 
leakage or repeat laparotomies 
Acute necrotizing pancreatitis  
Hematologic malignant disease  
Solid-organ transplantation  
Solid-organ tumors  
Neonates 
Especially low birth weight and 
preterm infants 
Broad-spectrum antibiotics therapy  
Central vascular catheter / total parenteral 
nutrition 
 
Hemodialysis  
Glucocorticoid / chemotherapy for cancer  
Candida colonization Especially if multifocal 
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Another factor involved in Candida spp. distribution is the affected population. Indeed, the age of the 
patient plays an important role. C. albicans is more frequent in neonates and young adults, while C. 
parapsilosis frequency decreases with the age of the patient and, conversely, C. glabrata frequency 
increases in older patients [1].  
The condition of the patients is also important for the distribution of Candida spp. Indeed, several 
conditions (listed in Table 1) are known risk factors for the development of candidemia, with each 
factor determining which Candida spp. will be favored. For instance, C. glabrata and C. krusei are 
relevant pathogens commonly isolated in stem cells recipient patients, while patients receiving solid 
organ transplantation are more often infected by C. albicans and C. glabrata [1]. 
A last factor playing a major role is the use of a specific antifungal and the duration of the treatment. 
Logically, the type of antifungal used in prophylaxis will select for Candida spp. more resistant to the 
used agent (Figure 2 B), and the longer the treatment, the more susceptible species will be replaced 
by more resistant ones (Figure 2A) [1, 2].  
 
Figure 2: Role of antifungal prophylaxis upon Candida spp. distribution.[2]  
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Candida albicans 
Due to the role of C. albicans in invasive candidiasis worldwide, a major focus is given to this species. 
C. albicans is a polymorphic yeast, belonging to the Ascomycota phylum, which can grow as budding 
yeast cells, pseudohyphae or true hyphae depending on the environmental conditions to which it is 
exposed, with each form playing a role in pathogenicity (Figure 3) [7]. Indeed, C. albicans strains 
blocked in either the yeast form or the hyphal form are known to show decreased virulence compared 
to a wild type (WT) strain, highlighting the necessity of a complete phenotypic morphogenesis switch 
for successful infection [7].  
Figure 3: Morphological forms of C. albicans. Adapted from Sudbery et al. [8].  
Candida spp. can be found in healthy individuals as harmless members of the commensal microbiota 
present on their skin, oral and vaginal mucosa and in the gastrointestinal tract [4, 9, 10]. However, 
following hormonal fluctuation due to menopause or to the use of hormonal treatment such as oral 
contraceptives [11], when the microbiota is disturbed by the use of broad spectrum antibiotics and 
when the host’s immune defenses are weakened (i.e. AIDS patients), Candida spp. can cause superficial 
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infections such as oral and vaginal infections (also known as thrush). These infections are characterized 
by the apparition of white spots on the surface of the mucosae which are constituted of fungal colonies 
[12, 13]. It has been estimated that approximately 75 % of all women will suffer from superficial 
candidiasis at least once in their lifetime (vulvovaginal candidiasis) [14]. On a more life-threatening 
side, it has been reported in most large national surveys in the US that 3-5 out of 100,000 persons in 
the population and 1-2 % of ICU patients will face candidemia [5]. This incidence, however, varies due 
to geographical and epidemiological local population factors among others.  
As stated above, C. albicans lives as a commensal of the mucosal surface of humans. However, when 
the mucosal microbiota equilibrium is altered, or the host immune defenses are reduced, C. albicans 
can switch from a commensal to an opportunistic lifestyle with the activation of different virulence 
factors. Indeed, when patients undergo strong immunosuppression such as neutropenic patients 
under highly active antiretroviral therapy (HAART), chemotherapy or organ transplantation, Candida 
spp. can cross the epithelial barrier, penetrate into the bloodstream and, from there, spread 
throughout the body and colonize internal organs such as the brain, the liver, the kidneys and the 
spleen (Figure 4). These infections are known as systemic or disseminated candidiasis [4, 12–15]. Risks 
of infections are increased by the use of catheters favoring biofilm formation, direct infection through 
the wound, or the use of broad-range spectrum antibiotics [4] (Figure 4). While superficial candidiasis 
is frequent and non-lethal, systemic candidiasis is associated with high mortality rates [14]. Candida 
spp. are found to be the seventh cause of health-care associated infections [16], and the fourth most 
common cause of nosocomial bloodstream infections in the USA and are associated with a crude 
mortality of 39.2 % despite antifungal therapies that are available (Table 2) [3, 17].  
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Figure 4: Routes of Candida infection and dissemination. Candida cells penetrate the organism via crossing of the 
gastrointestinal epithelium barrier or directly into the bloodstream via biofilm formation on intravascular catheters. Once in 
the bloodstream, Candida can disseminate throughout the body and colonize most of the organs and body parts. Adapted 
from Kullberg and Arendrup [2].   
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Table 2: Epidemiology of Candida spp. Incidence rate and distribution of pathogen most commonly isolated from nosocomial 
bloodstream infections (BSIs) (A). Incidence of most commonly isolated Candida spp. in BSI in Europe (EU) and North America 
(NAM) (B). Adapted from Wisplinghoff et al. [3] and Pfaller et al. [15].  
 
 
Organism 
Total Candida 
isolates (%)  
n = 256,882 
EU isolates (%) 
n = 109,643 
NAM isolates (%) 
n = 11,682 
C. albicans 65.3 67.9 48.9 
C. glabrata 11.3 11.3 21.1 
C. tropicalis 7.2 4.9 7.3 
C. parapsilosis 6.0 4.2 13.6 
C. krusei 2.4 3.4 3.1 
Other Candida 
spp.  
7.8 8.3 5.2 
 
  
Pathogen BSIs per 10,000 
admissions 
% of BSIs (rank) 
n = 20,978 
% of crude 
mortality (rank) 
Coagulase-negative 
Staphylococcus spp. 15.8 31.3 (1) 20.7 (8) 
Staphylococcus aureus 10.3 20.2 (2) 25.4 (6) 
Enterococcus spp.  4.8 9.4 (3) 33.9 (3) 
Candida spp.  4.6 9.0 (4) 39.2 (1) 
Escherichia coli 2.8 5.6 (5) 22.4 (7) 
Klebsiella spp.  2.4 4.8 (6) 27.6 (4) 
Pseudomonas aeruginosa 2.1 4.3 (7) 38.7 (2) 
Enterobacter spp.  1.9 3.9 (6)  26.7 (5) 
A 
B 
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Availability and limitations of current antifungal therapies 
The high mortality rate of systemic candidiasis can partially be explained by the apparition of antifungal 
resistance which rapidly limits the option of alternative treatments due to the few classes of available 
drugs (summarized in Figure 5) [19, 20]. Due to the high functional similarity between fungi and human 
cells, which are both eukaryotic organisms, only a few cellular processes are fungal-specific and can 
thus be targeted by antifungals. The development of antifungal agents is therefore more challenging 
due to the shared potential drug targets existing in fungi and their hosts [19]. Currently, only five 
categories of antifungals are available against Candida spp. which can be classified based on their 
targets (Figure 5). Despite acting on a defined target, an antifungal may have a different effect, or no 
effect at all, depending on the involved fungal species (Table 3) [20]. In the case of invasive candidiasis, 
the current treatment guidelines are well established with echinocandins prophylaxis (due to their 
broad efficacy spectrum) until the proper identification of the species is carried out (Figure 6). In the 
following sections, the characteristics of major antifungal agents will be summarized.  
Figure 5: C. albicans cell and the five major antifungal classes with their respective targets. 
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Table 3: Overview on the activity of antifungal agents in several pathogenic Candida species. Adapted from 
Delarze and Sanglard [20].  
Organism Antifungal agent 
 AMB1 FLC ITC VCZ PSZ AFG CAS MFG 5-FC 
C. albicans +2 + + + + + + + ±2 
C. glabrata + ± ± ± ± + + + ± 
C. krusei + -2 ± + + + + + - 
C. lusitaniae - + + + + + + + + 
C. parapsilosis + + + + + ± ± ± + 
C. tropicalis + + + + + + + + + 
1 (AMB) Amphotericin B, (FLC) Fluconazole, (ITC) Itraconazole, (VCZ) Voriconazole, (PSZ) Posaconazole, (AFG) Anidulafungin, 
(CAS) Caspofungin, (MFG) Micafungin and (5-FC) Flucytosine. 
2 Drugs with activity (+), no activity (-) and variable activities (±) against the specified organisms. 
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Table 4: resistance mechanisms of major antifungal drugs.Adapted from Spampinato and Leonardi [21].  
1 Reduced intracellular drug concentration 
2 decreased target affinity/processivity for the drug 
3 counteraction of the drug effect 
 
 
  
Antifungal 
class Genetic basis for resistance Functional basis for resistance 
Azoles 
- Upregulation of CDR1/CDR2 and MDR1 by point 
mutations in TAC1 and MRR1 transcription 
factors 
- Upregulation of drug transporters1 
- Point mutations in ERG11 - Decreased lanosterol 14-α-demethylase 
binding affinity for the drug2 
- Upregulation of ERG11 by gene duplication and 
transcription factor regulation 
- Increased lanosterol 14-α-demethylase 
concentration3 
- Point mutations in ERG3 - Alterations in the ergosterol pathways by 
C5 sterol desaturase inactivation3 
Echinocandins - Point mutations in FKS1 and FKS2 - Decreased glucan synthase processivity 
for the drug2 
Polyenes - Point mutations in ERG3 and ERG6 - Decreased ergosterol content in cells3 
Nucleoside 
analogs 
- Point mutations in FCY2 - Inactivation of cytosine permease 
affecting drug uptake1 
- Point mutations in FCY1 - Alterations in 5-fluorocytosine 
metabolism by cytosine deaminase or 
uracil phosphorybosyl transferase 
inactivation3 - Point mutations in FUR1 
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Figure 6: General guidelines for candidemia treatment. Adapted from Pappas et al. [5].  
 
Inhibitors of nucleic acid synthesis  
Pyrimidine analogues  
5-fluorocytosine (5-FC), also known as 5-flucytosine, is a fluorinated pyrimidine analog (Figure 7A) that 
interferes with pyrimidine metabolism, protein synthesis and DNA/RNA biosynthesis (Figure 7B). This 
compound is actively transported into the fungal cells via a cytosine permease and, once in the 
cytoplasm, is deaminated by a cytosine deaminase in 5-fluorouracil (5-FU) (Figure 7B). Uracil 
monophosphate (UMP) pyrophosphorylase then converts 5-FU into 5-fluorouridine monophosphate 
(5-FUMP), which can be phosphorylated in 5-fluorouridine triphosphate (5-FUTP) and inhibits protein 
synthesis by the integration of 5-FUTP into fungal RNA in place of UTP (Figure 7B) [19]. In addition, the 
conversion of 5-FUMP in 5-fluorodeoxyuridine monophosphate (5-FdUMP), an inhibitor of the 
thymidylate synthase by uridine monophosphate pyrophosphorylase blocks DNA synthesis and cell 
division by inhibition of thymidylate synthase, a key enzyme in the DNA synthesis (Figure 7B) [19, 22].  
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5-FC does not show direct toxicity against mammalian cells as they lack the cytosine deaminase 
enzyme. However, 5-FC can be converted to 5-FU by the intestinal bacterial microflora thus causing 
adverse effects such as nausea, diarrhea, vomiting and diffuse abdominal pain [22]. 
 
Figure 7: Pyrimidine analogs.  (A) Chemical structure comparison between 5-flucytosine (5-FC), 5-fluorouracil (5-FU) and 
cytosine. (B) Mode of action of 5-FC in the fungal cell. Adapted from Vermes et al. [22].  
 
Resistance to 5-FC is observed in 3-10 % of isolates in vitro and it has been observed that up to 30 % 
of isolates develop resistance during treatment. This resistance is linked to deficiencies in the enzymes 
involved in uptake (FCY2) and metabolism of 5-FC (FCY1 and FUR1) (Table 4) [19, 21, 23]. Due to this 
prevalence of resistance acquisition, 5-FC is usually used as monotherapy of life-threatening 
candidiasis or as adjunctive to amphotericin B or azoles treatments[15, 19]. 
14 
 
Fungal membrane disruptors 
Polyenes  
Polyenes were among the first antifungals available for clinical use. They are fungicidal and have a 
broad spectrum of activity compared to other antifungal drugs. Only three polyenes are currently 
available for clinical use including nystatin, natamycin and amphotericin B. These molecules are natural 
compounds isolated from bacteria species such as Streptomyces noursei, S. natalensis and S. nodosum, 
respectively (Figure 8A) [19]. These molecules have an amphiphilic structure and bind phospholipids 
in the membrane to form complexes with ergosterol, an important component of the fungal cell wall 
and absent in mammalian cells (Figure 8B). Two modes of action have been described. The first model 
consists of the formation of pores which disrupt the cell membrane and cause leakage of cytoplasmic 
content leading to fungal cell death (Figure 8B) [19, 23]. A more recently described model of action of 
polyenes consists of the formation of large extra-membranous aggregates which sequester ergosterol 
from fungal cell membranes (Figure 8B). By accumulating ergosterol, these sterol “sponges” disrupt 
membrane functions and lead to fungal cell death [23].  
Besides the intrinsic high affinity for ergosterol, polyenes also have a slight affinity for host cholesterol. 
This may explain the high toxicity of amphotericin B to host cells and adverse effects such as chills, 
fever, headache, nausea, vomiting and severe nephrotoxicity [18].  
Resistance to polyenes is uncommon and linked to a decreased in ergosterol content due to loss of 
function mutations in genes of the ergosterol biosynthetic pathway (for example ERG3 and ERG6,  
Figure 9), resulting in the accumulation of other sterols in the membrane [15, 21].  
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Figure 8: Polyenes.  (A) Chemical structures of the three clinically used polyenes: amphotericin B, nystatin and natamycin. (B) 
Mode of action of polyenes at the fungal cell’s membrane. Polyenes can either form a pore by binding to ergosterol (ion 
channel model) or bind and adsorb ergosterol and act as a “sterol sponge”. Adapted from Anderson et al. [23].  
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Figure 9: Ergosterol pathway in C. albicans. Antifungals targeting the pathway (azoles, allylamines and polyenes) are 
highlighted in red with their respective targets. The dashed arrows represent the alternative pathways activated under azole 
treatment. Adapted from Sanglard et al. [19] and Campoy and Adrio [24].  
 
Inhibitors of fungal cell wall synthesis 
Echinocandins 
Echinocandins are semisynthetic compounds derived from fungal natural products. Currently, only 
three echinocandins are available for clinical use: caspofungin, derived from pneumocandin B 
produced by Glarea lozoyensis, micafungin derived from echinocandin B produced by Aspergillus 
nidulans and finally anidulafungin, derived from a fermentation product of Coleophoma empetri 
(Figure 10A). These three compounds are non-competitive inhibitors of the β-(1,3)-ᴅ-glucan synthase 
complex and more specifically the subunits FKS1 and FKS2. The β-(1,3)-ᴅ-glucan synthase is an enzyme 
responsible for the synthesis of β-(1,3)-ᴅ-glucan, a polysaccharide constituting more than 50 % of the 
fungal cell wall (Figure 10B). Blocking the synthesis of β-(1,3)-ᴅ-glucan leads to a disruption of the 
structure and stability of the cell wall, resulting in osmotic instability and lysis of the fungal cell [19].  
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Due to their specificity for the fungal cell wall, echinocandins have low toxicity for mammalian cells. 
However, some adverse effects can be observed such as headache, rash, fever, liver toxicity, phlebitis, 
histamine release and hemolysis [18]. Echinocandins also have low interactions with other antifungals, 
allowing their use in combination with drugs like azoles or polyenes, which could avoid the 
development of antifungal resistance [25]. However, due to low absorption by the GI tract (due to their 
high molecular weight) and their short half-life, echinocandins must be injected once per day 
intravenously, limiting their clinical application [19, 25].  
Resistance to echinocandins is linked to specific mutations leading to amino acid substitutions in two 
different regions (known as Hot-spot 1 and 2 or HS1 and HS2) of the two subunits of the 1,3-β-glucan 
synthase complex, FKS1 and FKS2. These amino acid substitutions decrease the affinity of 
echinocandins to the enzyme active site (Table 4) [19, 26]. 
18 
 
 
Figure 10: Echinocandins. (A) Chemical structures of the three available echinocandins; caspofungin, micafungin and 
anidulafungin. (B) Mode of action of echinocandins. Echinocandins block the β-(1,3)-D glucan synthase subunits (Fks1 and 
Fks2), thus impairing cell wall formation. Adapted from Cowen [27]  
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Inhibitors of ergosterol biosynthesis 
One major difference between fungal and human cells is the presence of ergosterol as the major sterol 
in the fungal membrane instead of cholesterol in mammalian cells. Ergosterol is required for 
membrane fluidity, asymmetry and integrity which are essential for fungal growth and survival. Since 
ergosterol is a fungal-specific molecule, its biosynthetic pathway has been targeted by several drugs ( 
Figure 9) [28, 29].  
Allyamines 
Terbinafine and naftinine are the principal allylamines drugs used in the clinic, mainly for the treatment 
of dermatophytic infections (Figure 11). Allylamines are synthetic agents which inhibit ergosterol 
biosynthesis by binding to the squalene epoxidase Erg1, a key enzyme responsible for the conversion 
of squalene into lanosterol (Figure 9) [19, 29]. This inhibition results in the accumulation of high 
amounts of squalene inside the fungal cell and results in increased membrane permeability, alteration 
of the cellular organization and finally leads to cell death [19].  
 
Figure 11: Allylamines. Chemical structures of the two major allylamines used in clinic; terbinafine and naftinine.  
 
Allylamines display synergistic activities with other antifungal drugs, particularly with triazoles, the 
main drug class used against Candida spp., demonstrating a potentially useful strategy against azole-
resistant Candida spp. isolates. However, the effect of allylamines against Candida spp. appears to be 
relatively poor in vivo, limiting its clinical interest when used alone [29]. 
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Azoles  
Azoles are the first-line drugs used against Candida infections [30] due to their high tolerability in 
patients (even at high concentrations), limited side-effects, broad spectrum of activity, advantageous 
treatment cost as well as worldwide availability (Figure 12). Azoles possess a fungicidal activity against 
Aspergillus spp., but a fungistatic activity against Candida spp. and are devised in two major categories: 
the imidazoles (clotrimazole, miconazole and ketoconazole) (Figure 13A) and the triazoles 
(itraconazole, fluconazole, voriconazole, posaconazole and isavuconazole) (Figure 13B) [18]. 
Imidazoles were the first developed azoles. Due to their toxicity and side effects, the development and 
use of triazoles is now favored in the clinic. Triazoles can be separated into two groups. The first 
generation triazoles, represented by itraconazole and fluconazole (FLC) have a broad spectrum of 
activity but are not efficient against pathogens such as Scedosporium, Fusarium and Mucorales [19]. 
Due to its activity against different Candida spp., FLC has been established as the first-line antifungal 
against localized and systemic candidiasis, mainly against C. albicans. FLC prophylactic administration 
can be useful in patients at risk of infections, for example in immunocompromised patients [31]. The 
second generation of triazoles, represented by voriconazole, posaconazole and isavuconazole have a 
broader spectrum of activity than the first generation. Voriconazole is being used as a first-line drug 
against invasive Aspergillus fumigatus infections. Posaconazole generally exhibits increased activity as 
compared to other azoles and has a broader activity spectrum. It is used as prophylaxis against invasive 
candidiasis and aspergillosis [19]. 
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Figure 12: Worldwide FLC availability (A) and pricing in US $ (B). Adapted from www.antifungals-availability.org.  
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Figure 13: Azoles. Chemical structures of imidazoles (A) and triazoles (B). Azoles act by impairing ergosterol biosynthesis, 
leading to the accumulation of toxic sterols in the membrane (C). Adapted from Cowen [27].  
 
Azoles inhibit the production of ergosterol by targeting the cytochrome P450-dependent lanosterol 
14-α-demethylase, encoded by ERG11, which is responsible for the conversion of lanosterol into C14-
demethyl-lanosterol, a key element in ergosterol biosynthesis ( 
Figure 9). Azoles bind to the iron contained in the porphyrin unit of the active site of the enzyme, 
blocking its activity, thus resulting in the accumulation of lanosterol in the fungal cell [19]. The 
accumulated lanosterol is then processed by the cell into several methylated sterols among which a 
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toxic methylated sterol (14-methylergosta-8,24(28)-dien-3,6-diol) that is responsible for growth 
inhibition (Figure 9, Figure 13C) [28]. Each type of azole antifungal binds to the active sites with 
different affinities, determining their antifungal effect and their affinity for the host cytochrome P450s, 
which may predict their side-effects [19]. 
However, due to the wide use of azoles (mainly FLC) and their fungistatic activity against Candida spp., 
a strong selection for azole-resistant strains has been observed [15, 32]. The rapidly growing resistance 
of C. albicans to other commonly used antifungals is an important medical concern. Emergence of 
resistant strains also resulted in an increased mortality rate among patients [18]. 
Resistance mechanisms to azoles  
It has been observed that the repeated use of FLC can result in the acquisition of resistance in fungi. In 
fact, the fungistatic nature of FLC allows long-term fungal survival in the presence of high drug levels. 
This long exposure to drugs is known to increase the apparition of resistance in C. albicans. The 
mechanisms of resistance acquisition in C. albicans have been widely studied and are well 
characterized (Figure 14, Table 4 and Table 5). Drug resistance can be the result of the alteration of 
the drug target by mutations in order to diminish drug binding, the increase of the drug target 
concentration in the cell by up-regulation of specific genes, or even high levels of efflux pumps to 
prevent the accumulation of the drug in the cell (Figure 14) [32, 33]. 
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Figure 14: Resistance mechanisms of azoles and polyenes.  (A) Mode of actions of azoles and polyenes (white background) 
and the respective mechanisms of resistance (red background) in C. albicans. (B) Detailed mechanisms of resistance to azoles. 
Adapted from Cowen [27] and Vale-Silva [34].  
 
Alteration of Erg11 has been identified as a cause of resistance in many clinical isolates [35]. Several 
alterations of ERG11 such as point mutations and overexpression have been identified to result in 
resistance to azoles (Figure 14, Table 5). Mutations in ERG11 can cause structural or functional 
alterations of the active site that reduce the FLC ability to bind to its target (Table 5). Diminution of the 
drug affinity leads to an increase of resistance [30]. The increase of ERG11 expression has also been 
identified in many resistant C. albicans isolates (Figure 14, Table 5). Upc2, a zinc-cluster transcription 
factor, regulates ERG11 expression. It has been observed that gain-of-function mutations of this 
transcription factor can result in an increased expression of the target gene. Overexpression of ERG11, 
mediated by UPC2 mutations, results in increase of FLC resistance (Figure 14, Table 5) [32].  
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ERG3 is a gene responsible for the conversion of lanosterol into the toxic methylated intermediate 
responsible for cell growth defect during azole treatment (Figure 9). Its inactivation results in the 
absence of accumulation of this toxic compound, conferring azole resistance to the fungal cell (Figure 
14, Table 5). However, even if mutations repressing ERG3 transcription could be expected in C. albicans 
clinical isolates, they have not been reported yet [36]. 
Another frequently encountered resistance mechanism consists of the active export of the drug out of 
the cell (Figure 14). In C. albicans, three efflux pumps, the ATP Binding Cassette (ABC) transporters 
Cdr1 and Cdr2, and the major facilitator transporter Mdr1 are involved in resistance (Figure 14, Table 
5). In fact, many FLC-resistant strains overexpress at least one of these pumps. The transporters’ up-
regulated activity in resistant isolates is the result of gain-of-function mutations in zinc-cluster 
transcription factors Tac1 and Mrr1 that regulate CDR1, CDR2 and MDR1 expression, respectively 
(Table 5) [32].  
Highly resistant isolates often exhibit a combination of different resistance mechanisms. Accumulation 
of mutations results in an additive increase of resistance. Highly resistant strains resulting from strong 
FLC selective pressure are frequently found in patients treated for a long period [32]. It has been 
observed that other mechanisms can be involved in FLC resistance. For example, the transcription 
factor Cap1 is involved in oxidative stress response by inducing MDR1 expression. When Cap1 is 
hyperactive (C-terminally truncated), it causes a constitutive overexpression of MDR1 and has been 
linked to increased FLC resistance. Alternatively, Fcr1, another transcription factor, has been linked to 
increase FLC resistance when deleted. However, to our knowledge, these mechanisms have not yet 
been detected in clinical isolates [32]. It is also thought that zinc cluster transcription factors other 
than Mrr1, Tac1 and Upc2 might play a role in FLC resistance. Indeed, it has already been shown that 
hyperactive Mrr2 can control the expression of CDR1 and not CDR2, and has been linked to increased 
resistance both in vitro but not in clinical isolates so far [32]. Standardized antifungal susceptibility 
assays are essential to provide a clear diagnosis of fungal infections and their required treatments, 
especially when strains are causing severe infections or are unresponsive to routine treatments. 
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Table 5: Known mechanisms of resistance to azoles. Adapted from Morschhäuser et al. [32]. 
  
Gene Function Effect of mutation Resistance mechanism 
ERG3 
Transformation of lanosterol 
into a toxic sterol Loss-of-function of Δ
5,6
-desaturase No toxic sterol accumulation 
ERG11 
Target of azoles;  
First-step transformation of 
lanosterol into ergosterol 
Structural change in target enzyme Reduced drug binding 
MRR1 
Transcription factor (TF) 
regulating MDR1 expression Hyperactive TF Efflux pump overexpression (MDR1) 
TAC1 
TF regulating CDR1 and CDR2 
expression Hyperactive TF Efflux pump overexpression (CDR1, CDR2) 
UPC2 TF regulating ERG11 expression Hyperactive TF Drug target overexpression (ERG11) 
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Antifungal susceptibility assays 
Several techniques are available to establish the susceptibility profile of a defined Candida isolate. 
Most of them are based on drug diffusion in either a solid agar medium or in liquid conditions, with 
each protocol having its specific endpoint readout [5]. Despite having the same purpose (i.e. identifying 
susceptible and resistant isolates), each method has its advantages and flaws. Indeed, depending on 
the Candida species and the tested drug, a given protocol might be more optimal than the other (Table 
6) [5]. 
To standardize laboratory protocols and interpretation of drug susceptibility testing, two basic 
methods have been established. First, the Clinical and Laboratory Standard Institute (CLSI) (formerly 
the National Committee for Clinical Laboratory Standard) have established a reference method for 
broth dilution antifungal susceptibility testing of yeasts which aims to standardize antifungal 
susceptibility testing for yeasts that cause invasive infections. The CLSI method relies on visual 
observation of fungal growth in the presence of different antifungal concentrations in broth media. 
The growth in the tubes (or in U-shaped wells in the case of microtiter plates) containing the antifungal 
is visually compared to growth in control tubes without drug. The main readout of the test is the visual 
observation of the Minimum Inhibitory Concentration (MIC) defined by the CLSI as the lowest 
concentration of the drug that prevents visible growth of a microorganism in a broth dilution 
susceptibility test [37].  
Similarly to CLSI, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) developed 
a method relying on optical density reading by spectrophotometry of flat-bottomed micro-dilution 
plates to quantify fungal growth compared to a drug free control. The main readout of the test is also 
the determination of the MIC defined by EUCAST as the lowest antifungal concentration that inhibits 
growth of fungi within a defined period of time taking a cut-off of 50 % of growth as compared to the 
drug-free control [38].
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Table 6: Reference diagnostic methods available for antifungal susceptibility profiling. Adapted from Pappas et al. [5].  
Test 
(method) 
End point 
reading 
Resistance detection 
Advantages Disadvantages 
Echinocandins Azoles Amphotericin B 
EUCAST  
(microbroth 
dilution) 
Automated Easy Easy Easy • Pattern for the most 
resistant organism reported if 
mixed cultures are tested 
• Growth inhibition can be 
quantified in percent of 
growth control by a 
spectrophotometer 
• Objective endpoint reading 
• Not all antifungal compounds are commercially 
available 
• Most laboratories are not familiar with plate 
production and test principle 
• Requires an ELISA reader 
• The amphotericin B MICs tend to cluster in a 
narrow concentration range (which may lead to 
difficulties in correctly separating susceptible from 
resistant strains) 
CLSI  
(microbroth 
dilution) 
Visual (50 % 
or 100 % 
growth 
inhibition) 
Easy Difficult for 
isolates 
displaying 
trailing growth, 
which is 
defined as only 
partial growth 
inhibition over 
a wide 
concentration 
range 
Easy • Pattern for the most 
resistant organism reported if 
mixed cultures are tested 
• Growth inhibition can be 
quantified in percent of 
growth control by a 
spectrophotometer 
• Not all antifungal compounds are commercially 
available 
• Most laboratories are not familiar with plate 
production and test principle 
• Subjectivity in endpoint reading is inevitable 
• The amphotericin B MICs tend to cluster in a 
narrow concentration range 
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CLSI and EUCAST protocols differ in several technical aspects and variability can be observed in MIC 
values between both protocols while comparing the same strain treated with the same amount of 
drug. The different incubation times (24 h and 48 h for CLSI and 24 h for EUCAST), the sugar content 
of the culture’s media (0.2 % for CLSI and 2 % for EUCAST), and the different approaches to determinate 
the MIC in CLSI and in EUCAST might be the reason for these differences in values. In fact, the EUCAST 
spectrophotometry method allows a proper quantification of fungal growth and eases the comparison 
of results between laboratories, while the CLSI visual approach is more subjective thus more prone to 
misinterpretation [20].  
The EUCAST and CLSI defined two different limit values for a given drug: the epidemiological cut-off 
(ECOFF) and the clinical breakpoints (CBP), based on the MIC distribution in the pathogen’s population. 
There is a light variability in these values depending on the standard protocol used due to the 
difference between the readout in both techniques (Table 7). The ECOFF can be determined visually 
and corresponds to the limit above which an isolate is no more considered as WT [20]. As example, the 
ECOFF value for FLC in C. albicans is 1 µg/ml (Figure 15, Table 7). On the other hand, CBPs are specific 
MIC values for discrimination between resistant and susceptible strains [38] and should reflect the 
relationship between in vitro antifungal activity and therapy outcome (Figure 15) [20]. These values 
have been determined by EUCAST, relating different clinical parameters such as in vivo 
pharmacodynamics and pharmacokinetics, resistance mechanisms and clinical response [39]. In the 
case of FLC, C. albicans strains with a MIC ≤ 2 μg/ml are considered susceptible, while strains with MIC 
≥ 4 μg/ml are considered resistant. Therefore, 4 μg/ml is considered the CBP for FLC (Figure 15, Table 
7) [38]. Resistance can be observed as an increase in MIC compared to values measured in reference 
susceptible organisms (Figure 17B) [33].  
However, the power of the CBP to predict therapy outcome in C. albicans infections is limited. A 92 % 
success rate is observed over 550 events with FLC MICs of ≤ 2 μg/ml, while it decreases to 83 % success 
among 52 events with FLC MICs of ≥ 4μg/ml, and down to 37 % success over 212 events with MIC of 8 
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μg/ml [39]. These results demonstrate that antifungal susceptibility methods have a limited capacity 
to predict the response of fungal pathogens to antifungals in vivo. Strains determined as susceptible in 
vitro can thus still lead to therapeutic failure in animal experiments and more importantly in patients 
[20]. 
 
Figure 15: Distribution of FLC MIC values in C. albicans.  (A) Gaussian curve representation of the FLC MIC distribution in the 
C. albicans population. (B) Distribution of MIC values accordingly to the occurrence of FLC resistance mechanisms. Clinical 
breakpoint value for resistance (CBP) and epidemiological cutoff value (ECOFF) are represented with corresponding drug 
concentrations. Blue and red triangles (B) represent isolates with and without known resistance mechanisms, respectively. 
Adapted from Delarze and Sanglard [20].  
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Table 7: ECOFF and CBP of different antifungal agents and Candida species. Both CLSI and EUCAST values are represented. 
Adapted from Delarze and Sanglard [20].  
   ECOFF (µg/ml)  CBP (µg/ml) 
Species Method  FLC 
1 AFG1 MFG1  FLC AFG MFG 
       S
2 R2 S R S R 
C. albicans CLSI  0.5 ≤0.12 0.03  2 4 0.25 0.5 0.25 0.5 
 EUCAST  1 0.03 0.015  2 4 0.03 0.03 0.016 0.016 
C. glabrata CLSI  32 ≤0.25 ≤0.03  0.002 32 0.12 0.25 0.06 0.12 
 EUCAST  32 0.06 0.03  0.002 32 0.06 0.06 0.03 0.03 
C. parapsilosis CLSI  2 ≤4 4  2 4 2 4 2 4 
 EUCAST  2 4 2  2 4 0.002 4 0.002 2 
C. tropicalis CLSI  2 ≤0.12 ≤0.12  2 4 0.25 0.5 0.25 0.5 
 EUCAST  2 0.06 0.06  2 4 0.06 0.06 IE c IE 
C. krusei CLSI  64 ≤0.12 ≤0.12  -3 - 0.25 0.5 0.25 0.5 
 EUCAST  128 0.06 0.25  - - 0.06 0.06 IE IE 
1 (FLC) Fluconazole, (AFG) Anidulafungin, (MFG) Micafungin 
2 (S) Susceptible, (R) Resistant 
3 (-) Antifungal use not recommended for this species, (IE) Insufficient Evidence of that the species is a good target for therapy 
with the drug. 
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Antifungal tolerance: definitions, relevance and known mechanisms 
Definition of tolerance to antifungals 
Among all the factors than can dictate the outcome of antifungal treatments, the ability of the 
pathogen to tolerate the presence of the drug is often neglected [20]. Drug tolerance is a well-known 
phenomenon in the field of antimicrobials and is globally defined as the ability of a pathogen to 
withstand killing at drug concentrations above the MIC [40]. 
Antimicrobial tolerance was first described for bacteria treated with bactericidal antibiotics [41, 42]. 
In bacteria, tolerance arises in the presence of drug where a subpopulation of dormant cells resists the 
“cidal” effect of the treatment. These cells, also known as persister-cells, have no genetic discrepancies 
with the rest of the population, thus highlighting a role of epigenetic modifications instead of the 
acquisition of mutation(s) as is the case for resistance [41]. These tolerant persister-cells have also 
been identified as a subpopulation of bacterial biofilms and might be linked to disease resurgence in 
the patient [41].  
Antimicrobial tolerance has also been observed for fungal pathogens and can again be defined as the 
ability to survive at drug concentrations above the MIC. However, in comparison with antibacterial 
tolerance, it is necessary to adjust antifungal tolerance to the antifungal classes. Indeed, antifungal 
tolerance is mainly observed with fungistatic (i.e. azoles) rather than with fungicidal (i.e. 
echinocandins, polyenes) drugs. Somehow, one might say that fungal pathogens such as C. albicans 
are intrinsically tolerant to azoles as shown by their survival even at high drug concentration. However, 
the degree of azole tolerance can vary within the same species (Figure 16, Figure 17A) [20]. In 
susceptibility assays, tolerance is characterized by a phenomenon known as the trailing growth or 
residual growth that differentiates from an increase of MIC characterizing resistance mechanisms 
(Figure 16, Figure 17B-C) [20, 42].  
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Figure 16: Susceptibility profiles to FLC on Etest. Strain susceptible to FLC (MIC < 4 µg/ml) (A), resistant to FLC (MIC > 4 µg/ml) 
(B) and tolerant to FLC characterized by a well-defined susceptible MIC (MIC < 4 µg/ml) and a residual growth (trailing growth) 
in the inhibition area (C). Adapted from Budzyńska et al. [43].  
 
 
Figure 17: Susceptibility profiles to FLC in microdilutions assay. Susceptibility profiles of three clinical C. albicans isolates: 
isolate 1 is susceptible (MIC < 4 µg/ml), isolate 3 resistant (MIC > 4 µg/ml) and isolate 2 susceptible (MIC < 4 µg/ml) but with 
an increased residual growth, thus an increased tolerance to FLC (A). (B-C) Illustrations of the occurrence of antifungal 
resistance (B) and tolerance (C). The red curve corresponds to a susceptible wild type strain. An increased resistance is 
characterized by an increase of the MIC (panel B, blue dashed-curve) while an increase in tolerance is characterized by an 
increase of the residual growth without modification of the MIC (panel C, blue dashed-line). Adapted from Delarze and 
Sanglard [20].  
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Known mechanisms involved in FLC tolerance in C. albicans  
The different levels of trailing growth reflect the different degrees of tolerance and thus might have 
an incidence on therapy outcome [20]. Until now, tolerance mechanisms have been poorly studied. It 
has been demonstrated that the immunosuppressive drug cyclosporine A can act with FLC and could 
convert this fungistatic drug into a strong fungicidal agent in vitro, thus reflecting a loss of tolerance 
[44]. Cyclosporine A, associated with cyclophilin A (CYP), targets calcineurin, which is a protein 
phosphatase activated by a calcium-dependent pathway [33]. Calcineurin is essential for the response 
of C. albicans to stress generating agents such as changes in temperature or antifungal treatment. It 
has been demonstrated that exposure of the calcineurin subunit A (CNA/CMP1) deletion mutant to 
FLC results in a strong loss of viability reflecting a loss of tolerance for the drug. In contrast, the deletion 
of the CYP gene was viable in presence of FLC and cyclosporine A. Calcineurin regulates drug tolerance 
only and not resistance, since the presence or absence of its activity does not affect drug susceptibility 
in drug susceptibility assays [44]. Calcineurin was also shown to be a client protein of the chaperone 
heat shock protein 90 (Hsp90) [27]. Inhibition of Hsp90 results in a loss of calcineurin activity and, 
therefore, in a loss of tolerance such as observed with the CNA deletion mutant [20, 45]. In another 
study, it was shown that the membrane trafficking through the late endosome/ pre-vacuolar 
compartment (PVC) had an impact upon C. albicans FLC tolerance. In fact, deletion of VPS21, an 
endosomal Rab family GTPase, was involved in PVC trafficking and enhanced C. albicans growth in the 
presence of FLC despite depletion of cellular ergosterol. This enhanced growth appeared as trailing 
growth in standard susceptibility assays, thus pointing to a potential role of Vps21 in azole tolerance. 
The VPS21 deletion mutant presented less plasma membrane damage in presence of FLC than wild 
type strains. Indeed, the VPS21 mutant released less cytoplasmic content following FLC treatment. In 
addition, the VPS21 mutant contained abnormally high levels of intracellular Ca2+, thus potentially 
increasing the basal level of calcineurin expression and/or activation. Indeed, in presence of FLC, an 
increase of calcineurin expression was observed in the VPS21 mutant by using a reporter gene. A 
potential relationship between the endosomal trafficking and calcineurin pathway was thus 
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established which at least involved tolerance in VPS21 deletion mutants. Furthermore, it was observed 
that the trailing growth with FLC was more present at 35°C than at 30°C, indicating that the drug caused 
less membrane damage at 35°C [46]. 
It has also been observed that Rta3, a putative lipid translocase, is co-upregulated with multidrug 
transporters by the transcription factor TAC1 in resistant C. albicans strains. While deletion of RTA3 
increases the susceptibility to FLC, overexpression of RTA3 results in an increase of tolerance 
characterized by a trailing growth in the susceptible C. albicans strain SC5314. The mechanisms by 
which TAC1 and RTA3 contribute to tolerance still remain unclear [47]. 
Recently, it has also been reported in C. albicans that the genes FEN1 and FEN12, two genes involved 
in sphingolipid biosynthesis, might be involved in FLC tolerance. Indeed, it was observed that upon 
deletion of FEN1 or FEN12, tolerance level increased in the presence of FLC. The increased survival of 
the mutants seemed to be linked to an increased intracellular FLC concentration and a decreased level 
in the plasma membrane of the toxic sterol 14-methylergosta-8,24(28)-dien-3,6-diol responsible for 
the toxic effect of FLC in C. albicans. These modifications in toxic sterol concentrations were reflected 
by a high level of sphingolipids which may improve cell membrane strength [48]. 
Another recently published study highlighted a tolerance mechanism involving the pH response via the 
Rim pathway. This pathway includes Rim9, Rim21/Dfg16, Rim8, Rim20 and Rim13. Under neutral-
alkaline pH, this cascade leads to the cleavage of the C-terminal inhibitory domain of the transcription 
factor Rim101 leading to its activation. The culture medium’s pH was already known to impact the 
level of tolerance in vitro [42] and it has been observed that tolerance decreases under acidic 
conditions, while it is not affected in neutral conditions (pH 6-7) [42]. A phenotypic and transcriptomic 
analysis of the Rim pathway showed that all Rim proteins were important for FLC tolerance as their 
respective deletion mutants exhibited increased FLC susceptibility [49]. The transcriptomic comparison 
between a RIM101 deletion mutant and a WT strain at alkaline and acidic pH led to the identification 
of two Rim101 downstream targets including HSP90 and IPT1. HSP90 is already known to be involved 
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in antifungal tolerance on the opposite to IPT1, which encodes an enzyme involved in the biosynthesis 
of the most abundant sphingolipid in the plasma membrane (mannose-(inositol-P)2-ceramide) [49]. 
Interestingly, Ipt1 is part of the sphingolipid’s biosynthesis pathway, downstream of Fen1 and Fen12, 
both of which were reported as FLC tolerance mediators (see above). These data thus reinforce the 
idea that sphingolipids homeostasis is of relevance for FLC tolerance in C. albicans. 
Even if the above-listed mechanisms may lead to azole tolerance, the exact molecular basis of 
tolerance is not completely understood. Moreover, these mechanisms have not been proved to 
mediate tolerance in clinical isolates. Tolerance may allow a better survival of C. albicans at high drug 
concentrations. The strong selective pressure induced by administered drugs and persistence resulting 
from residual growth may favor the acquisition of resistance mechanisms and may ultimately lead to 
treatment failure. Unraveling genetic and epigenetic mechanisms underlying tolerance and the 
discovery of tolerance mediators are essential steps for the development of potential inhibitors that, 
in combination with FLC, might offer new strategies to fight against Candida infections.  
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Aims of this work 
In this project, our goal is to gain a better understanding of the mechanisms behind FLC tolerance in C. 
albicans. We aimed to better define FLC tolerance as well as to develop methods to rapidly and 
consistently identify tolerant isolates. These measures are necessary for the identification of genetic 
mediators of FLC tolerance.  
To reach this goal, the following main objectives were defined: 
 - To give a clear definition of FLC tolerance to avoid misleading with resistance. 
- To develop a method to identify and quantify FLC tolerance and to determine optimal test 
conditions. 
 - To identify tolerant clinical isolates for further investigations. 
- To identify new mediators of FLC tolerance using forward genetic approaches. 
- To characterize and confirm these candidate genes as mediators of FLC tolerance in C. 
albicans and especially clinical isolates. 
- To determine the FLC response imprint in tolerant clinical isolates at the transcriptomic level. 
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Summary of main findings 
In the first part of this thesis, a collection of known tolerant C. albicans clinical isolates was used to 
better defined FLC tolerance using the standard antifungal susceptibility assay protocol proposed by 
EUCAST. Basing ourselves on this protocol, a tolerance index (TI), reflecting the residual growth at FLC 
concentration above the FLC clinical breakpoint (4 µg/ml) was defined by conversion of the residual 
growth at 8 µg/ml FLC in an index ranging from 0 to 1 (TI = % of growth / 100). Selecting a single 
concentration to quantify tolerance allows an easy and quick way to assess tolerance of large strain 
collections. Establishment of the TI allowed the establishment of tolerance-thresholds at TI = 0.2 and 
TI = 0.8 or further discrimination between tolerant and resistant isolates. This definition and thresholds 
of tolerance as well as the effect of environmental pH on FLC tolerance were further confirmed using 
a collection of 172 clinical isolates which could be clustered depending of their TI and their response 
to pH.  
In the second part of this thesis, we used the definition of tolerance proposed in the first part to 
identify new genetic mediators of FLC tolerance. For this purpose, a collection of 579 strains was used, 
each overexpressing a specific gene on a doxycycline dependent manner and bearing specifics 
barcodes for their identification by sequencing. By pooling all strains in a single population and 
maintaining a selective pressure of FLC and doxycycline, we were able to enrich the pool in FLC-tolerant 
strains. The best candidates were tested in classical susceptibility assays to confirm their role in 
tolerance and three genes, CRZ1, GZF3 and YCK2 were related to an increased TI in when 
overexpressed. However, only CRZ1 and GZF3 overexpression reached the lower tolerance threshold 
and were further confirmed by overexpression in CRZ1 and GZF3 deletion mutant strains and by 
deletion in tolerant clinical isolates. Unfortunately, no negative regulators of tolerance could be 
identified.  
In the third and final part of this thesis, a transcriptomic approach was used to assess the footprint 
response to FLC in the wild type strain SC5314 and related tolerant clinical isolates. These clinical 
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isolates were obtained over 8 years of persistence in an endocarditis patient treated with FLC and 
showed increased FLC tolerance over time. This approach confirmed that SC5314 activates several 
pathways related to the presence of FLC, particularly the calcineurin pathway and its downstream 
effector CRZ1. This response to FLC was also observed in the related clinical isolates and, interestingly, 
the calcineurin pathway and CRZ1 were more overexpressed than in the susceptible SC5314. This 
overexpression pattern was also observed in the tolerant clinical isolates, thus suggesting the 
relevance of the calcineurin pathway for FLC tolerance in clinical isolates 
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Part one: Implementation of a tolerance index for the study and quantification 
of tolerance to fluconazole in Candida albicans. 
Abstract 
Candida spp. are major human pathogens and a major issue in intensive care units around the world. 
Candida spp. possess a high mortality rate despite the presence of antifungal treatments. One cause 
of these therapeutic failures is the acquisition of antifungal resistance by mutations in fungal genomes. 
In the case of the fungistatic azole fluconazole, the most widely used antifungal, the mechanisms of 
resistance have been extensively studied. However, some clinical isolates are known to be able to 
survive at high fluconazole concentrations without acquiring resistance mutations, a phenotype known 
as tolerance. Mechanisms behind fluconazole tolerance are not well studied, mainly due to the lack of 
a proper way to identify and quantify tolerance of clinical isolates. In this study, we proposed optimal 
culture conditions to study tolerance and presented a new easy and efficient method to identity and 
quantify tolerance to fluconazole. The method is based on the EUCAST microdilution susceptibility 
assay and is used to determine a tolerance index reflecting the level of tolerance in tested isolates. 
Tolerance indexes were used to delimit thresholds which can separate susceptible wild type isolates 
from tolerant and resistant ones.  
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Introduction 
Candida species are major fungal pathogens which can cause life-threatening systemic infection known 
as invasive candidiasis. Candida infection are linked to a high mortality rate despite the presence of 
treatment with antifungals. This high degree of therapeutic failures might be partially explained by 
acquisition of resistance upon treatment [15, 19]. In the case of the widely used fungistatic drug 
fluconazole, resistance mechanisms have been extensively studied [32]. However, despite an extensive 
knowledge of these mechanisms, the acquisition of resistance does not explain all therapeutic failures. 
Indeed, it has been observed that some isolates identified as susceptible to fluconazole in vitro cannot 
be treated efficiently in the patient. It is known that some clinical isolates of C. albicans tolerate the 
presence of fluconazole more than others. These are characterized by an increased growth, known as 
residual growth, at drug concentrations above their minimum inhibitory concentration (MIC). This 
residual growth, which is a characteristic of drug tolerance, is in general not coupled to an increased 
MIC (unlike resistance) and is thought to favor the acquisition of resistance mechanisms due to 
extended survival of some C. albicans isolates upon treatment. Tolerant isolates may also to be a 
source of reinfection upon arrest of antifungal treatment [20]. 
A few mechanisms have been linked to FLC tolerance in C. albicans in the past and involve stress 
response mediators such as the heat shock protein Hsp90 or calcineurin [21, 44, 45], membrane 
composition through membrane trafficking (VPS21) [46], lipid translocation (RTA3) [47] and 
sphingolipid homeostasis (FEN1, FEN12, IPT1) [50, 51], and also the pH response (RIM101) [49]. 
However, while it remains unclear how these mechanisms exactly play a role in tolerance, these might 
be used as potential drug targets to increase FLC efficacy. It is thus important to identify new mediators 
of tolerance. To be able to identify tolerant strains as well as genes involved in tolerance, one needs a 
reliable method to quantify tolerance to FLC. A method based on disk diffusion assay on an agar 
medium has already been proposed in agar diffusion tests by the group of J. Berman. This assay 
quantifies the density of growth in the inhibition area and compares this density with the diameters of 
inhibition [50, 51]. This technique needs images captured in constant conditions (lighting, exposition, 
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etc.) as well as software manipulations. Here we propose an alternative approach to quantify tolerance 
based on the EUCAST microdilution assay and the use of spectrophotometry to determine a so-called 
tolerance index (TI) that allows the comparison of tolerant isolates and the future identification of 
mediators of tolerance to FLC. This method can easily be implemented in other laboratories and for 
other Candida species. We also discuss the selection of optimal growth conditions for tolerance assays 
as well as the definition of tolerance thresholds for the assignment of clinical strains to different 
phenotypic categories.  
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Material and methods 
Strains used in this study 
The wild type (WT) strain SC5314 and the C. albicans clinical isolates used in this study were selected 
for their known susceptibility to FLC and belong to D. Sanglard’s lab collection (Table 8). SSI strains 
were kindly provided by M.C. Arendrup (Staten Serum Institute, Copenhagen, Denmark) and C. 
d’Enfert provided the CEC strain collection (Pasteur Institute, Paris, France) (Table 8 and 
Supplementary File 1 respectively). 
Table 8: Strains and clinical isolates used in this study. 
1Not Applicable/Not Available 
2As described by Marr et al. [42] 
3Boldfaced-underlined number indicate the year of sampling as 20xx 
4Information from M.C. Arendrup 
Lab ID Alternative ID 
FLC MIC  
(µg/ml) 
Comments Reference 
DSY486 SC5314 NA1 wild type laboratory strain [52] 
DSY2102 572-10 2 Low-High phenotype2 [42] 
DSY2103 578-8 2 Low-High phenotype  [42] 
DSY2104 623-11 2 Low-High phenotype  [42] 
DSY2105 630-20 2 Low-High phenotype  [42] 
DSY2106 630-11 2 Low-High phenotype  [42] 
DSY2107 707-15 0.5 Low-High phenotype  [42] 
DSY2108 34-023-096 1 Low-High phenotype  [42] 
DSY2109 34-504-040 2 Low-High phenotype  [42] 
DSY2110 34-028-117 1 Low-High phenotype  [42] 
DSY4452 1101-3343 NA Isolated from an endocarditis patient This study 
DSY4453 1052-9203 NA Isolated from an endocarditis patient This study 
DSY4454 0526-60203 NA Isolated from an endocarditis patient This study 
DSY4585 12 1206 15653 NA Isolated from an endocarditis patient This study 
DSY4586 12 1211 22503 NA Isolated from an endocarditis patient This study 
DSY4587 13 0411 12193 NA Isolated from an endocarditis patient This study 
DSY4588 13 0420 06733 NA Isolated from an endocarditis patient This study 
DSY4751 SSI 1489 0.25 "WT"4 This study 
DSY4752 SSI 2503 > 128 Resistant4 This study 
DSY4754 SSI 4622 0.125 Weak Trailing4 [53] 
DSY4758 SSI 5579 > 128 Heavy trailing4 [54] 
DSY4759 SSI 6028 0.25 Medium trailing4 This study 
DSY4806 SSI 3407 > 128 NA This study 
DSY4807 SSI 3408 0.25 NA This study 
DSY4808 SSI 5053 0.25 NA This study 
DSY4810 SSI 6037 0.25 NA This study 
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Media and growth conditions 
All strains were stored in 20 % glycerol at -80°C and routinely grown at 30°C under constant shaking 
(220 rpm) in complete Yeast Extract Peptone Dextrose (YEPD) medium (1 % Bacto peptone, Difco 
Laboratories, Basel, Switzerland), 0.5 % Yeast extract (Difco) and 2 % glucose (Fluka, Buchs, 
Switzerland). When grown on solid YEPD plates (YEPDA), 2 % agar (Difco) was added and plates were 
incubated at 35°C.  
For FLC susceptibility assays, strains were grown according to the EUCAST or CLSI recommendations 
[39, 40] in RPMI1640 medium with phenol-red (Sigma-Aldrich) complemented with 0.2 or 2 % glucose 
(Fluka, Buchs, Switzerland) and buffered with 0.33 M morpholinepropanesulfonic acid (MOPS). The pH 
was adjusted to pH 7.5, pH 7, pH 6 and pH 4.5, respectively, using NaOH or HCl. Stock solutions were 
prepared as 2x concentrated RPMI as recommended by EUCAST [38].  
FLC susceptibility and tolerance assays 
All FLC susceptibility assays were performed according to the Reference Method for Broth Dilution 
Antifungal Susceptibility Testing of Yeasts (M27-A3) [37] and the Method for the determination of broth 
dilution minimum Inhibitory concentrations of antifungal agents for yeasts (E.DEF 7.3.1) [38] with slight 
modifications when necessary. Susceptibility assays were performed in flat-bottom 96-well plates 
(Costar) and the fungal growth was measured spectrophotometrically for both methods. The minimal 
inhibitory concentration (MIC) was defined as the first concentration of drug inhibiting at least 50 % of 
fungal growth as compared to a drug free control. Strains with a MIC below 4 µg/ml FLC were defined 
as susceptible as described by EUCAST [38]. Susceptibility assays were performed in RPMI at pH 7.5, 
pH 7, pH 6 or pH 4. Tolerance assays were performed in the same conditions but using one fixed only 
at FLC concentration as specified in the corresponding experiment. 
Briefly, individual colonies of each tested strain were grown overnight in YEPD medium at 30°C under 
constant shaking (220 rpm). Cultures were centrifuged (5 min, 4600 rpm, 4°C) and washed twice with 
PBS (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, and pH 7.4). Cell concentration was estimated by 
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spectrophotometry (OD540 nm) and cells resuspended at 5 x 105 cells/ml in distilled water. Then, 100 µl 
of this suspension were transferred into the wells of flat-bottom 96-well plates (Costar) containing 100 
µl of 2x RPMI (0.2 or 2 % glucose for CLSI and EUCAST condition, respectively) complemented with 
256-0 µg/ml FLC in two-fold dilutions or fixed FLC concentrations (16 µg/ml), to obtain a final cell 
concentration of 2.5 x 105 cells/ml and FLC concentrations ranging from 128 to 0 µg/ml (8 µg/ml for 
tolerance assays) per well. Plates were incubated at 35°C without shaking for 24 h. Cell growth in each 
well was measured by spectrophotometry (OD570 nm) using a microplate reader (Multiskan Ascent) and 
compared to the drug free control after correction with a blank control. From these susceptibility 
curves, both the MIC and the tolerance index (TI), corresponding to the relative growth (% GC) at 8 
µg/ml FLC divided by a factor 100 (TI = % GC/100) were extracted for strain comparisons. The TI is used 
to determine the level of tolerance of the tested strains. 
Growth curve 
To determine the growth rate of selected C. albicans isolates, growth curves were performed in 
EUCAST culture conditions. Briefly, individual colonies of C. albicans clinical isolates were grown 
overnight at 30°C in YEPD medium under constant shaking (220 rpm). Cultures were centrifuged (5 
min, 4600 rpm, 4°C) and washed twice with PBS. Cell concentration was estimated by 
spectrophotometry (OD540 nm) and cells resuspended at 5 x 105 cells/ml in distilled water. and 100 µl of 
this suspension were transferred in the wells of a flat-bottom 96-well plates containing 100 µl of 2x 
RPMI (2 % glucose) adjusted to pH 7.5, pH 7, pH 6 and pH 4.5 to obtain a final cell concentration of 2.5 
x 105 cells/ml. Plates were incubated at 30°C without lids and the OD540 nm of each well automatically 
measured every 15 min for 24 h using a microplate reader (FLUOstar Omega, BMG Labtech). Plates 
were not incubated at 35°C as recommended for drug susceptibility assay due to evaporation issues. 
Growth rates were estimated in the exponential phase of the growth curves by calculating the 
exponential growth equation (non-linear regression) using GraphPad Prism. 
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Software and statistical analysis 
Graphics and statistical analysis were performed in GraphPad Prism 7.03 (GraphPad Software, Inc., La 
Jolla, CA, USA). The online software Morpheus (https://software.broadinstitute.org/morpheus) was 
used to create heatmaps for the tolerance profile screening.  
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Results 
Determination of optimal culture condition for FLC tolerance identification 
Several techniques are available to establish the antifungal susceptibility profiles of defined Candida 
isolates. Most of them are based on drug diffusion assays in either a solid agar medium or in liquid 
conditions, with each protocol having its specific endpoint readout [5]. Despite having the same 
purpose (i.e. identifying susceptible and resistant isolates), each method has its advantages and flaws. 
Indeed, depending on the Candida species and the tested drug, a given protocol might be more optimal 
than another [5]. Since a method for the identification and quantification of tolerance to FLC on agar 
medium has already been proposed by the group of J. Berman [51, 52], we focused here on the 
identification of tolerance using standardized susceptibility assays in microtiter plates (proposed by 
the EUCAST and the CLSI) as it could be implemented in most laboratories.  
First of all, to determine which method was the best to identify azole-tolerant strains, we performed 
drug susceptibility assays for known tolerant isolates (kindly provided by M.C. Arendrup, Table 8, 
Figure 18) using both EUCAST and CLSI protocols. In order to compare both methods, we decided to 
slightly modify the CLSI protocol by performing the assay in flat-bottom microtiter plates and using 
endpoint spectrophotometry as recommended by EUCAST. As stated by Marr et al. [42], the pH of the 
culture medium might influence the level of tolerance. Thus, we decided to perform FLC susceptibility 
assays at pH values of 7.5, 6 and 4.5. As shown in Figure 18, the tested strains clearly exhibited different 
growth profiles in the tested conditions, with a global increase of the residual growth at acidic pH.  
The clinical isolates DSY4751, DSY4754 and DSY4759 could be categorized as susceptible in all the 
tested conditions, as represented by their MIC below the breakpoint (CBP) of 4 µg/ml for FLC in C. 
albicans. However, each strain clearly exhibited a different level of residual growth above the MIC, 
ranging from low values (1-2 %) to around 50 % depending of the strain and the condition (Figure 18, 
blue, green and purple curves, respectively). On the other hand, strain DSY4752 was considered as 
resistant, with a relative growth remaining at around 100 % independently of the FLC concentration, 
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pH and the protocol tested (Figure 18, red curves). Finally, isolate DSY4758 was more ambiguous. 
Indeed, using the EUCAST definitions, DSY4758 should be considered as resistant as its relative growth 
almost never lied under the 50 % threshold, except at pH 7.5 for both protocols where it was equal to 
50 % (Figure 18, orange curves). However, when we compared the susceptibility profiles of DSY4758  
Figure 18: Comparison of EUCAST and CLSI conditions for the identification of tolerant C. albicans isolates using FLC 
susceptibility assays. Curves are representative of the mean relative growth of at least biological duplicates with their 
standard deviation. Vertical dotted lines correspond to the CBP (red line, 4 µg/ml FLC) and the concentration at which the 
tolerance index is established (TI, green line, 8 µg/ml).  
 
with those of the resistant strain DSY4752, a growth reduction could still be observed at low FLC 
concentrations (0-0.125 µg/ml FLC), even if growth stayed below 50 % (Figure 18). This growth 
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reduction suggests that FLC still possessed a fungistatic effect on DSY4758 and thus indicates that this 
strain might not be considered as resistant, but rather as highly tolerant to FLC. A more detailed 
analysis on the occurrence of resistance mechanism(s) in this strain may confirm this hypothesis. 
Establishment of a tolerance index and tolerance thresholds 
To determine which strains could be considered as tolerant, we decided to set thresholds which will 
help to assign strains as susceptible or resistant. We decided to consider all strains that show a 
decreased growth in the presence of FLC as tolerant, even if some strains would be considered 
resistant depending on EUCAST recommendation (i.e. strains remaining above the 50 % cut-off value). 
For such strains, additional controls should be undertaken to ascertain the absence of resistance 
mechanisms to FLC. On the other hand, susceptible isolates with low residual growth above the MIC 
(1-10 % relative to growth control) may be considered to exhibit wild type characteristics. Taken the 
isolates of Figure 18 as guides, it is proposed here to assign strains as tolerant to FLC when the residual 
growth ranges between 20 % and 80 % as compared to a drug-free control after 24 h incubation and 
at drug concentrations above the FLC CBP (4 µg/ml) (Figure 19A). Even though these thresholds are 
not based on the occurrence of molecular markers of tolerance, they still allow a discrimination that 
will be useful in this study. These threshold ranges were further validated with additional strain 
collections (see below). To facilitate strain comparisons, a tolerance index (TI) was established. This 
index (ranging from 0 to 1) reflects the relative growth at 8 µg/ml FLC (TI = % of growth/100) and was 
chosen since it is above the CBP for FLC (4 µg/ml) (Figure 19A). Strains with a TI between 0.2 and 0.8 
are thus considered as tolerant (Figure 19B). The choice of using only the residual growth at a 
concentration of 8 µg/ml FLC instead of measuring the mean residual growth at all concentrations 
above the CBP (which might be more precise) was made to facilitate the screening of large strain 
collections. 
For further discrimination between tolerant strains, a level of tolerance was established which was 
adapted from the work of Rueda et al. [55]. Indeed, Rueda et al., defined tolerance as an inhibition of 
50 
 
the growth by the drug in at least four consecutive wells which maintained a residual growth with 
increasing concentrations of the drug [55]. From this definition, they proposed the following categories 
which are based on the relative growth as compared to the drug free growth control (% GC): (i) no 
tolerance (≤ 5 % GC), moderate tolerance (6-24 % GC) and strong tolerance (25-49 % GC). Strains with 
a relative growth above 50 % GC were considered as resistant according to EUCAST recommendations 
[55]. In our case, as we decided to consider all strains showing growth reduction in presence of FLC as 
tolerant, we propose the following thresholds and categories of tolerance: strains with TIs between 
0.2 and 0.25 were defined as low trailers, between 0.25 and 0.5 as medium trailers and between 0.5 
and 0.8 as heavy trailers. Strains with TIs above the 0.8 threshold (TI > 0.8) were indicative of 
resistance, since such strains do not respond to growth inhibition by FLC at a concentration of 8 µg/ml. 
Strains with a TI under the 0.2 threshold (TI < 0.2) indicate that they are fully FLC-susceptible and, since 
they differ from tolerant strains by their residual growth, were categorized as “wild type” as suggested 
above.  
 
Figure 19: Identification of tolerant strains and definition of tolerance index (TI). Panel A represents 5 clinical isolates with 
different susceptibility profiles to FLC. The level of tolerance is characterized by the tolerance index (TI, green dashed-line) 
which corresponds to the residual growth above the FLC clinical breakpoint (CBP, red dashed-line) at 8 µg/ml FLC (green 
dashed-line). Panel B represents the TI as bar-plot after transformation into an index ranging from 0 to 1 (TI = Y/100, Y being 
the relative growth in % from panel A). This TI allows the discrimination between wild type susceptible isolates (blue strain, 
TI < 0.2), susceptible but tolerant isolates (indigo, orange and purple strains, 0.2 ≤ TI ≤ 0.8) and true resistant isolates (grey 
isolate, TI > 0.8).  
Selection of culture conditions for the identification of tolerance 
Using these definitions of tolerance and these thresholds, we analyzed which of the CLSI and EUCAST 
protocols was optimal for the assessment of tolerance in C. albicans. For this, we determine the TIs of 
the five previously used clinical isolates (Table 8) and compared them using both the CLSI and the 
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EUCAST methods (Figure 20). Fundamentally, no differences between the two protocols could be 
observed except for DSY4759 at pH 6 (Figure 20B). The absence of differences between both protocols 
was confirmed by the high correlation between the TIs in both approaches at every tested pH (R2 > 
0.88, Figure 20D). Despite the absence of differences, the CLSI method seemed to slightly increase the 
tolerance of most strains tested even if this observation was not significant (Figure 20A-C). Due to the 
similarities between both CLSI and EUCAST conditions to assess tolerance, we decided to use the 
EUCAST protocol as our standard protocol to assess and identify tolerance in C. albicans as it does not 
require any modification of the approach, unlike the CLSI method where the readout and culture 
conditions were slightly modified.  
 
Figure 20: Comparison of CLSI and EUCAST protocols for the identification of tolerant isolates. Comparison was performed 
at pH 7.5,6 and 4.5 (panel A, B and C respectively) to assess the pH effect upon tolerance as stated by Marr et al. [42]. Panel 
D represents the correlation between both approaches with the respective R2 corresponding to each tested pH (Two-tailed 
Pearson correlation. confidence interval =95 %). Each bar corresponds to the mean of biological duplicates. Statistical 
significance was calculated using Sidak’s multiple comparison tests (two-way ANOVA, 95 % confidence interval). P-values: 
0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***), < 0.0001 (****). 
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Application of the tolerance assay for the identification of tolerant strains 
To confirm the efficiency of the TI to identify tolerant strains, we next performed a small-scale 
screening of 28 strains (also including the strains DSY4751 to DSY4759 discussed above) (Figure 21, 
Table 8, including the WT strain SC5314 as a susceptibility control. To extend our view of the pH effect 
on tolerance and to be exactly in the EUCAST standard conditions, a fourth condition at pH 7 was 
added. Using our definition of tolerance, we obtained 7 strains out of 28 with a TI between 0.2 and 
0.8, whatever the tested pH condition (DSY2110, DSY4586, DSY4587, DSY4809, DSY4759, DSY4754, 
and DSY4758) (Figure 21A). All these strains originate from patients with either candidemia or 
endocarditis (Table 8). Out of these tolerant isolates, three strains could be defined as heavy trailers 
(0.5 ≤ TI ≤ 0.8), but in a pH-dependent manner. Indeed, strains DSY4759 and DSY4754 had a TI > 0.5 at 
pH 4.5 only, while DSY4758 exhibited a TI > 0.5 at pH 6 and 4.5. However, these strains exhibited TIs < 
0.5 at more alkaline pH (Figure 21A). 
Interestingly, and according to the work of Marr et al. [42], we were also able to observe an effect of 
the culture pH upon tolerance (Figure 21A). However, unlike their observations, the tolerance level of 
the tested strains seemed to increase at acidic pH. Indeed, most of the tested strains exhibited TIs 
between 0.2 and 0.5 at pH 4.5. Fifteen strains defined as wild type at pHs 7.5, 7 and 6 became tolerant 
(0.2 ≤ TI < 0.5) at pH 4.5 (Figure 21A and B). The pH-dependent effect of the pH on tolerance is 
consistent with previous publications [42], but is strain-dependent. Additional strains must be 
screened to confirm a more general effect of the pH on tolerance. 
53 
 
 
Figure 21: Screening of clinical isolates and TI determination.  TI level at different pH conditions of 28 C. albicans strains 
(Panel A). Red columns correspond to selected isolates (Panel B) used to calculate their growth rates and to correlate them 
with their respective TIs (Panel C). Horizontal dashed lines represent the TI = 0.2, 0.5 and 0.8 thresholds used to determine 
the tolerance profile to FLC. Each bar corresponds to the mean of at least 3 biological replicates. Correlation analysis was 
done using a two-tailed Pearson correlation (confidence interval =95 %).  
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To exclude that these differences in tolerance levels are not simply due to differential growth between 
strains and growth conditions, the growth rates of 10 selected isolates (Figure 21A, red columns and 
Figure 21B) were calculated for the exponential phase after 24 h in conditions similar to tolerance 
assays. The growth rate (h-1) of each strain was then compared to its respective TI in the same 
conditions (Figure 21C, right panel). No correlation could be observed between growth rates and TIs 
(R2 = 0.003; Figure 21C), indicating that a growth rate difference does not explain an increased 
tolerance to FLC. Thus, other yet unknown mechanisms must be involved in FLC tolerance. 
Now that the protocol for identification of tolerant strains was optimized, a larger isolate collection 
was tested. In collaboration with the group of C. d’Enfert (Pasteur Institute, Paris), a screen of 154 
clinical isolates (Supplementary File 1) was undertaken to determine TIs at pH 7.5, 7, 6 and 4.5 (Figure 
22). Data from our previous screen (strains SC5314, DSY4752, DSY4758, DSY4808 and DSY4809) were 
also included as controls for a total of 159 tested strains.  
From the available data we were able to identify 6 main categories of phenotypes, according to the 
level of tolerance of the tested strains (Figure 22). A first category contained susceptible strains with 
TIs between 0 and 0.2 at all tested pH levels (Figure 22, category 1). As defined earlier, the wild type 
isolates belong to this category of strains. A second category contained a few strains which were clearly 
resistant (TI > 0.8) in all conditions (Figure 22, category 6). Between these two categories, several 
profiles corresponding to tolerant stains were observed. Indeed, strains from category 2 (Figure 22) 
were clearly tolerant (0.2 < TI > 0.5), but only at acidic pH (pH 4.5). On the other side, strains from 
category 3 (Figure 22) were tolerant, but only at alkaline and neutral (for some) pH (pHs 7.5 and 7, 
respectively). Some strains were also tolerant, but at both alkaline and acidic pHs (Figure 22, category 
4). We were also able to identify strains which were tolerant at all (or almost all) tested pH levels. 
These strains also showed the highest tolerance of all tested strains (0.5 ≤ TI ≤ 0.8) and, some of them 
at a TI limit that could assign them as resistant (TI > 0.8) at some pH levels (Figure 22, category 5).  
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Figure 22: Tolerance screen of 159 C. albicans strain. The heatmap represents the mean TI values of at least biological 
duplicates. The “Susceptible” and “Non-susceptible” categories of the legend are based on the EUCAST definitions. Detailed 
results can be found in Supplementary File 1.  
 
Conclusions  
Up to now, most of C. albicans treatment failures with FLC were imputed to the development of 
resistance, however, in some cases, strains defined as susceptible were also observed to cause 
treatment failures. Tolerance, by its increased survival in the presence of drug, may also be involved 
in such failures. Up to now, tolerance mechanisms have been poorly studied and characterized and 
remain unclear. In this project, we aimed to better define tolerance to FLC and to identify tolerance 
mediators in C. albicans. Indeed, nowadays, tolerance is too often confounded with the description of 
drug resistance in published studies. In this study, we aimed first to establish a clearer definition of 
tolerance and, second, to propose a simple method for its quantification in order to compare the FLC 
tolerance between different strains. Microdilution susceptibility assays are widely used to assess 
antifungal susceptibility of fungi. The two standardized protocols (i.e. CLSI and EUCAST) slightly differ 
from each other, the main differences being the initial inoculum, the glucose concentration and the 
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endpoint readout in different types of microtiter plates. By adjusting the CLSI protocol to use the same 
readouts as the EUCAST protocol, we were able to compare the susceptibility of different C. albicans 
clinical isolates. However, to be able to quantify and compare the tolerance of the different isolates, 
we first proposed an adequate definition of tolerance for microdilution assays. Using the optical 
readout of the EUCAST protocol, we decided to consider as tolerant all strains that show a decreased 
growth in the presence of FLC, but with their residual growth ranging between 20 and 80 % of growth 
as compared to drug-free control after 24 h incubation and at drug concentrations above the FLC CBP 
(4 µg/ml). This measure distinguishes these isolates from those that are true susceptible (i.e. wild type 
isolates) and true resistant ones. Isolates exhibiting residual growth above 50 % should be further 
analyzed for the occurrence of known FLC resistance mechanisms. To be able to quantify FLC tolerance 
and compare strains, we established a tolerance index (TI) which reflects the relative growth of isolates 
at 8 µg/ml FLC (TI = % of growth/100). Among strains considered as tolerant (0.2 ≤ TI ≤ 0.8), further 
discrimination was made based on the work of Rueda et al. [55], who proposed categories of tolerance 
according to EUCAST and thus avoiding all strains with a TI ≥ 0.5 which were considered as resistant. 
Here we proposed extended thresholds, considering all strains affected by FLC as tolerant, and 
different levels of tolerance that included low trailers (0.2 ≤ TI < 0.25), medium trailers (0.25 ≤ TI < 0.5) 
and heavy trailers (0.5 ≤ TI ≤ 0.8). 
Using this new TI to determine which of the CLSI or the EUCAST conditions were optimal to assess 
tolerance in clinical isolates, we showed that no major differences between these methods could be 
observed after 24 h incubation. The CLSI culture conditions seemed however to slightly increase 
tolerance, but not significantly. Thus, to be as close as possible to the standardized protocols (i.e. 
without modifications), the EUCAST protocol was chosen as the standard condition for further 
tolerance assays. The selection of a single dilution to assess the level of tolerance (8 µg/ml) allowed us 
to develop a rapid and convenient method to perform a large screening of tolerance by performing 
assays at this single concentration (“Tolerance assay”). This versatile method can easily be adapted to 
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other Candida spp. as well as other antifungal agents. It can also be used for the screening of synergy 
between different drugs.  
Using this newly established protocol, we first performed a screening of 28 clinical C. albicans isolates 
(already characterized as susceptible or resistant) to identify tolerant strains and to characterize the 
effect of culture pH on residual growth. This screening allowed the identification of 7 strains out of 28 
that were tolerant at every pH conditions tested. The tolerance level of the other strains was 
influenced by the tested pH. Indeed, 15 strains defined as WT (TI < 0.2) at pH 7.5, 7 and 6 became 
tolerant at pH 4.5 (TI ≥ 0.2). We rejected the role of altered growth patterns in this increase of tolerance 
by estimating the correlation between the TI and the growth rate of the corresponding isolates. This 
pH effect upon tolerance was also observed in a second and larger screen of 159 C. albicans strains 
where different tolerance categories could be established. Indeed, of the 159 tested strains, 73 were 
considered as WT (TI < 0.2) at all tested pHs. Twenty-four isolates showed a tolerance between TI = 
0.2 and 0.5 at pH 7.5, against 22 isolates tolerant at pH 4.5 only. A few strains (10) were tolerant at 
both pH 7.5 and 4.5. Only 2 strains were tolerant at all tested pHs, but with a high tolerance level (0.5 
≤ TI ≤ 0.8). Isolate DSY4758 was also tolerant at all pHs except at pH 4.5 where it was borderline with 
the upper threshold of tolerance (TI = 0.81). Interestingly, out of the 9 isolates which were considered 
as resistant to FLC (TI > 0.8) at one or more pH, 6 were known to harbor amino acid substitutions linked 
to resistance in ERG11, TAC1 and UPC2 (Table 9), and 5 were resistant at all pH values. The TI threshold 
that was chosen here for assigning strains as resistant appeared therefore validated since tested 
resistant strains harbored known genetic alterations associated with resistance mechanisms. So far, 
our observations highlighted a strain-dependent effect of pH upon FLC tolerance. The tendency of 
decreasing tolerance with decreasing pH was reported earlier by Marr et al. [42] and more recently by 
Rosenberg et al. [51]. It is not clear as to why our results differ from these published results. The 
methods used in these studies referred to minimal culture medium and to agar diffusion assays, 
respectively. Thus, one might argue that these assay conditions could have impacted on the obtained 
results. Since different isolates were used in these different studies including ours, it is difficult to 
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identity the cause of such disagreements. Another study published by Luna-Tapia et al. in which a 
VSP21 mutant exhibited high tolerance to FLC assayed the mutant at both pH 7 and pH 3 [46]. In this 
work, a CLSI protocol was used which therefore was more closely related to the conditions tested here. 
Luna-Tapia et al. demonstrated that tolerance of the VSP21 mutant was decreased at pH 3 compared 
to neutral conditions [46]. While these data support pH dependency on FLC tolerance, the results used 
a specific mutant which might trigger pH-specific response and might differ from clinical wild type 
isolates. Thus, pH dependency of FLC tolerance remains controversial.  
To conclude, the different screens performed in this study showed the effectiveness of our tolerance 
assay protocol which, in addition with the establishment of the TI, offers an easy and rapid way to 
identify tolerant isolates for further study and which can be implemented as a routine protocol in most 
laboratories. This tolerance assay can also be easily modified and adapted to other antifungals and 
fungal pathogens.  
 
Table 9: Amino acid substitutions leading to azole-resistance in CEC strains resistant to FLC. 
1Amino acid substitutions previously involved in azole resistance or described as a gain-of-function mutation  
2New mutations 
3Not Applicable 
hHeterozygous mutation 
 
  
Lab ID CEC ID 
FLC MIC 
(µg/ml) 
Amino acid substitutions 
Erg11 Tac1 Upc2 
DSY5096 CEC718 >256 Y132H1, P236S2, S405F A736T G657D 
NA3 CEC4509 >256 R157K H263Y, H838Y, C858Y NA 
NA CEC4503 >256 R157K H263Y, H838Y, C858Y NA 
NA CEC4520 >256 Y132H, G45OE H263Y, P971S NA 
NA CEC4525 >256 Y64H, T123I, Y132H, R467I H263Y, P971S D654Nh 
NA CEC4528 8 G448E A737T, N823K, C858Y  NA 
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Part two: Identification and characterization of the transcription factors CRZ1 
and GZF3 as mediators of tolerance to fluconazole in C. albicans. 
Abstract 
 
Candida albicans remains a challenging human fungal pathogen, mainly due to the limited treatment 
options available and the acquisition of resistance leading to treatment failures. Resistance 
mechanisms to azoles, mainly fluconazole (FLC), the most widely used antifungal have been extensively 
studied in the past decades. However, another phenomenon, called antifungal tolerance, 
characterized by the ability to withstand growth in the presence of high drug concentrations without 
acquiring resistance mutations may also be involved.  
Little is known about mechanisms behind FLC tolerance but identifying mediators of tolerance might 
lead to the development of new treatment strategies by increasing fluconazole efficiency. In this study 
we proposed an approach based on the use of a collection of 579 strains, each overexpressing a specific 
gene and possessing a distinct barcode allowing its identification by sequencing. By pooling the whole 
collection and by maintaining the isolates under strong FLC pressure for several days, we were able to 
identify 79 strains which were enriched and 39 which were depleted in the pool in the presence of the 
drug. Out of these, two transcription factors CRZ1 and GZF3 were further confirmed to be positive 
mediators of FLC tolerance and their role was confirmed by overexpression of each gene in deletion 
mutants. We show here that GZF3 acts probably downstream of CRZ1. Each of these factors were 
deleted in a set of clinical strains exhibiting FLC tolerance. Our results show that CRZ1 plays a critical 
role in FLC tolerance in these strains while GZF3 seems to be less important.  
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Introduction 
Candida albicans is one of the most commonly isolated pathogens in intensive care unit worldwide 
and remains a challenging organism despite the different treatment strategies available [1, 3]. The high 
degree of treatment failure can partially be explained by the limited number of antifungal classes 
available and the acquisition of resistance upon treatment [19, 21]. In the past decades, the resistance 
mechanisms to fluconazole (FLC), the most widely used antifungal drug, have been extensively studied 
and are well understood [32]. Unfortunately, resistance is not the only factor leading to treatment 
failure and it has been proposed that strains with an increased tolerance to the drug might also 
contribute to this effect. These strains, known as tolerant strains, are characterized by an increased 
residual growth at drug concentrations above their minimum inhibitory concentration (MIC) but 
without acquiring any known antifungal resistance mechanisms. Tolerance to FLC is thought to be an 
appropriate condition for the acquisition of resistance mutations and/or to be a source of reinfection 
upon arrest of the treatment [20]. Unlike resistance, mechanisms behind tolerance to FLC are still 
understudied and only a few potential mechanisms have been reported, involving majors stress 
response pathways (through HSP90 and calcineurin) [21, 45, 46], response to pH (through RIM101) 
[49] and membrane composition modifications (VSP21, FEN1/FEN12, IPT1) [46]. Even if it remains 
unclear how these mechanisms result in tolerance, their mediators may be used as potential drug 
targets to increase FLC efficacy [20]. It is thus important to identify new mediators of tolerance. 
In order to better understand tolerance and to identify additional mechanisms, we used here a novel 
approach based on a systematic gene overexpression (OE) strategy. Gene OE may lead to the 
identification of genes potentially involved in tolerance to FLC. Using a collection of 579 strains under 
doxycycline (Dox)- dependent OE, with each strain tagged with a specific DNA barcode (BC), we were 
able to identify and characterize two putative positive mediators of tolerance consisting of the 
transcription factors CRZ1 and GZF3. In addition to this positive selection of tolerance the OE strategy 
helped to identify regulators that were decreasing tolerance, so-called negative tolerance regulators. 
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Material and methods 
Strains used in this study 
The collection of 579 Tet-inducible overexpression barcoded C. albicans strains used in this study was 
kindly provided by Pr. Christophe D’Enfert (Pasteur Institute, Paris, France) (Table 11, Supplementary 
file 2). Each strain of the collection overexpresses a specific gene (or gene of interest, GOI) encoding 
transcription factors, protein kinases, protein phosphatases, proteins related to DNA replication, 
recombination and repair, predicted cell surface proteins, or others, under the control of tetracycline. 
The collection was constructed as described by Chauvel et al. [56]. 
To test optimal overexpression culture condition, the strain CEC3083, overexpressing the Gaussia 
princeps luciferase (gLUC) was used. This strain was built in parallel to the OE collection and also 
provided by Pr. C. D’Enfert (Table 11) [56].  
The clinical C. albicans isolates (Table 10) used for the overexpression of the candidate negative 
regulators of tolerance (Table 12, Supplementary Table 1) and for the deletion of the candidate 
positive mediators (Table 14) were selected from their tolerance profile and were part of D. Sanglard 
laboratory collection. 
The CRZ1 and GZF3 deletion mutants used for the identification of the role of both gene upon tolerance 
and to build the double crz1Δ/Δ, gzf3Δ/Δ mutant originated from the Homann’s transcription factor 
deletion library and are listed in Table 13 [57]. 
The wild type (WT) strain used in the different experiments was the strain SC5314. In other 
experiments, the control strains were the parental clinical isolates used to construct the OE and 
deletion strains or the WT strain of the Homman’s collection (Table 10, Table 13) [53, 54]. 
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Table 10: Reference strains and clinical isolates used in this study. 
Lab ID Alternative ID Type of isolate Comment Genotype Reference 
DSY386 SC5314 NA1 Wild type laboratory strain Reference strain [52] 
DSY2904 BWP17 NA SC5314-derived strain ura3Δ::λimm434/ura3Δ::λimm434,iro1∆::λimm434/iro1∆::λimm434, 
his1∆::hisG/his1∆::hisG, arg4∆::hisG/arg4∆::hisG 
[58] 
DSY3291 SN152 NA SC5314-derived strain URA3/ura3Δ::λimm434, IRO1/iro1Δ::λimm434, his1Δ::hisG/his1Δ::hisG, 
arg4Δ::dpl200/arg4Δ::dpl200, leu2Δ::dpl200/leu2Δ::dpl200 
[59] 
DSY2110 34-028-117 Blood Low-High phenotype2  Unknown [42] 
DSY4454 0526-6020 Blood Isolated from endocarditis 
patient (2005)3 
Unknown This study 
DSY4588 13 0420 0673 Blood Isolated from endocarditis 
patient (2013)3 
Unknown This study 
DSY4754 SSI 4622 NA Weak Trailing4 Unknown [53] 
1Not available 
2As described by Marr et al. [42] 
3Isolates were isolated from the same patient 
4Information provided by M.C. Arendrup 
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Table 11: Parental strains of the OE collection and derivative. The collection was built by transforming the CEC2907 strain with a collection of CIp10-PTET-GOI plasmids and have a genotype derived from CEC3083 
[56]. The detailed collection can be found in Supplementary File 2.  
Lab ID Alternative ID Parental strain Transformed plasmid Genotype Reference 
NA1 CEC161 BWP17 NA ura3Δ::λimm434/ura3Δ::λimm434, iro1∆::λimm434/iro1∆::λimm434, 
his1Δ::hisG/HIS1, arg4Δ::hisG/ARG4 
[60] 
DSY4993 CEC2907 CEC161 pNIMX ura3Δ::λimm434/ura3Δ::λimm434, iro1∆::λimm434/iro1∆::λimm434, 
his1Δ::hisG/HIS1, arg4Δ::hisG/ARG4, ADH1/adh1::PTDH3-cartTA::SAT1 
[56] 
DSY4737 CEC3083 CEC2907 CIp10-PTET-gLUC59 ura3Δ::λimm434/ura3Δ::λimm434, iro1∆::λimm434/iro1∆::λimm434, 
his1Δ::hisG/HIS1, arg4Δ::hisG/ARG4, ADH1/adh1::PTDH3-cartTA::SAT1, 
RPS1/RPS1::CIp10-PTET-gLUC59 
[56] 
NA CPY2 CEC2907 pDS1945 ura3Δ::λimm434/ura3Δ::λimm434, iro1∆::λimm434/iro1∆::λimm434, 
his1Δ::hisG/HIS1, arg4Δ::hisG/ARG4, ADH1/adh1::PTDH3-cartTA::SAT1, 
RPS1/RPS1::CIp10-PTET-GTW 
This study 
1Not Available 
 
Table 12: Clinical isolates and derivatives used for the OE of putative negative regulators of tolerance.  
Alternative ID Parental strain Transformed plasmid Genotype Reference 
CPY21 DSY4588 pSFSUI ura3Δ::FRT/ura3Δ::FRT This study 
CPY23 DSY4454 pSFSUI ura3Δ::FRT/ura3Δ::FRT This study 
CPY25 SC5314 pSFSUI ura3Δ::FRT/ura3Δ::FRT This study 
CPY27 DSY4754 pSFSUI ura3Δ::FRT/ura3Δ::FRT This study 
CPY29 DSY2110 pSFSUI ura3Δ::FRT/ura3Δ::FRT This study 
CPY421 CPY29 pNIMX ura3Δ::FRT/ura3Δ::FRT, ADH1/adh1::PTDH3-cartTA::SAT1 This study 
CPY431 CPY23 pNIMX ura3Δ::FRT/ura3Δ::FRT, ADH1/adh1::PTDH3-cartTA::SAT1 This study 
CPY441 CPY21 pNIMX ura3Δ::FRT/ura3Δ::FRT, ADH1/adh1::PTDH3-cartTA::SAT1 This study 
CPY451 CPY27 pNIMX ura3Δ::FRT/ura3Δ::FRT, ADH1/adh1::PTDH3-cartTA::SAT1 This study 
 1The derivative strains transformed with the CIp10-PTET-GOI plasmids are detailed in Supplementary Table 1 
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Table 13: CRZ1 and GZF3 mutant strains used for the OE of either CRZ1 or GZF3. 
Lab ID Alternative ID 
Parental 
strain 
Transformed 
plasmid 
Genotype1 Reference 
NA2 "Wild type"3 SN152 NA URA3/ura3∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2 [57] 
NA TF068 SN152 NA URA3/ura3∆, IRO1/iro1∆, his1∆/∆, arg4∆/∆, leu2∆/∆, crz1∆::CdLEU2/crz1∆::CmHIS14 [57] 
NA TF101 SN152 NA URA3/ura3∆, IRO1/iro1∆, his1∆/∆, arg4∆/∆, leu2∆/∆, gzf3∆::CdLEU2/gzf3∆::CmHIS1 [57] 
DSY5253 EDY16-3 TF068 pSFSU1 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1 This study 
DSY5254 EDY17-3 TF101 pSFSU1 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, gzf3∆::CdLEU2/gzf3∆::CmHIS1 This study 
DSY5270 EDY35 "Wild type"3 pSFSU1 ura3∆/∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2 This study 
DSY5255 EDY20-3 EDY16-3 pNIMX ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1 
This study 
DSY5256 EDY21-1 EDY17-3 pNIMX ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, gzf3∆::CdLEU2/gzf3∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1 
This study 
DSY5273 EDY38 EDY35 pNIMX ura3∆/∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1 
This study 
DSY5274 EDY39 EDY38 pDS1945 ura3∆/∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GTW 
This study 
DSY5275 EDY40 EDY38 pDS1997 ura3∆/∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GZF3 
This study 
DSY5276 EDY41 EDY38 pDS1998 ura3∆/∆, IRO1/iro1∆, his1Δ/his1Δ::HIS1, arg4Δ/Δ, leu2Δ/leu2Δ::LEU2, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-CRZ1 
This study 
DSY5271 EDY36 EDY20-3 pDS1945 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GTW 
This study 
DSY5257 EDY22 EDY20-3 pDS1997 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GZF3 
This study 
DSY5259 EDY24 EDY20-3 pDS1998 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-CRZ1 
This study 
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DSY5272 EDY37 EDY21-1 pDS1945 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, gzf3∆::CdLEU2/gzf3∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GTW 
This study 
DSY5260 EDY25 EDY21-1 pDS1997 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, gzf3∆::CdLEU2/gzf3∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GZF3 
This study 
DSY5258 EDY23 EDY21-1 pDS1998 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, gzf3∆::CdLEU2/gzf3∆::CmHIS1, 
ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-CRZ1 
This study 
DSY5263 EDY28 EDY16-3 pED20-7 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
gzf3∆/∆ 
This study 
DSY5265 EDY30 EDY28 pNIMX ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
gzf3∆/∆, ADH1/adh1Δ::PTDH3-cartTA::SAT1 
This study 
DSY5269 EDY34 EDY30 pDS1945 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
gzf3∆/∆, ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GTW 
This study 
DSY5267 EDY32 EDY30 pDS1997 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
gzf3∆/∆, ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-GZF3 
This study 
DSY5266 EDY31 EDY30 pDS1998 ura3∆/∆, IRO1/iro1∆, his1Δ/Δ, arg4Δ/Δ, leu2Δ/Δ, crz1∆::CdLEU2/crz1∆::CmHIS1, 
gzf3∆/∆, ADH1/adh1Δ::PTDH3-cartTA::SAT1, RPS1/RPS1::CIp10-PTET-CRZ1 
This study 
1The complete genotype can be found in Supplementary Table 2 
2Not Available  
3Refers to Homann’s “Wild type” strain [57] 
4Cd = C. dubliniensis, Cm = C. maltosa 
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Table 14: CRZ1 and GZF3 deletion mutants in tolerant clinical isolates. 
Lab ID Alternative ID Parental strain Transformed plasmid Genotype Reference 
DSY5208 NA1 DSY2110 pED19-2 CRZ1/crz1∆::FRT This study 
DSY5227 NA DSY5208 pED19-2 crz1∆::FRT/crz1∆::FRT This study 
NA LBY62 DSY5227 pLB1 crz1∆/crz1∆::FRT::CRZ1 This study 
DSY5210 NA DSY2110 pED20-7 GZF3/gzf3∆::FRT This study 
DSY5230 NA DSY5210 pED20-7 gzf3∆::FRT/gzf3∆::FRT This study 
DSY52791 NA DSY5230 pET3 gzf3∆::FRT/gzf3∆::GZF3 This study 
DSY5235 NA DSY4454 pED19-2 CRZ1/crz1∆::FRT This study 
DSY5236 NA DSY5235 pED19-2 crz1∆::FRT/crz1∆::FRT This study 
NA LBY82 DSY5236 pLB1 crz1∆/crz1∆::FRT::CRZ1 This study 
DSY5225 NA DSY4457 pED20-7 GZF3/gzf3∆::FRT This study 
DSY5231 NA DSY5225 pED20-7 gzf3∆::FRT/gzf3∆::FRT This study 
DSY52801 NA DSY5231 pET3 gzf3∆::FRT/gzf3∆::GZF3 This study 
DSY5209 NA DSY4588 pED19-2 CRZ1/crz1∆::FRT This study 
DSY5229 NA DSY5209 pED19-2 crz1∆::FRT/crz1∆::FRT This study 
NA LBY72 DSY5229 pLB1 crz1∆/crz1∆::FRT::CRZ1 This study 
DSY5217 NA DSY4588 pED20-7 GZF3/gzf3∆::FRT This study 
DSY5252 NA DSY5217 pET2-1 gzf3∆::FRT/gzf3∆::FRT This study 
DSY52771 NA DSY5252 pET3 gzf3∆::FRT/gzf3∆::GZF3 This study 
DSY5224 NA DSY4754 pED19-2 CRZ1/crz1∆::FRT This study 
DSY5237 NA DSY5224 pED19-2 crz1∆::FRT/crz1∆::FRT This study 
NA LBY92 DSY5237 pLB1 crz1∆/crz1∆::FRT::CRZ1 This study 
DSY5218 NA DSY4754 pED20-7 GZF3/gzf3∆::FRT This study 
DSY5239 NA DSY5218 pED20-7 gzf3∆::FRT/gzf3∆::FRT This study 
DSY52781 NA DSY5239 pET3 gzf3∆::FRT/gzf3∆::GZF3 This study 
1Not Available 
2Revertant were built by reinsertion of the SC5314 allele at the deleted locus   
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Media and growth conditions 
All strains were stored in 20 % glycerol at -80°C and routinely grown at 30°C under constant shaking 
(220 rpm) in complete Yeast Extract Peptone Dextrose (YEPD) medium (1 % Bacto peptone, Difco 
Laboratories, Basel, Switzerland), 0.5 % Yeast extract (Difco Laboratories, Basel, Switzerland) and 2 % 
glucose (Fluka, Buchs, Switzerland). When grown on solid YEPD plates (YEPDA), 2 % agar (Difco 
Laboratories, Basel, Switzerland) was added and plates were incubated at 35°C.  
For FLC susceptibility and tolerance assays, strains were grown in RPMI1640 medium (Sigma-Aldrich) 
complemented with 2 % glucose (Fluka, Buchs, Switzerland) and buffered with 0.33 M 
morpholinepropanesulfonic acid (MOPS) according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) recommendations [38]. The pH was adjusted to pH 7.5, pH 7, pH 6 and 
pH 4.5 respectively, using NaOH or HCl. Double strength stock solutions were prepared as 
recommended by EUCAST. RPMI was supplemented or not with FLC (Toronto Research Chemicals), 
Doxycycline (Dox) (Sigma-Aldrich) and iron (FeCl3) to compensate iron chelation by the Dox when 
necessary [61]. For luciferase assays, water-soluble coelenterazine (CTZ, Nanolight Technologies, USA) 
was added prior to measurement. 
Primers and plasmids 
All primers used in this study are listed in Supplementary Table 4 and were synthesized and delivered 
by Kaneka Eurogentec S.A.. Plasmids used in this study are listed in Supplementary Table 3. The maps 
of each plasmid can be found in Supplementary Figure 1. The insertion of each plasmid and gene 
deletion were verified by PCR as stated in Supplementary Table 4. All reactions were amplified as 
follows: a first cycle with 4 min of denaturation at 94°C, 1 min of annealing (temperatures are indicated 
in Supplementary Table 4) and an elongation step at 72°C (elongation times are indicated in 
Supplementary Table 4). This first cycle was followed by 30 cycles in the same conditions. Finally, a 
final elongation step at 72°C for 10 min was performed. 
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Escherichia coli DH5α was used as a host for plasmid construction and propagation. Bacteria were 
grown in Luria-Bertani (LB) broth or LB 2 % agar plates, supplemented with 100 µg/ml ampicillin 
(AppliChem) or 34 µg/ml chloramphenicol (Fluka, Buchs, Switzerland) when required and incubated at 
37°C. 
Yeast transformation 
Yeasts were transformed by a lithium-acetate procedure with slight modifications as previously 
described [62]. Nourseothricin resistant (NourR) transformants were selected on YEPD agar plates 
complemented with 200 μg/ml nourseothricin (Werner Bioagents, Germany). For selection of Ura+ 
transformants, the cells were resuspended in 100 µl Tris-EDTA (TE) buffer (0.1 M Tris, pH 7.5, 10 mM 
EDTA, pH 8) and plated on Yeast Nitrogen Base (YNB, Difco Laboratories, Basel, Switzerland) minimal 
medium complemented with Complete Supplemented Medium without uracil (CSM-URA, MP 
Biomedicals, LLC, CA, USA) (0.67 % YNB, 2 % glucose, 0.79 g/L CSM-URA, 2 % agar). 
Construction of Deletion Mutants and Revertant Strains  
The clinical isolates DSY2110, DSY4454, DSY4754 and DSY4588 as well as the “WT”, the crz1 ∆/∆ and 
the gzf3∆/∆ strains from the Homann’s collection [57] were used to delete: (i) URA3, in order to 
transform the strains with the OE system [56] and (ii) either CRZ1, GZF3 or both to assess their role in 
FLC tolerance. All gene deletions were performed by insertion of the PCR amplified 5’ and 3’ 
untranslated regions (UTR, 500bp) into the SAT1-flipper plasmid pSFS2A [63]. Details for the resulting 
plasmids could be found in Supplementary Table 3. pSFS2A contains the SAT1-flipping cassette which 
replace the target gene by the nourseothricin resistance gene SAT1 under the control of the ACT1 
promoter. It also introduces a flippase (FLP) under the control of a maltose-inducible promoter (MAL2). 
The whole deletion cassette is flanked by two flippase recognition target (FRT) sequences, allowing the 
flipping of the deletion cassette and the recovery of the SAT1 marker which can then be reused in the 
deleted strain. To obtain homozygous mutants, the deletion plasmids were thus inserted twice.  
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URA3 was deleted using the plasmid pSFSU1 (Supplementary Table 3, Supplementary Figure 1). Due 
to technical issues with some clones, the second allele was deleted by plating the heterozygous 
mutants on 5-fluoro-orotic acid (5-FOA) to force deletion of the second allele as already described [64]. 
For deletion of CRZ1 and GZF3, the plasmids pED19-2, pED20-7 and pET2-1 were used, respectively 
(Supplementary Table 3, Supplementary figure 1). The plasmid pET2-1 was only used to delete the 
second GZF3 allele of DSY5217 (which failed with pED20-7), resulting in strain DSY5252 (Table 13) 
All plasmids were transformed into their target strains after digestion by KpnI and SacI to isolate the 
SAT1 flipper-cassette. The transformants were plated and selected on YEPD plates containing 200 
µg/ml nourseothricin. The cassette was flipped-out by picking singles colonies and incubating them 
overnight (o/n) in YEP maltose (2 % maltose instead of glucose) and nourseothricin-sensitive colonies 
were recovered by plating on YEPD plates complemented with 15 µg/ml nourseothricin. At this 
concentration, susceptible colonies are still able to grow but more slowly than resistant ones, thus 
yielding smaller colonies which can be picked up, resuspended in TE buffer and plated on both YEPD 
or YEPD-nourseothricin (100 µg/ml) to confirm their susceptible phenotype and thus confirming the 
flipping-out of the cassette and deletion of the allele. The same procedure was used for deletion of the 
second allele. 
To verify the gene deletions of the selected isolates, the presence of the wild type allele was verified 
by PCR using specific primers for each allele (Supplementary Table 4) after each recovery of the SAT1 
flipping cassette.  
To construct revertant strains in which CRZ1 and GZF3 were reintroduced in the background of deletion 
mutants (Table 14), the wild type alleles from SC5314 and corresponding 5’- and 3’- UTR (± 500 bp) 
were reinserted by replacing the 5’-UTR of the deletion plasmid by the CRZ1 and GZF3 amplified genes 
(Supplementary Figure 1), resulting in plasmids pLB1 and pET3, respectively (Supplementary Table 3). 
The wild type alleles were then reintroduced in addition to the SAT1-flipper cassette into the 
homozygous mutants by KpnI and SacI digestion of the plasmids (Supplementary Figure 1).  
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Determination of optimal Dox concentration for OE 
To optimize the culture conditions for overexpression with the OE collection, the ability of Dox to 
induce OE was evaluated using the gLUC-OE strain CEC3083 (Table 11). Briefly, individual colonies were 
grown o/n in liquid YEPD medium at 30°C under constant shaking. The culture was then centrifuged (5 
min, 4600 rpm, 4°C) and the cell pellet washed twice with phosphate buffered saline (PBS). Cells were 
then resuspended at 7.5 x 106 cells/ml in RPMI medium at pHs 7.5, 7, 6 and 4.5. Each inoculum was 
split in five subcultures and complemented with 100, 50, 10 and 2 and 0 µg/ml Dox, respectively. 
Cultures were then incubated for 24 h at 30°C under constant shaking. The next day, 50 µl of each 
culture were transferred into the wells of a flat-bottom, half-area, black microtiter plate (COSTAR). The 
plates were placed in a luminometer (FLUOstar Omega, BMG Labtech) and 50 µl of 2.5 µM water 
soluble CTZ (Nanolight Technologies, USA) injected prior to the measurement of luciferase activity of 
each well. The settings of the luminometer were the following: Top optic; Emission filter: Lens; Gain: 
3600; Injection volume: 50 µl, Injection speed: 400 µl/s; Shaking: 200 rpm, double orbital, 3 s before 
reading; Measurement start time: 4.4 s, Measurement interval time: 1.0 s; Incubation: 30°C. In addition 
to the biological replicate, each inoculum was tested as technical duplicate on the same plate.  
Iron compensation of the FLC-Dox synergistic effect 
Due to the known synergistic effect of Dox with FLC [64], cell viability in the presence of both FLC and 
Dox in the presence and absence of FeCl3 was assessed using serial dilution spotting assay on YEPD 
agar plates. Briefly, individual colonies of the strain SC5314 were grown o/n at 30°C under constant 
shaking in YEPD medium. The culture was then centrifuged (5 min, 4600 rpm, 4°C) and the cell pellet 
washed twice with PBS. Cells were then resuspended at 2.5 x 105 cells/ml in RPMI medium at pH 6 and 
split into six subcultures complemented with: (i) growth control, (ii) 32 µg/ml FLC, (iii) 10 or 100 µg/ml 
Dox only, (iv) 1mM FeCl3 only, (v) 32 µg/ml FLC and 10 or 100 µg/ml Dox , (vi) 32 µg/ml FLC and 10 or 
100 µg/ml Dox and 1mM FeCl3. Two hundred microliters of each condition were transferred in the first 
column of a 96-well plate (COSTAR), adding a blank control with only RPMI medium, and the plate was 
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incubated at 35°C for 24 h. The next day, four 10-fold serial dilutions were performed for each 
subculture and 5 µl of each well were spotted onto YEPD plates and incubated for 24 h at 35°C. 
FLC susceptibility and tolerance assays 
All FLC susceptibility assays were performed according to the Method for the determination of broth 
dilution minimum Inhibitory concentrations of antifungal agents for yeasts [38] as recommended by 
the EUCAST, with slight modifications when necessary. The minimal inhibitory concentration (MIC) was 
defined as the concentration of drug inhibiting at least 50 % of fungal growth as compared to a drug 
free control. Strains with a MIC below 4 µg/ml FLC were defined as susceptible as described by EUCAST 
[38]. Susceptibility assays were performed in RPMI at pHs 7.5, 7, 6 or 4.5 with additions of Dox and 
FeCl3 when necessary, as stated in the corresponding experiments. Tolerance assays were performed 
in the same conditions but using only a fixed FLC concentration as specified in the corresponding 
experiment. 
Briefly, individual colonies of each tested strain were grown overnight in YEPD medium at 30°C under 
constant shaking. Cultures were centrifuged (5 min, 4600 rpm, 4°C) and washed twice with PBS. Cell 
concentration was estimated by spectrophotometry (OD540 nm) and cells were resuspended at 5 x 105 
cells/ml in distilled water. Then, 100 µl of this suspension were transferred into the wells of 96-well 
plates (Costar) containing 100 µl of 2x RPMI complemented with 64-0 µg/ml FLC in two-fold dilutions 
or fixed FLC concentrations (16 µg/ml), to obtain a final cell concentration of 2.5 x 105 cells/ml and FLC 
concentration ranging from 32 to 0 µg/ml (8 µg/ml for tolerance assays) per well. Plates were 
incubated at 35°C without shaking for 24 h. Cell growth in each well was measured by 
spectrophotometry (OD570 nm) using a microplate reader (Multiskan Ascent) and compared to the drug 
free control after correction with a blank control. From these susceptibility curves, both the MIC and 
the tolerance index (TI), corresponding to the relative growth (% GC) at 8 µg/ml FLC divided by a factor 
100 (TI = % GC/100) were determined for strain comparisons. The TI is used to determine the level of 
tolerance and was already described earlier (Delarze et al., unpublished, Thesis part 1).  
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To assess the tolerance level of every single strain of the OE collection and to remain in the same 
conditions compared to the enrichment assay, tolerance assays of the collection were performed at a 
final concentration of 32 µg/ml FLC instead of 8 µg/ml.  
Susceptible strains (i.e. MIC < 4 µg/ml FLC) with a TI between 0.2 and 0.8 were considered as tolerant 
while strains with TI < 0.2 were considered as susceptible (i.e. exhibiting a WT tolerance profile) and 
the ones with TI > 0.8 were considered as resistant, as described earlier (Delarze et al., unpublished, 
Thesis part 1). 
Calcium induction of tolerance 
In order to rise the basal tolerance level and test our negative regulators candidate genes, calcium 
(CaCl2) was added in the RPMI medium of the tolerance assays. First, serial 2-fold dilutions of CaCl2 
(from 100 to 0 µg/ml) were tested to determine the best CaCl2 concentration for our assay. A fixed 
concentration of 50 µg/ml CaCl2 was chosen to determine the tolerance profile of our candidate genes 
in the presence of FLC (8 µg/ml), Dox (5 µg/ml) and FeCl3 (0.05 mM).  
Pool enrichment in tolerant/resistant strains 
In order to enrich the pooled OE collection in FLC tolerant/resistant isolates, strains were grown in 
RPMI 2 % glucose at pH 6 in the presence of 1mM FeCl3 and with or without 100 µg/ml Dox and 32 
µg/ml FLC. To be as close as possible to our drug susceptibility assay conditions (EUCAST 
recommendations), cells were cultured in 96-well plates with each well containing 200 µl of cell 
suspension in RPMI. Each condition represents 20 ml of culture.  
Briefly, a pool of the 579-strain collection was incubated o/n in YEPD at 35°C under constant shaking. 
The next day, the cells were centrifuged (5 min, 4600 rpm, 4°C) and washed twice with PBS. The cell 
pellet was resuspended at 107 cells/ml in RPMI pH 6 and this inoculum was split in four 20 ml 
subcultures. The remainders of the overnight culture were centrifuged and the pellet frozen (-20°C) 
prior to DNA extraction after the enrichment to estimate the initial population of our pool (Day 0). The 
four subcultures were respectively complemented with: (i) 32 µg/ml FLC, (ii) 100 µg/ml Dox, (iii) 32 
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µg/ml FLC and 100 µg/ml Dox. The last subculture was the growth control in which nor FLC or Dox were 
added. Each subculture was also complemented with 1 mM FeCl3 to avoid the synergistic FLC-Dox 
effect. Two hundred microliter of these subcultures were then transferred in each well of 96-well 
plates, leaving two wells as contamination control. The plates were then incubated 24 h at 35°C.  
Every day for the next 5 days, cells from the overnight culture in 96-well plates were recovered using 
a multi-channel pipette and recovered into a 50 ml tube. The cultures were then processed as at Day 
0. First, the cells were centrifuged (5 min, 4600 rpm, 4°C) and washed twice with PBS and resuspended 
at 107 cells/ml in 20 ml fresh RPMI in four new 50 ml tubes prior to addition of FLC, Dox and FeCl3. The 
rest of the overnight cultures are then centrifuged again and frozen (-20°C) until DNA extraction.  
Genomic DNA extraction 
Genomic DNA was prepared by spheroplasting from frozen cell pellets. Briefly, thawed cells were 
washed twice in TE buffer and resuspended in 5 ml PRO Buffer solution (EDTA 25 mM, Tris pH 7.5, 1 M 
and Sorbitol 1 M), 50 µl of 100T Zymolyase (10 mg/ml, Seikagaku, Tokyo, Japan) and 5 µl β-
mercaptoethanol (Applichem). After 15 min incubation at 37°C, cells were centrifuged (4600 rpm, 5 
min, room temperature (RT)) and pellets resuspended in 2 ml Lysis buffer (EDTA 0.1 M, Tris 0.1 M pH 
7.5, and SDS 0.5 %) and 50 µg/ml Proteinase K (Roche Diagnostics). Cells were incubated for 30 min at 
65°C. Then 500 µl K-acetate (4 M) were added and cells were incubated for 10 min on ice. Cells were 
then centrifuged (15 min, 4600 rpm, 4°C), the supernatant was transferred in 14 ml tubes and nucleic 
acids were precipitated with 5 ml 100 % EtOH. Samples were centrifuged (10 min, 4600 rpm, 4°C), the 
supernatant discarded, and the pellet resuspended in 500 µl TE buffer complemented with 100 µg/ml 
RNase A. Samples were incubated 15 min at 37°C and DNA was precipitated by adding 500 µl 
isopropanol. Samples were transferred into 1.5 ml tubes and centrifuged (15000 rpm, 1 min, RT). 
Supernatants were discarded and pellets washed once with ethanol 70 %. Samples were air-dried and 
the pellets resuspended in 300 µl TE buffer. DNA concentration at 260 nm was measured using a 
NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific) and volumes adjusted with TE buffer 
to obtain a final DNA concentration of 5 ng/µl. 
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Amplification of the barcodes 
In order to estimate the strain presence in the different populations, the BC of each cell was amplified 
by PCR to be sequenced following the 16S Metagenomic Sequencing Library Preparation protocol 
(Illumina) recommendations to add so-called Illumina overhang sequences to the amplicons 
(Supplementary Table 4). However, to avoid mistakes during the sequencing due to the similar flanking 
regions of the BC amplicons, spacer bases (0, 4, 8 and 12 N) were added to the forward primers to shift 
the signal during sequencing (Supplementary Table 4). Briefly, approximatively 12.5 ng of DNA 
extraction was used for BC amplification using the Phusion High-Fidelity DNA Polymerase (NEB) 
following manufacturer recommendations. The only modification to the preparation of the samples 
was to use four forward primers instead of one (Supplementary Table 4), each diluted to a 1:4 ratio. 
The PCRs were performed in a peqSTAR 2x thermal cycler (PEQLAB-VWR) with the following program: 
3 min at 95°C followed by 30 cycles at 95°C, 57.9°C and 72°C for 30 s each. A final elongation was 
performed for 5 min at 72°C. To increase the quality of our samples, the whole PCR products were 
loaded on a 1 % agarose gel for electrophoresis and bands of interest purified using the NucleoSpin® 
Gel and PCR Clean-up kit (MACHEREY-NAGEL) following manufacturer recommendations. 
Library preparation and sequencing 
Library construction was performed at the Lausanne Genome Technologies Facility (LGTF, University 
of Lausanne – Centre for Integrative Genomics). Libraries were prepared adapting the 16S 
Metagenomic Sequencing Library Preparation protocol (Illumina) according to manufacturer 
recommendations. MiSEQ Illumina 300 bp single-end sequencing was performed on the libraries by 
the LGTF.  
Barcode quantification  
The barcode quantification of the populations from the pool enrichment assay was performed using a 
script developed by Marion Patxot (Supplementary File 3). Each sequenced library was outputted as a 
FASTQ file. To process the sequencing data, a bioinformatics pipeline was set up using Perl 
75 
 
programming language (v. 5.24.0) and bash Shell (v. 3.2.57 for Mac OS X 10.11.16). Briefly, the pipeline 
counts the occurrence of known barcode sequences in a FASTQ file by running a MegaBLAST. There 
are two inputs to the pipeline: the FASTQ file and a text file containing the name and sequence of each 
barcode. Both files are first converted into FASTA format. Each barcode sequence is then aligned to 
each read in the FASTQ file. The alignment allowed 8 mismatches. The pipeline outputs the occurrence 
of each barcode as a text file. The sequence data was processed using the developed pipeline. Counts 
for each time point and condition were merged into a single text file with bash Shell (v. 3.2.57 – Mac 
OS X 10.11.6). The proportion of each strain in the population was subsequently calculated and plotted 
using Open Source R Software (v. 3.2.4, http://www.R-project.org/). In a second step, counts were 
analyzed using the WT statistical guideline for DMS studies described by Matuszewski et al. [54] . This 
approach calculates a selection of coefficient estimators using the log ratios of the number of counts 
for strains over the number of counts for the reference. 
Software and statistical analysis 
Graphics and statistical analysis were performed in GraphPad Prism 7.03 (GraphPad Software, Inc., La 
Jolla, CA, USA). The online software Morpheus (https://software.broadinstitute.org/morpheus) was 
used to creates the heatmaps of the enrichment assay. Plasmid maps were realized on Adobe 
Illustrator CC 2018 (Adobe Inc., San Jose, CA, USA) 
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Results 
Identification of optimal OE culture conditions 
Gene OE was chosen to identify mediators of FLC tolerance. To achieve this purpose, a 579-strains 
collection reported in Chauvel et al. [56] was used, with each strain overexpressing a specific gene on 
a Dox-dependent manner (Figure 23C). Briefly, the OE system consists of two distinct plasmids. First, a 
vector (pNIMX) expressing the Tetracycline (TET)-binding transactivator (TA) under the control of the 
TDH3 promoter (PTDH3) is introduced in the parental strain CEC161, which is derived from BWP17,  
Figure 23: Doxycycline-dependent overexpression system. (A) Maps of the plasmids pNIMX and CIp10-PTET-GOI used for the 
construction of the library. (B) Construction of the OE collection. First pNIMX was transformed in CEC161 after digestion by 
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SacI/SacII leading to the strain CEC2097 used as receptacle for the CIp10-PTET-GOI plasmid collection, after linearization by I-
SceI, leading to the final 579 Dox-dependent OE strain collection. (C) Schematic representation of the Dox-dependent OE 
system.  
yielding strain CEC2097 [56] (Figure 23A and B). Next, the CIp10-PTET plasmid collection (579 plasmids), 
with each plasmid expressing a gene of interest (GOI, listed in Supplementary File 2) under the control 
of a TET-inducible promoter (PTET) (Supplementary Figure 1) was introduced in CEC2097 (Figure 23B). 
These second plasmids also bear specifics 20 bp tags (or barcodes, BC) allowing their identification by 
sequencing (Figure 23), thus enabling the design of pool experiments. In this work, the pooled strains 
were subjected to FLC selection in the presence doxycycline. Under these conditions, strains expressing 
genes mediating tolerance may be favored over those with wild type characteristics.  
However, prior to selection experiments with this collection of pooled strains, optimal OE conditions 
had to be determined. We chose to grow the C. albicans OE collection in RPMI medium to be consistent 
with EUCAST culture conditions. It was necessary to determine at which Dox concentration a significant 
OE could be detected. To address this question, a Dox-dependent Gaussia princeps luciferase (gLUC) 
reporter strain (CEC3083, Table 11) was used. This strain emits luminescence after addition of the gLUC 
substrate (coelenterazine). The emitted light is expected to be proportional to the level of gLUC 
expression and thus to the level of supplemented Dox. This strain was used to determine the optimal 
pH and Dox concentration for the pool enrichment assay (Figure 24A). First of all, it appeared that the 
Tet-inducible OE system was leaky: even in absence of Dox, luminescence could be detected (3x101 < 
RLU < 3x102), thus reflecting a basal gLUC expression level (Figure 24A). This basal luminescence was 
measured independently of the Dox concentration and the tested pH and might be a source of 
variability for further experiments. A second observation was that, as expected, gLUC expression was 
correlated with Dox concentration present in the growing medium (Figure 24A). However, the 
luminescence signal became saturated at 100 µg/ml Dox and at both pH 7 and 7.5 (RLU > 2x106, Figure 
24A). The medium pH also influenced the level of detected luminescence. Indeed, at pH 4.5, the signal 
was at least 10-fold lower compared to the other pH conditions and independently of the Dox 
concentration with RLU between 3x103 and 4x104 at pH 4.5 versus RLU between 3x105 and 2x106 at 
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higher pH (Figure 24A). The luminescence signals resulting from Dox addition appeared similar 
between pHs 6, 7 and 7.5 (3x105 < RLU < 2x106, Figure 24A). Thus, with these observations, pH 6 and 
7 seemed to be the optimal conditions for gene OE. However, another point had to be assessed before 
our experiment. Indeed, it is known that Dox acts synergistically with FLC, converting this drug into a 
fungicidal rather than fungistatic drug. This synergistic effect is due to the ability of Dox to chelate iron 
but can be reversed by addition of iron (FeCl3) in the medium [61]. To verify whether iron was able to 
avoid this synergistic effect in our conditions, the C. albicans strain SC5314 was grown in presence or 
absence of FLC, Dox and FeCl3, and cell viability was measured after 24 h by serial dilution spotting on 
YEPD plate (Figure 24B). As expected, a clear reduction of growth in the presence of FLC was observed, 
while in the presence of Dox only (10 µg/ml and 100 µg/ml), fungal growth was not affected (Figure 
24B). On the other hand, the growth in presence of both FLC and Dox was drastically reduced, with 
almost no growth at 100 µg/ml Dox, confirming the synergistic effect between both drugs (Figure 24B). 
The addition of 1 mM FeCl3 allowed a partial growth recovery at 100 µg /ml Dox while growth at 10 
µg/ml Dox was similar to FLC only (Figure 24B). Thus, it seemed that experimental conditions using 10 
µg/ml Dox could be optimal. However, as we aimed here to select resistant/tolerant strains in the 
following experiments, a strong OE with 100 µg/ml Dox was favored to select extreme phenotypes. 
Due to iron precipitation and luminescent signal saturation at 100 µg/ml Dox in RPMI at pH 7, pH 6 
was selected to perform our OE experiments.  
 
79 
 
 
Figure 24: Dox efficiency and cell viability. (A) Light emission (in relative luminescence units, RLU) of the strain DSY4737, 
overexpressing gLUC59, after 24 h, at different pH and Dox concentrations. Each bar corresponds to the mean RLU of 
biological triplicates (B) SC5314 (WT) cell viability assessed by 10-fold dilutions spotting of culture at the defined conditions 
([FLC] = 32 µg/ml, [FeCl3] = 1 mM, C+ = SC5314 cells only, C- = cell-free control). Pictures are representative of a biological 
duplicate.  
 
Enrichment in resistant/tolerant OE strains in pool assay 
In order to identify new mediators of tolerance using the OE collection, an enrichment in tolerant 
strains from a pool was performed (Figure 25). Briefly, the 579 strains were pooled and grown under 
strong FLC pressure (32 µg/ml) and in the presence or absence of Dox (100 µg/ml). To select tolerant 
strains, the culture was maintained for 5 days with daily re-inoculation into fresh media to maintain 
FLC and Dox concentrations. After 5 days of subculture, the fraction of each strain in the population 
was estimated for each tested condition by sequencing of the BC (Figure 25).  
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Figure 25: Summarized pool enrichment principle. See Material and Methods section for details 
 
To evaluate the effect of this prolonged culture on the evolution of population, the population of the 
fifth day (D5) in the absence of Dox and FLC (D5 (D-F-)) was compared to the initial population (D0). The 
mean ratio D5 (F-D-)/D0 measured for all strains was 0.99 (Figure 26), suggesting that strains were 
± FLC 
± Dox 
± FLC 
± Dox 
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represented in the same proportion at D5 and D0 and confirming that fluctuations in populations at D5 
are due to the different growth conditions (Figure 26, top line). To evaluate the effect of FLC and Dox, 
the proportion of each strain in the presence of both compounds (D5 (D+F+)) was compared to the 
reference condition (D5 (D-F-)) (Figure 26, second line). Strains were up to 600-fold enriched and 25-
fold depleted in the presence of FLC and Dox as compared to the reference (Supplementary File 2). 
Comparison of the population in the presence of FLC only (D5 (D-F+)) to the reference allowed the 
identification of intrinsically resistant/tolerant strains with strains up to 900-fold enriched in presence 
of FLC and highly sensitive strains which were up to 15-fold depleted (Figure 26, third line, 
Supplementary File 2). To determine the effect of Dox in the absence of FLC on the population, the 
population in presence of Dox only (D5 (D+F-)) was compared to the reference condition. Here, strains 
were up to 15-fold enriched and up to 500-fold depleted at D5 (D+F-), indicating a slight effect of Dox 
on the population which is probably linked to the non-tightly regulated OE system (Figure 26, fourth 
line, Supplementary File 2). Finally, the effect of Dox in presence of FLC was estimated by comparing 
the population D5 (D+F+) to the population D5 (D-F+) (Figure 26, bottom line). This last comparison is 
expected to give valuable insight into the genes that mediate a selective growth advantage in the 
population when overexpressed in presence of FLC. In this comparison 78 strains were at least 2-fold 
enriched and 39 strains 2-fold depleted when their respective genes were overexpressed under strong 
FLC pressure (Figure 26, Supplementary File 2). Among them, the three top strains were those 
overexpressing GZF3, orf19.399, and CRZ1 (60-fold, 38-fold and 25-fold enriched, respectively) (Table 
15). On the other hand, the three strains which were the least represented in the pool were the strains 
overexpressing the orf19.2097, SFL2 and CPH1 (18-fold, 11-fold and 9-fold depleted, respectively 
(Table 15). 
82 
 
 
 
Figure 26: Comparisons of the population of the 579-Tet-inducible OE strains collection pool after 5 days of enrichment. The Heatmap represents the comparison between the cultures at day 
5 (D5) and the initial population (D0), in presence (F+) or absence (F-) of FLC (32 µg/ml), and in the presence (D+) or absence (D-) of 100 µg/ml Dox. Each line represents the mean relative count 
ratio of biological duplicates. The heatmap is filtered based on the (D5 (D+F+) / D5 (D-F+)) comparison. Detailed-data can be found in Supplementary File 2.  
 
 
- 
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Table 15: Top 10 enriched and depleted strains after 5 days of subculture. The effect of 5 days of subculture (D5 (D-/F-)/D0) 
and the effect of the gene OE in presence of FLC (comparison with the initial pool population (D5 (D+/F+)/(D-/F+)) on the 
pooled population is represented as the fold change of the presence of a strain in the population. 
1 D = Doxycycline, F = Fluconazole, +/- = presence/absence of the drug 
2 D0 = initial population (Day 0), D5 = population after 5 days on enrichment 
3 Not Available 
 
 
 
  
 orf n° 
Gene 
name 
(D-F-)1/D0 2 D5 2 (D+F+)/(D-F+) Category 
Top 10 
enriched 
strains 
orf19.2842 GZF3 1.07 60.60 Transcription factor 
orf19.399 NA3 1.08 38.63 Protein kinase 
orf19.7359 CRZ1 1.07 25.87 Transcription factor 
orf19.5157 NA 1.18 9.43 Protein phosphatase 
orf19.5335 SGS1 1.36 9.36 DNA replication/recombination/repair 
orf19.3715 ASF1 0.96 8.07 DNA replication/recombination/repair 
orf19.2324 UBA4 1.25 7.73 Protein phosphatase 
orf19.4166 ZCF21 1.14 6.93 Transcription factor 
orf19.2320 NA 1.41 6.86 Protein kinase 
orf19.2907 PGA42 1.14 6.21 Cell wall genes 
Top 10 
depleted 
strains 
orf19.217 NA 0.81 0.30 Transcription factor 
orf19.4979 KNS1 1.38 0.25 Protein kinase 
orf19.3300 ZPR1 0.43 0.21 Transcription factor 
orf19.1189 NA 0.99 0.20 DNA replication/recombination/repair 
orf19.6936 RAD53 0.99 0.15 Protein kinase 
orf19.7208 CSK1 0.97 0.14 Protein kinase 
orf19.5032 SIM1 0.26 0.13 Various 
orf19.4433 CPH1 0.86 0.11 Transcription factor 
orf19.3969 SFL2 0.87 0.09 Transcription factor 
orf19.2097 NA 0.83 0.05 Transcription factor 
0          1         10
Fold change (-)
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Single strain FLC tolerance profiling 
To avoid a bias caused by growth in pools and to confirm the candidate genes identified in the pool 
enrichment procedure, the tolerance profile of each strain in the collection was tested individually 
(Figure 27). Growth in the presence of FLC and Dox (D+F+) and in the presence of FLC only (D-F+) were 
compared to growth in the F-D- control condition. Relative growths in the presence of Dox and FLC 
(D+F+) ranged from 14 % to 67 % as compared to the F-D- control condition, while relative growths 
under FLC pressure only (D-F+) was comprised between 8 % and 65 % (Figure 27A, Supplementary File 
4).  
Figure 27: Single strain tolerance profiling.  (A) Heatmap representing the relative growth of the 579 Tet-inducible OE BC 
strains collection at pH 6, in presence of 32 µg/ml FLC pressure (F+) and in presence (D+) or absence (D-) of 100 µg/ml Dox. 
Each line represents the mean relative growth of biological triplicates. (B) Heatmap highlighting the effect of Dox induction 
upon FLC tolerance represented as the growth ratio between the condition with and without Dox ((D+F+)/(D-F+)).  
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   Relative growth 
(% GC)1 
Fold change (-)  
 orf n° 
Gene 
name 
D-F+ 2 D+F+ (D+F+)/(D-/F+) Category 
Top 10 
strains 
with 
increased 
tolerance 
orf19.2842 GZF3 12.44 26.35 2.14 Transcription factor 
orf19.4401 YVH1 9.67 19.82 2.05 Protein phosphatase 
orf19.2538 PTC2 12.75 25.43 2.02 Protein phosphatase 
orf19.7001 YCK2 14.03 28.24 2.01 Protein kinase 
orf19.3356 ESP1 11.32 22.34 1.97 DNA replication/recombination/repair 
orf19.5144 PGA28 11.61 22.87 1.97 Cell wall genes 
orf19.6792 RRD1 13.17 25.83 1.96 Protein phosphatase 
orf19.799 STE4 13.06 25.42 1.95 Other signaling comp 
orf19.5636 RBT5 10.36 20.09 1.94 Cell wall genes 
orf19.5257 LCB4 14.57 27.58 1.94 Various 
10 strains 
ranking 
last in the 
TI screen 
orf19.3199 PIKA 13.76 17.56 1.32 Various 
orf19.3294 MBF1 13.47 17.61 1.31 Transcription factor 
orf19.1759 PHO23 18.91 24.34 1.31 Transcription factor 
orf19.4377 KRE1 16.48 20.01 1.28 Cell wall genes 
orf19.4473 NA3 55.66 67.60 1.24 Uncharacterized 
orf19.7652 CKA1 17.28 19.70 1.23 Protein kinase 
orf19.6926 CSC25 13.31 15.76 1.20 Protein kinase 
orf19.3589 SPO11 14.05 16.82 1.20 DNA replication/recombination/repair 
orf19.7473 NA 53.59 63.65 1.18 DNA replication/recombination/repair 
orf19.7208 CSK1 65.37 34.08 0.52 Protein kinase 
1 % of the drug free growth control 
2 D = Doxycycline, F = Fluconazole, +/- = presence/absence of the drug 
3 NA = Not Available  
Table 16: Highlight of the 10 top-hit strains showing the highest and lowest growth ratio of the single strain assay. 
0          1          2
Fold change (-)
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In order to select tolerant/resistant strains, isolates with a relative growth at least 2-fold higher in the 
presence of Dox and FLC (D+F+) than in presence of FLC only (D-F+) were selected (Figure 27B). 
Interestingly, unlike results obtained from the pool enrichment assay (78 strains at least 2-fold 
enriched), only four strains exhibited a 2-fold increase of growth in presence of FLC and Dox in the 
single strain assay. This suggests a strong pool effect in the pool enrichment assay. These four strains 
included those overexpressing GZF3 (2.14-fold growth increase), YVH1 (2.05-fold increase), PTC2 (2.02-
fold increase), and YCK2 (2.01-fold increase) (Figure 27B, Table 16). On the other hand, no strains had 
a growth at least 2-fold reduced when Dox was added. Indeed, only the strain overexpressing CSK1 
showed a decreased growth in presence of Dox (0.52-fold decrease), but this growth depletion was 
due to an abnormal high growth (65 % of the growth control) when grown in presence of FLC only 
(Figure 27B). The difficulty to observe growth reduction upon Dox induction in presence of FLC might 
be due to the already low tolerance level of the parental CEC161 strain used to build the collection. 
Interestingly, the GZF3 OE strain was the best hit in both approaches, making it an engaging potential 
mediator of FLC tolerance. Using results from both the enrichment and the single strains assays, a total 
of twelve strains were selected for further characterization of their FLC susceptibility and tolerance 
profile including the strains overexpressing GZF3, CRZ1, PTC2, YVH1, YCK2, orf19.399, orf19.5157, 
orf19.2320, SGS1, ASF1, UBA4 and ZCF21. 
 
Putative negative regulators of tolerance 
Calcium induced tolerance 
While the gene OE was useful to identify positive regulators of FLC tolerance, the same forward genetic 
approach may be used to identify genes that, when overexpressed, could decrease the growth of 
strains at supra-MIC drug concentrations. With regards to the performed enrichment assay in the 
presence of FLC and Dox, the potential negative regulators of tolerance were more difficult to validate 
due to the already low basal tolerance level of the C. albicans parental strain (CEC161) used to 
construct the OE collection (Figure 24B) [56]. Therefore, we attempted to increase the basal tolerance 
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level of the depleted strains in the above-mentioned pool enrichment assay. Indeed, calcium (CaCl2) is 
a known modulator of tolerance necessary for the activation of the calcineurin pathway known to 
increase FLC tolerance [44]. As a pilot experiment, the strain overexpressing ZPR1 (4.8-fold depleted 
in the enrichment assay), was selected to determine its tolerance level in presence of FLC, Dox and 
serial dilutions of CaCl2 (Figure 28). At pH 4.5, there was no clear effect of calcium at all tested CaCl2 
concentrations. However, tolerance levels started to increase significantly at 1.56, 3.125 and 12.5 mM 
CaCl2 at pH 7.5, pH 7 and pH 6, respectively (Figure 28A-C). Due to a strong tolerance induction above 
the lower tolerance threshold (TI = 0.2) at all pH conditions tested except pH 4.5 (Figure 28, Figure 29), 
the concentration of 50 mM CaCl2 was selected to test whether negative regulators could be validated 
using the other 7 most-depleted genes of the enrichment assay.  
 
Figure 28: Calcium induction of the ZPR1-OE strain FLC tolerance. Tolerance assays were performed at pHs 7.5, 7, 6 and 4.5 
in presence of FLC (8 µg/ml), in presence (+) or absence (-) of Dox (5µg/ml), in the presence (+) or absence (-) of CaCl2 (from 
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100 mM, two-fold dilutions) and complemented with FeCl3 (0.5 mM). Horizontal dashed lines represent the 20, 50 and 80 % 
of growth (respectively, TI = 0.2, 0.5 and 0.8) thresholds used to determine the tolerance profile. Each data set represents 
the mean of technical duplicates.  
 
The fluctuations in tolerance of the strains overexpressing orf19.2097, SFL2, CPH1, SIM1, RAD53, 
orf19.1189, ZPR1, orf19.217, PIF1, RAD51, MDM34, GLC7 and UGA32 were thus tested in presence of 
FLC and CaCl2 with or without Dox induction (Figure 30). Globally, significant changes in TI under Dox 
induction could be observed mainly at pH 7 and pH 6 for the orf19.1189-OE strain in the absence of 
CaCl2 (Figure 30). 
 
Figure 29: Susceptibility profiles of the ZPR1-OE 
strain. Tolerance assays were performed at pHs 7.5, 
7, 6 and 4.5 in presence of FLC (8 g/ml), in the 
presence (Dox+) or absence (Dox-) of Dox (5 g/ml), 
in the presence (CaCl2 +) or absence (CaCl2 -) of 
calcium (50 mM) and complemented with FeCl3 (0.5 
mM). The horizontal dashed line represents the lower 
threshold of tolerance (TI = 0.2) and the limit of 
susceptibility (TI = 0.5) as described by EUCAST. 
Statistical significance was calculated by Sidak’s 
multiple comparison tests (two-way ANOVA, 95 % 
confidence interval) comparing the Dox- and Dox+ 
conditions of each strain. Each bar is representative of 
biological duplicates. P-values: (ns) ≤ 0.1235, (*) ≤ 
0.0332, (**) ≤ 0.0021, (***) ≤ 0.0002, (****) ≤ 0.0001.  
 
 
The addition of CaCl2 efficiently increased basal tolerance levels at pH 6, pH 7 and pH 7.5 regardless of 
the strain allowing to reach higher tolerance levels (0.2 < TI > 0.8). However, the presence of Dox was 
not significantly altering tolerance. It is likely that FLC tolerance activated by the calcineurin pathway 
masked the potential negative regulation of the tested strains. Based on these observations, another 
approach was selected to test these putative negative regulators of tolerance using known FLC-
tolerant clinical isolates.
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Figure 30: Tolerance profiles of putative negative regulators of FLC tolerance. Tolerance was assessed in presence (Dox+) or absence (Dox-) of 5 µg/ml Dox and in presence (+) or absence (-) of 50 mM CaCl2 and 
0.5 mM FeCl3. Horizontal dashed lines represent the lower and upper thresholds of tolerance (TI = 0.2 and 0.8 respectively) as well as the limit of susceptibility (TI = 0.5) as described by EUCAST. Statistical 
significance was calculated by Sidak’s multiple comparison tests (two-way ANOVA, 95 % confidence interval) comparing the Dox- and Dox+ conditions of each strain. Each bar is representative of the mean of 
biological duplicates. P-values: (ns) ≤ 0.1235, (*) ≤ 0.0332, (**) ≤ 0.0021, (***) ≤ 0.0002, (****) ≤ 0.0001.
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Negative regulators OE in tolerant clinical isolates  
To test the putative negative regulators of tolerance identified previously without using calcium 
induction, each gene was overexpressed into clinical isolates already known to display high levels of 
tolerance. The clinical isolates DSY2110, DSY4454, DSY4588 and DSY4754 (Table 12, Figure 31) were 
selected based on their tolerance profiles. These isolates were either tolerant or susceptible to FLC at 
pHS 7.5, 7, 6 and 4.5 (Figure 31).  
 
Figure 31: Tolerance of selected 
clinical isolates. TI levels of the WT 
strain (SC5314) and of 4 clinical 
isolates at 4 different pH conditions 
are shown. Horizontal dashed lines 
represent the lower and upper 
thresholds of tolerance (TI = 0.2 and 
0.8, respectively), and the limit of 
susceptibility (TI = 0.5) as described 
by EUCAST. Each bar corresponds to 
the mean of at least biological 
duplicates.  
 
 
 
 
The OE system for each selected gene was cloned into the strains (Table 12, Supplementary Table 1) 
as described by Chauvel et al. [56]. Unfortunately, the plasmid overexpressing orf19.2097 (i.e. the gene 
resulting in the most depleted strain of the enrichment when OE) could not be linearized using any 
available restriction enzymes for genome integration. In addition to the genes tested in the calcium 
tolerance induction assay (i.e. SFL2, CPH1, SIM1, RAD53, orf19.1189, ZPR1, orf19.217, PIF1, RAD51, 
MDM34, GLC7 and UGA32), the plasmids overexpressing CSK1, RAD6 and KNS1 were also transformed 
(Supplementary Table 1 and 3). Each clinical isolate and its respective OE-clones were then tested in 
tolerance assays in presence or absence of Dox to observe any potential alteration of tolerance upon 
overexpression of the selected genes (Figure 32). To quantify the modification of tolerance upon Dox 
addition, we defined a tolerance ratio (TR), which compares growth in presence of FLC in 
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presence/absence of Dox. Thus, a TR = 1 indicated no growth difference between both conditions. A 
TR < 1 reflects that the overexpressed gene could be a suppressor of FLC tolerance whereas a TR > 1 
will indicate that the GOI could be a positive regulator of tolerance. When growth was absent in the 
presence of FLC in both conditions, a TR could not be calculated (Figure 32).  
Overall, the TR at pH 4.5 were below a value of 1. This tendency was also observed in control strains 
bearing an empty OE plasmid (Figure 32). Therefore, this effect could not be attributed to specific 
genes or specific strains and could be resulting from an effect of the pH upon tolerance in the tested 
conditions. In addition, the strains derived from DSY4454 exhibited a surprisingly high number of 
positive scores (i.e. a significant decrease of TR compared with the respective control strain). It is likely 
that the DSY4454 background is more susceptible to the OE system than other clinical strains. Thus, 
the results obtained by this strain were not further evaluated. Another global finding was that strains 
derived from DSY4588, including the control strain, showed growth deficiencies at pH 7 and pH 7.5 in 
the presence of FLC as if the OE system drastically increases FLC susceptibility. This susceptibility was 
not observed in the initial clinical isolates (Figure 32). Comparisons of TR at these pH values were thus 
more difficult. Growth at pH 6 appeared the most optimal condition when considering the entire set 
of mutants. Overall, we observed several conditions in which TRs were significantly decreased relative 
to the control strain at a specific pH. Interestingly, the overexpression of SFL2 and CPH1 (in DSY2110) 
as well as CSK1 (in DSY4754) significantly decreased tolerance at all pH (TR < 1) on a strain-specific 
manner (Figure 32), thus making them interesting putative repressors of FLC tolerance. However, none 
of the tested genes could be clearly identified as a general repressor of FLC tolerance when comparing 
all the different strains. This underscored a strain-specific behavior of these genes in the presence of 
FLC and is certainly due to the different genetic backgrounds of the tested clinical isolates.  
 
92 
 
 
Figure 32: Tolerance ratio of selected Tet-inducible clinical isolates. Heatmaps correspond to the comparisons of the TIs at pHs 7.5, 7, 6 and 4.5 under FLC pressure (8 µg/ml) between growth in presence and 
absence of 5 µg/ml Dox. FeCl3 (0.5 mM) was added to avoid the synergistic FLC-Dox effect. Each square corresponds to the mean tolerance ratio (TR) (Dox+/Dox-) of biological triplicates. Briefly, a TR = 1 indicates 
that the specified gene OE has no effect upon tolerance, a TR > 1 indicates that the gene OE results in a better growth in presence of the drug and Dox and a TR < 1 indicates a loss of tolerance upon the selected 
genes Dox induction. Grey and yellow squares indicate samples with no detectable growth in presence of FLC (no TR could be defined) and samples which could not be analyzed, respectively. Statistical significance 
was determined using Kruskal-Wallis non-parametric tests (Dunn’s correction). P-values: (ns) ≤ 0.1235, (*) ≤ 0.0332, (**) ≤ 0.0021, (***) ≤ 0.0002, (****) ≤ 0.0001. A table with the corresponding strains name can 
be found in Supplementary table 1. 
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Putative positive regulators of tolerance 
FLC susceptibility profile of putative positive mediators 
In opposite to the identification of negative regulators of FLC tolerance, the identification of positive 
regulators was not impaired by the low basal tolerance level of the BWP17-derived parental strain 
CEC161 used to construct the OE collection. Thus, strains selected from both the pool enrichment and 
the single strain assays (Figure 26 and Figure 27) were tested individually to establish their FLC 
susceptibility profiles at pH 6 in the presence of Dox. Only pH 6 was tested to remain consistent with 
the pool enrichment assay. A total of 12 strains of the OE collection were tested, including strains 
overexpressing GZF3, CRZ1, PTC2, YVH1, YCK2, orf19.399, orf19.5157, orf19.2320, SGS1, ASF1, UBA4 
and ZCF21 (Supplementary File 2), in addition to the WT SC5314 which was used as a susceptibility 
control.  
Overall, no strains could be considered as tolerant as defined earlier for clinical isolates (i.e. TI ≥ 0.2) 
at 100 µg/ml Dox. However, all strains showed a two-fold dilution increase in MIC under Dox induction 
conditions (0.125 µg/ml FLC to 0.25 µg/ml FLC), except for the strain overexpressing GZF3 which 
reached a MIC of 0.5 µg/ml in presence of Dox. Nevertheless, MIC values remained below the FLC CBP 
(i.e. 4 µg/ml FLC) (Figure 33A, left panel). With regards to the tolerance level, all strains had an equal 
or lower TI in the presence of Dox, except for the GZF3 and CRZ1 OE strains that exhibited a significantly 
higher TI (from TI = 0.07 to 0.12 and 0.16, respectively). However, all TI levels remained under the 
tolerance threshold defined earlier for clinical isolates (i.e. TI < 0.2) (Figure 33A, right panel).  
Due to a global increase in MIC values at 100 µg/ml Dox, strains were also tested at 10 µg/ml Dox to 
test whether this increase was concentration-dependent. At this Dox concentration, every strain 
presented a similar MIC independently of Dox induction, with all MICs remaining at around 0.125 
µg/ml FLC except for the GZF3 OE strain which reached a MIC of 0.25 µg/ml FLC (Figure 33B, left panel).  
Here again, no increases in tolerance levels could be observed for most of the strains under Dox 
induction, except for the strains overexpressing GZF3 (TI = 0.048 to 0.2), CRZ1 (TI = 0.07 to 0.21) and 
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YCK2 (TI = 0.06 to 0.14). However, only GZF3 and CRZ1 OE allowed a tolerance increase above the 
lower tolerance threshold of TI = 0.2 (Figure 33B, right panel). 
 
Figure 33: Susceptibility profiles of selected Tet-inducible strains in the presence Dox. Susceptibility profiles were performed 
at pH 6, in a range of FLC concentrations (0-16 µg/ml), in the presence (Dox+) or absence (Dox-) of doxycycline and 
complemented with 1 mM FeCl3. FLC susceptibility at 100 µg/ml (A) and 10 µg/ml (B) Dox represented by their modal MIC 
value (left panel) and TI at 8 µg/ml FLC (right panel). Standard deviations of the MIC values were calculated based on the 
mean MIC of each sample. The horizontal dashed line represents the lower threshold of tolerance (TI = 0.2) and the limit of 
susceptibility (TI = 0.5) as defined by EUCAST. Each bar is representative of biological triplicates. Statistical significance was 
determined using Sidak’s multiple comparison tests (Two-way ANOVA, Confidence interval = 95 %). P-values: (*) ≤ 0.05, (**) 
≤ 0.01, (****) ≤ 0.0001.  
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CRZ1 and GZF3 OE in deletion mutants 
In order to better understand the mechanisms behind tolerance and the potential relation between 
CRZ1 and GZF3, each gene was overexpressed in simple and double mutants. For this purpose, a 
crz1∆/∆, gzf3∆/∆ double mutant (EDY28-2, Table 13) was constructed using the crz1∆/∆ mutant from 
the Homann’s deletion mutant collection [57]. The OE system for either CRZ1 or GZF3 was then 
transformed in this double mutant, in both Homann’s crz1∆/∆ and gzf3∆/∆ single mutants as well as 
in the parental WT strain of the Homann’s collection (Table 13). The plasmid overexpressing an empty 
overexpression plasmid (i.e. CIp10-PTET-GTW, Supplementary Table 3) was also transformed in each 
strain as control of the OE system (Table 13). The FLC susceptibility profiles of these strains were then 
established in presence or absence of Dox and FLC to assess their respective MICs and TIs (Figure 34). 
FeCl3 was once again used to avoid the synergistic effect between FLC and Dox. These susceptibility 
assays were performed at pHs 7 and 6 to avoid the growth defect observed at pH 7.5 and the iron 
precipitation observed at pH 4.5. 
Overall, all strains had similar MIC values in presence or absence of Dox. The MIC for all tested strains 
at pH 7 was equal to 0.0625 µg/ml FLC with negligible variability (i.e. MIC = 0.125 µg/ml FLC). The 
gzf3∆/∆ mutant overexpressing CRZ1 showed the highest increase in MIC value, reaching 0.25 µg/ml 
FLC in presence of Dox (Figure 34A). Globally, the susceptibility profile remained the same at pH 6, 
with only the MIC values of all WT and crz1∆/∆-derived strains increasing at pH 7 from 0.0625 µg/ml 
to 0.125 µg/ml FLC (Figure 34C). However, the MICs of all strains in all the tested conditions remained 
well below the CBP of 4 µg/ml FLC. With regards to FLC tolerance, all strains showed a basal TI under 
the lower tolerance threshold (i.e. TI = 0.2) at both pH values in absence of Dox, with TIs ranging from 
0.04 to 0.17 (Figure 34B and D). As expected, no significant fluctuation of the TI could be observed for 
the CIp10-PTET-GTW overexpressing control strains at both tested pH values, with their TIs remaining 
below the lower tolerance threshold (TI values between 0.04 and 0.08, Figure 34B and D). Consistently 
with observations of the pool enrichment assay, CRZ1 and GZF3 OE resulted in a significant increase of 
the TI in a WT background. The TI increased from 0.08 to 0.2 for both the CRZ1 and GZF3 OE strain at 
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pH 7 and from 0.09 to 0.18 for the CRZ1 OE strain and 0.09 to 0.14 for the GZF3 OE strain at pH 6 
(Figure 34B and D, respectively). Despite a significant increase in tolerance, only CRZ1 OE at pH 7 
reached the lower tolerance threshold in the WT genetic background. Looking at the deletion mutants, 
significant increase in TI could be observed at both pHs in the gzf3∆/∆ mutant under CRZ1 and GZF3 
OE. Indeed, TI increased from 0.17 to 0.28 and 0.16 to 0.31 at pH 7 and from 0.07 to 0.13 and 0.07 to 
0.14 at pH 6 for CRZ1 and GZF3 OE, respectively (Figure 34B and D), thus reaching the lower threshold 
of tolerance at pH 7. On the other hand, only CRZ1 OE resulted in an increased in tolerance in the 
double crz1∆/∆, gzf3∆/∆ mutant, but significantly at pH 7 only with a TI increasing from 0.09 to 0.21 
and with a tendency at pH 6 with an increase from 0.04 to 0.09. No effect of GZF3 OE on the tolerance 
level could be observed in the double crz1∆/∆, gzf3∆/∆ mutant with TI values of about 0.09 and 0.05 
at pHs 7 and 6, respectively (Figure 34B and D). Interestingly, no effect of GZF3 OE could be observed 
in the crz1∆/∆ mutant, with TI fluctuation between 0.08 and 0.06 at pH 7 and about 0.05 at pH 6 (Figure 
34B and D). However, CRZ1 OE in this mutant background resulted under Dox induction in an increased 
tolerance from TI = 0.23 to 0.32 and from TI = 0.08 to 0.21 at pH 7 and 6, respectively (Figure 34B and 
D). To summarize, our results indicate that overexpressing CRZ1 results in an increased FLC tolerance 
in all mutant backgrounds but, on the other hand, GZF3 OE increases tolerance only when CRZ1 was 
present (Figure 34B and D). 
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Figure 34: Susceptibility profile of the 
CRZ1 and GZF3 mutants overexpressing 
either CRZ1, GZF3.  (A, C) Susceptibility 
to FLC is represented as the modal MIC 
value with standard deviation calculated 
on the mean MIC of all replicates. (B, D) 
Tolerance profile of the mutant strains. 
The mean TI and standard deviations are 
represented. Horizontal dashed lines 
represent the lower threshold of 
tolerance (TI = 2), and the upper limit of 
susceptibility (TI = 0.5) as described by 
EUCAST. Each data set represents the 
mean (or mode) of biological duplicates. 
Statistical significances (B, D) were 
estimated using Sidak’s multiple 
comparison tests (2-way ANOVA, 95 % 
confidence interval) between Dox- and 
Dox + conditions in the same mutants 
set. P-values: (****) ≤ 0.0001. A figure 
with the corresponding strains name can 
be found in Supplementary Figure 2.  
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CRZ1 and GZF3 deletions in tolerant clinical isolates 
To confirm the role of CRZ1 and GZF3 in promoting tolerance to fluconazole not only in laboratory 
strains, either one or both allele of each gene were deleted in the C. albicans clinical isolates DSY2110, 
DSY4454, DSY4754 and DSY4588, already known to exhibit different level of FLC tolerance (Table 12, 
Table 14, Figure 31). Revertant strains were constructed by reinsertion of CRZ1 and GZF3 alleles from 
the reference isolate SC5314 as a control (Table 14). The FLC susceptibility profiles of each mutant and 
associated parental clinical isolates were assessed at pHs 7.5, 7, 6 and 4.5 and their MIC values and TIs 
extracted for comparisons (Figure 35 and Figure 36).  
Globally, no differences could be observed between the MIC values of the original clinical isolates and 
their respective mutants, with all MICs standing below the FLC clinical breakpoint (CBP) of 4 µg/ml. In 
general, MICs slightly increased at more acidic pH (Figure 35). The isolate DSY2110 and its derived 
mutants showed mean MIC values of 0.5 µg/ml for the parental strain and 0.25 µg/ml for all the mutant 
strains at any pH (Figure 35A). DSY4454 and its derived mutants exhibited also similar MIC patterns as 
described in DSY2110 (ranging from 0.125 to 0.25 µg/ml FLC) which depended on the pH value. The 
mutants derived from DSY4454 were slightly more susceptible with MICs ranging from 0.0625 to 0.25 
µg/ml (Figure 35B). The isolate DSY4588 and its derived mutants showed the same MIC levels than the 
previous strains, with MICs ranging from 0.125 to 0.25 µg/ml for the parental strains and from 0.0625 
to 0.5 µg/ml for the mutants (Figure 35D). On the other hand, the isolate DSY4754 and its derived 
mutants exhibited an altered growth at pHs 7.5 and 7, resulting in aberrant MIC values reaching 16 
µg/ml at pH 7.5 and ranging between 0.03125 and 0.25 µg/ml at pH 7 but with a high variability. The 
susceptibility results for DSY4754 and derivatives at these pH values should thus be carefully 
considered (Figure 35C).  
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Figure 35: Fluconazole susceptibility profiles of the clinical isolates and their respective deletion mutants and revertant for CRZ1 and GZF3.Susceptibility to FLC is represented as modal MIC 
values. Error bars indicate the standard deviation based on the mean MIC values. Doted lines show the CBP for FLC (4 µg/ml). Each bar corresponds to biological duplicate.
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When inspecting variations of FLC tolerance, a general reduction of tolerance levels was observed at 
acidic pH independently of the genetic background or of CRZ1 and GZF3 deletions (Figure 36). On the 
other hand, the effect of the deletion of CRZ1 or GZF3 upon tolerance seemed to be dependent on 
both the pH and the genetic background of the parental clinical isolate.  
In the DSY2110 background, both heterozygous and homozygous CRZ1 deletions as well as CRZ1 
complementation in the revertant strain resulted in a decreased FLC tolerance (Figure 36A) 
Unfortunately, no restoration of the initial tolerance level in the DSY2110 revertant strains could be 
observed. However, the homozygous crz1Δ/Δ mutant was consistently less tolerant than its 
heterozygous counterpart at all pHs, except pH 4.5 (Figure 36A, red bars). Regarding GZF3 mutants in 
the DSY2110 background, deletion of only one allele did not have any effect upon tolerance. However, 
the deletion of both alleles resulted in reduced tolerance at pHs 6 and 4. Interestingly, the homozygous 
GZF3 deletion resulted in increased tolerance level at pH 7.5. However, this was only observed in the 
DSY2110 background and at this pH condition. Complementation of GZF3 consistently restored 
tolerance to the heterozygous mutant level, except at pH 7.5 (Figure 36A, green bars).  
When inspecting DSY4454 and its derived mutants, a global reduction of tolerance could be observed 
for all mutants and revertant strains of both CRZ1 and GZF3 at any tested pH. Only GZF3 mutants at 
pH 4.5 exhibited tolerance level similar to the parental isolate DSY4454. However, no differences could 
be observed between the heterozygous and homozygous mutants of both CRZ1 and GZF3, and no 
effect of the complementation of both genes could be observed in this genetic background (Figure 
36B). 
Concerning DSY4754 and its derived mutant strains, all CRZ1 mutants showed a reduced tolerance at 
pHs 7.5 and 7. At pHs 6 and 4.5, only the homozygous CRZ1 mutant showed a significant tolerance 
reduction. The revertant strain restored tolerance to level similar to the DSY4754 parental strain at pH 
7.5 but only to the heterozygous level at pHs 7 and 6. At pH 4.5, the revertant showed no difference 
with the homozygous mutant (Figure 36C, red bars). On the other hand, both GZF3 mutant strains 
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retained tolerance of DSY4754 at all tested conditions, except for the GZF3 revertant at pH 7 in which 
a tolerance decrease could be measured as compared to DSY4754 (Figure 36C, green bars).  
Finally, both CRZ1 mutants derived from DSY4588 all showed reduced tolerance at any tested pH 
condition. However, the homozygous mutant had a significantly lower tolerance than the 
heterozygous mutant only at pH 7. CRZ1 complementation restored tolerance to heterozygous levels 
at pH 7 and with a tendency at pH 7.5. However, no difference could be observed at pHs 6 and 4.5 with 
tolerance level similar the homozygous mutant (Figure 36D, red bars). With regards to GZF3, only the 
homozygous mutant and the revertant strain exhibited a reduced tolerance, and only at pHs 7 and 6. 
GZF3 complementation did not restored tolerance in this genetic background and the heterozygous 
mutant did not show any loss of tolerance as compared to DSY4588. No reduction of tolerance could 
be observed for the GZF3 mutant strains at pHs 7.5 and 4.5 (Figure 36D, green bars). 
Taken together, the results of CRZ1 and/or GZF3 deletions and reversions revealed that CRZ1 was the 
factor that most prominently altered FLC tolerance of the clinical stains. The results were dependent 
on the tested pHs and on the genetic background of the isolates. 
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Figure 36: Tolerance levels of the different deletions mutants for both CRZ1 and GZF3 in the DSY2110 (A), DSY4454 (B), DSY4754 (C) and DSY4588 (D) genetic backgrounds. Each bar corresponds to at least 
biological duplicates. Statistical significance was calculated using Turkey multiple comparison tests (95 % confidence interval). P-values: 0.1234 (ns), ≤ 0.0332 (*), ≤ 0.0021 (**), ≤ 9.0002 (***), ≤ 0.0001 (****). 
Blue stars correspond to the comparison with the parental clinical isolates (blue bars). Black stars correspond to the comparisons between related mutant strains. A figure with the corresponding strains name 
can be found in Supplementary Figure 3.
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Conclusions 
Until now, tolerance to fluconazole has been an understudied research topic. Tolerance has been 
linked to an increased survival in the presence of FLC which may ultimately lead to the acquisition of 
genome mutations and/or may serve as a source of reinfection upon arrest of the treatment. 
Identifying genetic mediators of FLC tolerance could lead to the development of new treatment 
strategies which will increase FLC efficiency in patients. In this study, we developed a forward genetic 
screen with a pool enrichment approach using a collection of 579 barcoded strains. Each of these 
strains overexpressed a specific gene under the control of doxycycline [57, 66]. The same set of pooled 
strains was used by Znaidi et al. [65] in a genetic screen performed in a murine model of gastro-
intestinal colonization. In this study, the authors used the barcodes to identify strains of interest that 
were enriched and/or depleted in the animal model in the presence of Dox. Different from the barcode 
sequencing system used in the present study, Znaidi et al. [65] used a barcode detection system based 
on microarrays on which all barcode tags were deposited. In the animal model selection system, only 
one gene, CRZ2, was identified as conferring a selective growth advantage when overexpressed in the 
animal gut. CRZ2 encodes a zinc finger transcription factor of the C2H2 family that is similar to the 
calcineurin target Crz1p, however it is not involved in calcium signaling [66]. The microarray detection 
approach to quantify the barcode population from recovered isolates could have been less sensitive 
than the barcode sequencing approach used here. Barcode sequencing provides the absolute counts 
of barcodes that occur in a given sample which can be compared to any other sample, while microarray 
analysis provides an indirect quantification through labelling with two different fluorescent dyes and 
calculating their ratios. This may provide an explanation as to why only CRZ2 was identified in the work 
of Znaidi et al. [65]. By maintaining, in the present study, the pooled collection under strong FLC 
pressure for five days in the presence and absence of Dox, we were first able to identify enriched and 
depleted isolates in these conditions (78 strains at least 2-fold enriched and 39 strains at least 2-fold 
depleted). The susceptibility profiles of these candidate genes were further investigated in single strain 
assays to address potential pool effects in the enrichment assay. We applied here a threshold 
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definition of tolerance for clinical strains as described earlier in this thesis (Delarze et al., unpublished, 
Thesis part 1). This allowed the discrimination between resistant (TI > 0.8), tolerant (0.2 ≤ TI ≤ 0.8) and 
non-tolerant susceptible strains (TI < 0.2). Unfortunately, this single-strain assay did not allow to 
identify isolates with decreased tolerance level under Dox induction, probably due to the already low 
basal tolerance level of the CEC161 parental strain used to build the collection. This basal tolerance 
level strongly impaired possible conclusions derived from the overexpression of the putative negative 
regulators of tolerance. Our attempt to increase the basal tolerance level with the addition of calcium 
in isolates derived from CEC161 (thus stimulating the calcineurin pathway) resulted in strong tolerance 
induction. This calcium-mediated induction probably masked the potential effects that could originate 
from tested putative negative regulators. However, using the overexpression system in known clinical 
isolates, we were finally able to observe reductions of the levels of tolerance, but these were 
dependent on both the genetic background and the pH condition tested. Three genes seemed to 
deplete FLC tolerance in all conditions and several genetic backgrounds: the transcription factors CPH1 
and SFL2, involved in cell morphology (formation of biofilm and filamentation, respectively) and the 
putative mitogen-activated protein (MAP) kinase CSK1 which currently has an unknown role in C. 
albicans (the ortholog of SMK1 in S. cerevisiae is involved in sporulation). The identification of these 
three putative negative regulators of FLC tolerance was part of a preliminary experiment and further 
investigations need to be performed to confirm them as true negative regulators. However, our 
experiments showed the limitation and the difficulties in identifying such regulators. Here we suggest 
that the use of tolerant clinical isolates can be a promising approach to identify and confirm additional 
candidate genes responsible for FLC tolerance. 
On the other hand, from the initial 12 proposed and putative mediators of FLC tolerance, at least two 
could be linked to a significant increase of tolerance under Dox induction (TI > 0.2). One of these two 
genes was the calcineurin-regulated transcription factor CRZ1, already identified to play a role in FLC 
tolerance by Onyewu et al. [67] and Karababa et al. [66]. To act as a transcription factor, Crz1 needs to 
be translocated to the nucleus. This is achieved by dephosphorylation via calcineurin, which is known 
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to act as a protein phosphatase [66]. In this work, we showed that CRZ1 overexpression is triggering 
FLC tolerance, which may be achieved by transcriptional activation and thus a shift in the balance 
towards dephosphorylated Crz1. The relationship between CRZ1 overexpression and Crz1 
dephosphorylation has not been tested here but needs to be addressed in future investigations. The 
other identified gene was the putative GATA-type transcription factor GZF3, of which the S. cerevisiae 
ortholog negatively regulates nitrogen catabolic gene expression [68]. Little is known about GZF3 
function in C. albicans, but it was shown to be induced, via Cap1, in oxidative stress conditions [69]. 
Most of the information on GZF3 come from Homann’s and Noble’s phenotypic screens [58, 71]. In 
their works, they observed that the homozygous gzf3Δ/Δ mutant resulted in abnormal growth on 
Spider medium and decreased competitive fitness in a mice systemic infection model [58, 71]. Homann 
et al. also observed an increased susceptibility to heat, FLC, lithium chloride, copper and rapamycin 
[57]. However, no genetic clues could explain those phenotypes so far. To our knowledge, it is the first 
time here that GZF3 has been linked to an increase of FLC tolerance when overexpressed in C. albicans. 
A third gene, YCK2, was also identified. This gene encodes a plasma membrane protein similar to the 
S. cerevisiae casein kinase I, which is required for the membrane trafficking of Pdr5 (the ortholog of 
the multidrug transporter CDR1 in S. cerevisiae) to the cell surfaces [71]. YCK2 overexpression 
significantly increased FLC tolerance. However, it did not reach the threshold of tolerance (TI < 0.2) 
defined for clinical isolates. This gene remains however a good candidate for future investigations on 
molecular mechanisms behind FLC tolerance. The single strain assay also confirmed our pool 
enrichment protocol to be a valuable approach for the identification of putative positive mediators of 
FLC tolerance. Additional enrichment experiments using extended OE collections might reveal novel 
insights into the mechanisms behind this phenotype. 
To further characterize the possible interactions existing between CRZ1 and GZF3 (since both could 
mediate FLC tolerance), we observed that GZF3 significantly increased tolerance when overexpressed, 
but only when at least a single copy of CRZ1 was present. On the opposite, the overexpression of CRZ1 
resulted in increased tolerance in every condition tested, even in the absence of GZF3. This highlights 
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that CRZ1 controls the expression of one or more intermediary proteins or cofactors necessary for 
GZF3 activity, which in its turn could activate other regulators of tolerance. Taking the hypothesis that 
CRZ1 and GFZ3 are part of a same pathway, our results suggest that GZF3 acts downstream of CRZ1. 
Further investigation of CRZ1 target genes via RNA sequencing or chromatin immunoprecipitation may 
reveal such proteins necessary to GZF3 activity. In addition, using a Dox-free overexpression system 
would be more optimal in such investigations to avoid the synergistic effect between Dox and FLC. This 
negative effect was compensated here by the addition of iron in the culture media.  
Both CRZ1 and GZF3 were also shown to play a role in FLC tolerance in clinically relevant isolates. CRZ1 
deletion significantly reduces FLC tolerance in the four tested strains to levels below the tolerance 
threshold (TI < 0.2) of clinical isolates. On the other hand, GZF3 deletion was able to reduce tolerance 
levels but only when both alleles were deleted. The pH of the medium also had an visible influence on 
tolerance as already described by Marr et al. [42], but the reduction of tolerance by CRZ1 and GZF3 
deletions was independent of the tested pH conditions, thus highlighting diverse additional 
pathways/mechanisms behind the development of tolerance. 
Experiments aimed to re-introduce CRZ1 and GZF3 in the background of deletion mutants in clinical 
strains yielded different phenotypic complementation results (Figure 36). For example, revertant 
isolates from strains DSY2110 and DSY4454 did not revert to initial parent wild type levels. This 
apparent lack of phenotypic reversion may have several reasons. First, the CRZ1 allele re-introduced 
in the mutant may not be functional. However, separate successful phenotypic revision of SDS (a cell 
wall destabilizing agent) susceptibility in these revertant strains argues against this hypothesis 
(Supplementary Figure 4). Second, the reversion of the full initial phenotype may require that two CRZ1 
copies are being re-introduced at their genomic loci. Third, the reversion of the initial phenotype 
requires the presence of CRZ1 alleles originating from the clinical strains and not from SC5314. Since 
the CZR1/crz1∆ heterozygote mutants exhibit intermediate tolerance phenotypes (Figure 36), the third 
option may be a likely explanation. To confirm this hypothesis, future experiments should introduce 
the CRZ1 alleles from the parental clinical strains in their respective homozygote mutants. This last 
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hypothesis suggests that CRZ1 alleles from these clinical strains could exhibit polymorphisms 
responsible for the gain of FLC tolerance.  
In a recent study published by the group of J. Berman, some mechanistic insights into the basis of FLC 
tolerance were given [51]. As suggested by our results, this study highlighted that, using chemically-
induced phenotypes, the calcineurin pathway was implicated in the development of azole tolerance. 
One major difference between the present study and Berman’s results was that tolerance assays were 
carried out in static growth conditions on agar plates (i.e. disk diffusion assays), whereas here liquid 
media were used. The study of Rosenberg et al. used mutants constructed in laboratory strains (for 
example crz1, cnb1) and reduction of trailing growth on disk diffusion assays to support their 
hypothesis [51]. In addition, this study indicated that the development of tolerance in clinical strains 
still susceptible to FLC was attributed to distinct subpopulations [51]. This was inferred by growth 
assays showing that isolates with high tolerance profiles were growing better in the presence of FLC 
than isolates with low tolerance profiles. The subpopulation argument seems therefore questionable 
since single cell analysis was not performed. An interesting approach from the work of Rosenberg et 
al. was the estimation of FLC accumulation in several isolates using a fluorescent FLC derivative [51]. 
The general trend of their results showed that high tolerance was correlated with decreased 
accumulation of the fluorescent probe, thus probably contributing to the final tolerance phenotype 
[51]. Among other interesting observations, Rosenberg et al. observed that tolerant strains were more 
likely to be isolated from FLC-treated patients than others, which suggested that C. albicans may adapt 
to this drug [51]. If azole treatment is prolonged, tolerant isolates may persist and, thus, may cause 
more severe damage to the host. However, the relationship between occurrence of FLC tolerance and 
FLC efficacy is still not clearly established in C. albicans. A study from Astvad et al. undertaken with C. 
tropicalis isolates exhibiting different tolerance profiles tested FLC efficacy in systemic mice infection 
models [72]. The data of this study established that high FLC tolerance compromised the efficacy of 
FLC in the mice, thus suggesting a clinical relevance of the tolerance phenomenon [72].  
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To conclude, the enrichment approach developed here can easily be adapted to test other antifungal 
drugs and to different Candida species. Optimistically, one can imagine performing this type of 
enrichment in a collection representing the whole C. albicans transcriptome to uncover novel 
mediators involved in the response to FLC and to highlight additional mechanisms. By analysis of the 
mechanisms and identification of mediators, it may be possible to develop inhibitors which may lead 
to optimized treatments against clinically challenging C. albicans isolates. 
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Part three: Transcriptomic imprints of fluconazole response in the wild type 
strain SC5314 and tolerant clinical isolates. 
Abstract 
Fungal infections are challenging to treat, mainly due to the limited number of antifungal drugs 
available. Among them, the azole fluconazole (FLC) has been widely used for the treatment of Candida 
albicans infections. Acquired resistance to fluconazole has been extensively studied in the past. 
However, another phenomenon called antifungal tolerance, characterized by an extended survival in 
presence of the drug without acquiring mutations linked to resistance might also play a role in FLC 
treatment failures of C. albicans infections. Little is known about FLC tolerance, and most of the 
observations were made in laboratory conditions. Some genetic clues have been linked to FLC 
tolerance, but no clear mechanisms could explain the extended survival under high FLC concentrations 
yet. In addition, the link between tolerance and therapeutic failure still need to be addressed.  
In this study, we used a transcriptomic approach to further investigate the response of C. albicans to 
FLC in standardized antifungal susceptibility assay conditions. This was first carried out in the 
laboratory strain SC5314 and next in known tolerant clinical isolates sampled from the same patient 
over an 8 years period which exhibited increased FLC tolerance over time. The data of this work 
showed that the SC5314 transcriptome highlighted not only known drug-induced responses but also 
the participation of several calcineurin-dependent genes. This suggested that FLC recruits this pathway 
known to be critical for C. albicans survival in presence of drugs. The clinical isolates showed also a 
corresponding classical drug-induced transcriptional response along with calcineurin-dependent 
genes. Interestingly, CRZ1, that codes for a transcriptional factor activated by calcineurin, was more 
expressed in the clinical tolerant isolates that parent wild types. This result mimics artificial CRZ1 
overexpression and resulting FLC tolerance of laboratory isolates and suggests that CRZ1 could be the 
critical mediator of tolerance in the clinical isolates. The targets of CRZ1 may therefore be critical for 
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tolerance and their identification could reveal the molecular mechanisms behind the development of 
tolerance in C. albicans.  
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Introduction 
Transcriptomics is a powerful technology to address gene function and to get insights in circuits 
activated upon environmental perturbations. Chemical stress can induce transcriptional changes 
reflecting both general (e.g. detoxification pathways) and specific responses of the organism to 
alteration of one or more biological pathways that are affected by treatment with the chemical. When 
transcriptional signatures are compared to comprehensive transcript profiling data of gene deletions, 
drug-gene associations can be established. One nice example reflecting this concept is the study by 
Hughes et al. in which gene expression profiles of yeast cells treated with both known and unknown 
drugs were compared with a compendium of transcript profiles from an array of yeast deletion 
mutants [73]. Several transcriptional studies have shown that inhibition of an antifungal drug target 
leads to increased expression of genes that function in the same pathway. This is a compensatory 
response to the reduced activity of the target gene. A clear example reflecting this hypothesis is the 
study conducted by Rogers and coworkers, which characterized the transcriptional profiles of C. 
albicans cells treated with different antifungal agents including azoles, polyenes, echinocandins [74] 
and ciclopirox [75]. Strong induction of most of the genes involved in ergosterol biosynthesis, including 
ERG11 encoding the target of azoles, was observed upon treatment with ketoconazole [74]. Similarly, 
cell-wall maintenance-encoding genes were induced upon caspofungin treatment, and, interestingly, 
down-regulation of ERG3 and ERG11 were detected following incubation with amphotericin B [74]. 
Consistent with the notion that ciclopirox olamine acts as an iron chelator, alteration of the expression 
of iron uptake genes was observed [75], which was in agreement with data from a similar study that 
used qRT-PCR [76].  
While drug exposed conditions can be helpful in revealing biological meaningful data, the use of clinical 
strains with specific phenotypes is also useful to identify the mechanisms that control these 
phenotypes. For example, azole-resistant isolates from different origins that were investigated by 
transcriptional profiling were used to predict expression patterns resulting from transcription factor 
alterations. For example, Morschhäuser et al. used clinical strains overexpressing MDR1, a major 
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facilitator superfamily transporter responsible for azole resistance to identify MRR1, the 
transcriptional regulator of MDR1 [77]. It turned out that MRR1 was upregulated in the azole-resistant 
strains, which facilitated its identification as a regulator of azole resistance. 
In this work, we used transcriptional profiling of clinical strains with known FLC tolerance indexes (TI). 
These strains, known as FLC-susceptible, were exposed to FLC under conditions defined to establish 
tolerance profiles. The results were compared with a wild type isolate (SC5314) known as FLC-
susceptible and with low FLC tolerance. Our results highlight that the calcineurin pathway can be 
stimulated in the presence of FLC and that tolerant clinical strains exhibit increased transcriptional 
activity of calcineurin-dependent genes.  
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Material and methods 
Strains used in this study 
All clinical C. albicans isolates used for the RNA extraction are listed in Table 17 and were sequentially 
isolated from a same patient with a C. albicans endocarditis. The wild type strain SC5314 was used to 
identify the basal response to supra-MIC concentration of FLC (8 µg/ml).  
 
Table 17: Clinical isolates used for RNAseq with their MIC values for different antifungal drugs. 
Isolate a 
MIC (µg/ml) 
FLC VRC CAS 5-FC AMB 
DSY4454 (0526-6020) 0.25 0.0078 0.25 0.0315 0.125 
DSY4452 (1101-334) 0.5 0.015 0.25 0.0625 0.25 
DSY4588 (13 0420 0673) 0.25 0.015 0.25 0.015 0.25 
1For each isolate, a code originating from the diagnostic laboratory of the CHUV is provided in parentheses with 
underscored numbers indicating the year of sampling 
2(FLC) Fluconazole, (VRC) Voriconazole, (CAS) Caspofungin, (5-FC) Flucytosine, (AMB) Amphotericin B 
 
Media and growth conditions 
All strains were stored in 20 % glycerol at -80°C and routinely grown at 30°C under constant shaking 
(220 rpm) in complete Yeast Extract Peptone Dextrose (YEPD) medium (1 % Bacto peptone, Difco 
Laboratories, Basel, Switzerland), 0.5 % Yeast extract (Difco) and 2 % glucose (Fluka, Buchs, 
Switzerland). When grown on solid YEPD plates (YEPDA), 2 % agar (Difco) was added and plates were 
incubated at 35°C.  
For culture in presence of supra-MIC concentrations of FLC, strains were grown according to the 
EUCAST “Method for the determination of broth dilution minimum Inhibitory concentrations of 
antifungal agents for yeasts” (E.DEF 7.3.1) [38], with slight modifications. Cultures were done in 
RPMI1640 medium with phenol-red (Sigma-Aldrich) complemented with 2 % glucose (Fluka, Buchs, 
Switzerland) and buffered with 0.33 M morpholinepropanesulfonic acid (MOPS). The pH was adjusted 
to pH 7 using NaOH. Stock solutions were prepared as 2x concentrated RPMI as recommended by 
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EUCAST [38]. Cells were grown in presence or absence of a fixed FLC concentration of 8 µg/ml as used 
for the identification of FLC tolerance (Delarze et al., unpublished, Thesis part 1 and 2). 
Briefly, individual colonies of each tested strain were grown overnight in YEPD medium at 30°C under 
constant shaking (220 rpm). Cultures were centrifuged (5 min, 4600 rpm, 4°C) and washed twice with 
PBS (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, and pH 7.4). Cell concentration was estimated by 
spectrophotometry (OD540 nm) and cells were resuspended at 5 x 105 cells/ml in distilled water. Then, 
100 µl of this suspension were transferred into the wells of flat-bottom 96-well plates (Costar) 
containing 100 µl of 2x RPMI (2 % glucose) complemented or not with 16 µg/ml FLC to obtain a final 
cell concentration of 2.5 x 105 cells/ml and 8 µg/ml FLC per well. Each tested condition corresponded 
to a whole 96-well plate (with two contamination control wells) and represented approximatively 18.8 
ml of culture in total. Plates were incubated at 35°C without shaking for 24 h. The next day, plates were 
centrifuged (5 min, 3700 rpm, 35°C) and the supernatant discarded. To preserve the RNA before RNA 
extraction, 25 µl of RNAlater (Ambion) was added per well and the plates were incubated at 4°C for at 
least an hour. Plates were then stored at -80°C prior to RNA extraction.  
RNA extraction 
All nucleic acids were extracted by mechanical disruption using glass beads and phenol-chloroform 
separation as described previously with slight modifications [78]. Briefly, the culture plates preserved 
in RNAlater were thawed on ice and cells from each plate recovered by addition of 150 µl diethyl 
pyrocarbonate (DEPC)-treated distilled water in wells of the first column and pooled progressively 
toward the last column of the plates. These cell suspensions were collected in RNase-free micro-
centrifuge tubes (Eppendorf) kept on ice. The RNAlater was removed after centrifugation (5 min, 14000 
rpm, 4°C) and cell pellets were resuspended in 300 µl RNA buffer (0.5M EDTA [pH 8], 20 % SDS, 1 M 
LiCl, 1 M Tris-HCl [pH 7.5]) and transferred to 2 ml screw cap tubes (Sarstedt). Approximatively 0.3 g 
of acid washed glass beads (0.5 mm) (SIGMA) were added in addition to 300 µl of phenol-chloroform-
isoamylalcohol (24:24:1). Cells were mechanically disrupted (1 pulse, 5 sec, 5000 rpm, 4°C) in a 
Precellys Evolution tissue homogenizer (Bertin instruments, Montigny-le-Bretonneux, France). Tubes 
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were centrifuged (10 min, 14000 rpm, 4°C) and 300 l of the aqueous phase was transferred into new 
screw-cap tubes containing 300 l phenol-chloroform-isoamylalcohol. Tubes were vortexed (10 sec, 
full speed) and centrifuged once more (10 min, 14000 rpm, 4°C) before transferring 250 l of the 
aqueous phase into RNA-free micro-centrifuge tubes. To ensure the complete removal of phenol, a 
last centrifugation (5 min, 14000 rpm, 4°C) was performed and 200 l transferred in new RNA-free 
micro-centrifuge tubes. Nucleic acids were then precipitated with 600 l 100 % EtOH (-20°C) for 15 
min on dry-ice, and the pellets were finally washed with 800 l 70 % EtOH (-20°C) and air-dried before 
resuspension in 50 l H2O DEPC (4°C). Nucleic acid concentration and quality was verified by 
spectrophotometry (NanoDrop 1000 Spectrophotometer) and adjusted to 10 µg/45 µl in DEPC-treated 
water. The nucleic acids were stored at -80°C prior to DNase treatment.  
DNase treatment 
Genomic DNA was removed by DNase treatment using the DNA-free DNA Removal Kit (Invitrogen) 
following manufacturer’s recommendation and samples were stored at -80°C.  
Determination of RNA quality 
RNA concentration was measured with a Nanodrop-1000 (Witec AG, Switzerland). Tubes were stored at -
80C until analysis. RNA quality was analyzed using a Fragment Analyzer (Advanced Analytical 
Technologies, Ankeny, IA, USA) according to manufacturer’s instructions. The Lausanne Genomic 
Technologies Facility (LGTF) which performed the RNA sequencing recommended a A260/280 ratio > 1.9, 
A260/230 ratio > 1.8 and an RNA Integrity Number (RIN) > 7.0 to perform RNAseq.  
RNA sequencing and RNAseq data mining  
Library preparation and sequencing were carried out by the LGTF and the sequencing was performed 
on an Illumina HiSeq 2500 system (Illumina, San Diego, CA, USA), using the TruSeq Stranded RNA, 125 
bp single read protocol. The analysis was performed with three biological replicates for each condition. 
RNAseq data were processed using CLC Genomic Workbench Version 10.1.1 (Qiagen). Reads were 
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aligned to the C. albicans SC5314 genome and read counts were normalized using the quantile 
approach method. All conditions were compared with each other and filtered according to a specific 
statistical cut-off as explained in the Results section. 
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Results 
Transcriptional profile of SC5314 in the presence of FLC 
The C. albicans strain SC5314 is the classical laboratory strain that is commonly used by the research 
community and from which the genome has been annotated. 
As shown in earlier chapters of this thesis, SC5314 is a strain exhibiting a relatively low level of FLC 
tolerance (generally below the TI threshold of 0.2). It was therefore of interest to address the 
transcriptional profile of this strain in the presence of FLC under the conditions where tolerance is 
tested and to compare the obtained profile with those of clinical strains exhibiting high FLC tolerance. 
RNAseq data were obtained as described in Material and Methods and were analyzed with the help of 
a dedicated software package (CLC Genomics Workbench, V 10.1.1). Genes that were significantly 
differentially regulated by the presence of FLC (FDR ≤ 0.05) leading to an expression change of at least 
2-fold were first selected (Supplementary File 5). A total of 1641 genes followed these selection 
criteria.  
These expression data were first analyzed by Gene Ontology term enrichment. Enriched GO terms of 
genes up- and downregulated in the presence of FLC are shown in Figure 37. FLC is known to perturb 
the expression of genes involved in sterol biosynthesis and those mediating azole efflux [79]. The data 
of Figure 37 are consistent with these observations since processes involving ergosterol biosynthesis, 
azole transport and response to stress are enriched in FLC-upregulated genes. Interestingly, processes 
related to vesicle-mediated transport and azole transport were closely clustered, thus indicating a 
functional relationship between both processes. Another relevant enriched process derived from 
upregulated genes includes the glyoxylate cycle, which suggests that FLC mediates a change in the 
metabolic state in C. albicans. Since processes involving cell wall organization and hyphal growth are 
enriched in FLC-upregulated genes, this suggests that this drug may alter cell wall composition as well 
as morphogenesis in C. albicans. Consistent with these observations, it has been reported in C. albicans 
that FLC is able to induce a switch from the yeast form to elongated growth reminiscent of hyphal 
growth [80]. Lastly, our data indicate an enrichment for multi-organism processes, which correspond 
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to genes involved in biofilm formation. This suggests that the growth conditions chosen here to address 
FLC tolerance may favor biofilm formation.  
With regards downregulated genes in the presence of FLC, the data of Figure 37 show that processes 
related to glucose catabolism are enriched. This suggests a rewiring of glucose metabolism induced by 
FLC. These data are consistent with the upregulation of genes involved in the glyoxylate cycle as above- 
 
Figure 37: Schematic representation of GO terms enriched in genes up- (left panel) and down-regulated (right panel) by 
FLC in C. albicans. Go term enrichments were performed with the online tool Fungifun (https://elbe.hki-jena.de/fungifun/). 
Enriched GO categories were next visualized with the online tool Revigo (http://revigo.irb.hr) which groups redundant GO 
terms according to semantic similarity-based scatterplots.  
 
mentioned. Oxidation-reduction processes as well as processes involving reactive oxygen species (ROS) 
metabolism are identified in the data of Figure 37 and thus indicate an impact of FLC on oxido-
reductive processes. Lastly, processes related to translation are among the enriched processes in FLC-
downregulated genes. FLC has a growth inhibitory function and this is reflected by down-regulation of 
genes of the translation machinery. 
To compare the genes up- and downregulated by FLC in SC5314 with transcriptional profiles published 
in the literature, a gene set enrichment approach (GSEA, for Gene Set Enrichment Analysis) was used. 
The list of transcriptional profiles that was used here comprises 307 different conditions 
(Supplementary File 6) in which (i) C. albicans was exposed to different antifungal agents, (ii) C. albicans 
mutants were exposed to different growth conditions, (iii) C. albicans was exposed to host cells and 
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(iv) C. albicans was grown in vitro under conditions mimicking host environments. The GSEA list also 
contains C. albicans genes with binding sites for several transcription factors. In general, the used 
conditions are divided into lists of up-and down-regulated genes. The software compares a query list 
of up- and down-regulated genes with existing gene lists and identifies those that overlap through 
statistical evaluation. A network of associated gene lists can be formed using visualization software 
such as Cytoscape (GSEA enrichment map) depending on the overlaps between conditions.  
Figure 38 shows the GSEA enrichment map of genes up- and downregulated by FLC in SC5314. One can 
observe three major networks, two containing blue nodes and one with red nodes, which indicates a 
separation between genes down- and upregulated, respectively, in the presence of FLC. On the other 
hand, several other nodes, in which down- and upregulated genes could be found, were not 
overlapping with existing datasets.  
The GSEA map highlights several features. First, the genes regulated by FLC in SC5314 overlap well with 
published datasets in which C. albicans was exposed to FLC in different growth conditions. The 
connected nodes “FLUCONAZOLE_UP”, “KETCONAZOLE_UP”, “FLC3H_UP” were overlapping with 
most FLC-upregulated genes in SC5314. FLUCONAZOLE_UP data originate from a study [81] in which 
C. albicans was exposed for 6 h in the presence of 10 µg/ml FLC in YEPD at 30°C. FLC3H_UP data are 
from a study [82] in which C. albicans was treated with 0.5 µg/ml FLC for 3 h in RPMI medium at 37 °C. 
KETCONAZOLE_UP data are from a study [83] in which C. albicans was exposed to 0.04 µg/ml 
ketoconazole for 3.5 h in YEPD at 30°C. All these experiments were performed under agitation in liquid 
cultures. The growth conditions used here were different from the 96-well microtiter plate format of 
the EUCAST. Even though these conditions were quite different from the published studies, the GSEA 
could identify significant overlaps between these conditions (Figure 39). A core group of 29 genes could 
be found in all the data sets (Figure 39). Considering that most FLC-downregulated genes are also found 
in the nodes “KETOCONAZOLE_DN”, “FLC3H-DN” and “FLUCONAZOLE_DN”, the results obtained here 
are consistent with already published transcriptional data of FLC-exposed cells. 
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When inspecting other nodes overlapping with the FLC-regulated genes of SC5314, it was of interest 
to identify those labelled as “CALCINEURIN”, “CNA_CRZ1” and “CNA 20 min_up”. The gene lists from 
these nodes originate from a study published by Karababa et al. [66] in which calcineurin- and CRZ1-
dependent genes were identified. The overlaps between these different nodes are shown in Figure 40 
and show that most of the FLC-regulated genes are upregulated in these nodes. A common set of 20 
genes was present among these different nodes, in which CRZ1, a critical gene of the calcineurin 
pathway [66], was present. 
These nodes were connected to those assembling FLC-exposure data as above-mentioned. 
“CALCINEURIN” and “CNA 20 MIN_UP” were connected with the node “UPC2_UP”, which comprises 
genes upregulated in the absence of UPC2 under anaerobic conditions [83]. UPC2 is known to regulate 
several genes involved in sterol biosynthesis [83], a pathway affected by FLC. “UPC2_UP” is next 
connected to the FLC response nodes. Inspection of the genes on the edges between “CALCINEURIN” 
and “CNA 20 MIN_UP” and “UPC2_UP” revealed 20 and 18 genes, respectively (Supplementary File 7). 
Among these genes, CRZ1 was again identified. As a matter of fact, CRZ1 was 2.5-fold upregulated by 
FLC in SC5314 (Supplementary File 5), which corroborates with the effect of CRZ1 overexpression on 
FLC tolerance that was demonstrated earlier in this work. Interestingly, GZF3, which was another gene 
conferring FLC tolerance when overexpressed, was also upregulated (2.5-fold) by FLC in SC5314. Taken 
together, these data highlight a relationship between calcineurin signaling and response of C. albicans 
to FLC.  
Several other nodes were identified by GSEA and contain genes that are upregulated in response to 
drugs, including FLC, yet not connected to the calcineurin pathway. These nodes include for example 
“MILBE_UP”, “FLUODIOXONIL_UP”, “FR59_15MIN_UP”, “FLUPHENAZINE294_UP” and indicate that 
FLC invokes a response shared by other drugs. In some cases the drug response is mirrored by FLC-
downregulated genes in nodes reflecting gene down-regulation by drug response (Figure 38, 
“MILBE_DN”, “FLUODIOXONIL_DN”, “FLUPHENAZINE294_DN”). 
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When scrutinizing nodes that matched down-regulated genes in the presence of FLC (blue nodes), two 
major clusters were identified. In one of them, nodes related to hyphal growth (“HYPHAE_LEE_UP”, 
“HYPHAE_SPIDER_UP”, “HYPHAE_FBS37B_UP”) were present. These gene lists include genes that are 
upregulated when C. albicans switches from the yeast form to the hyphal form. Therefore, our data 
suggests that genes involved in hyphal formation tend to be downregulated by FLC in C. albicans. These 
results are consistent with some studies showing that azoles can modify the dynamics of the switch 
between the yeast and hyphal phase [84].  
The other cluster of nodes connects several processes related to the response of C. albicans to host 
conditions or to host cells (“IN VIVO_DN”, “CAECUM_DN”, “RNASEQ120MIN_DN”). The data of these 
nodes comprises genes down-regulated under host conditions. FLC-downregulated genes are enriched 
in these conditions thus suggesting that the response of C. albicans to FLC can also modify C. albicans 
host response. The significance of these results is not clear yet.  
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Figure 38: GSEA enrichment map of FLC regulated genes in C. albicans SC5314. Analysis parameters were as follows: norm, meandiv; scoring_scheme, weighted; set_min, 15; nperm, 1000; set_max, 500. GSEA 
results were uploaded into Cytoscape 3.0 with the following parameters: P value cutoff, 0.01; FDR q value, 0.05. Red nodes represent enriched gene lists in upregulated genes from the GSEA. Blue nodes represent 
enriched gene lists in downregulated genes from the GSEA. Nodes are connected by edges when overlaps exist between nodes. The size of nodes reflects the total number of genes that are connected by edges 
to neighboring nodes. Edge thickness reflects the level of confidence between nodes. 
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Figure 39: Venn diagram of FLC-regulated genes in C. albicans. Gene lists derived from the GSEA plot of Figure 38 
(Supplementary File 6) were used in the online tool available at http://bioinformatics.psb.ugent.be/webtools/Venn/. From 
265 genes overlapping between the gene list “FLUCONAZOLE_UP” and the SC5314 data (1641 regulated genes), 212 were 
FLC-upregulated.  
 
 
 
Figure 40: Venn diagram of genes within the calcineurin-CRZ1 cluster of the GSEA. The gene lists of each node were 
extracted from the GSEA analysis (Supplementary File 7) and a Venn Diagram was constructed with the online tool available 
at http://bioinformatics.psb.ugent.be/webtools/Venn/. For each node the number of up-and downregulated genes by FLC is 
indicated.  
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Transcriptional profiles of clinical strains in the presence of FLC 
After the analysis of the transcriptional response of SC5314 to FLC, it was of interest to address the 
same type of response using C. albicans clinical isolates with known high FLC TIs. The chosen strains 
were originating from a group of related strains including DSY4454, DSY4452 and DSY4588. These 
strains were recovered from a patient suffering of endocarditis which was treated for an extensive 
period with FLC (8 years). DSY4454 was the earliest strain recovered (2005) from the patient, while 
DSY4588 was the latest (2013) (Table 17). Patient and sampling details are given in Table 18. 
The relationship between strains was investigated with Multi Locus Sequence Typing (MLST, 
Supplementary File 8) [85]. A single loss of heterozygosity (LOH) event was detected in the SYA1 allele 
of isolate DSY4588 as compared to the other strains, thus suggesting that micro-evolution between 
the strains could have occurred. However, the MLST results indicated that the strains were from the 
same type, thus suggesting a strong genetic relationship between them. 
 
 
Figure 41: Tolerance profile of the C. albicans clinical isolates. 
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Table 18: Details on the endocarditis patient and the collected isolates. 
1(AMB) Amphotericin B, (FLC) Fluconazole, (CSP) Caspofungin, (5FC) Flucytosine 
2(IV) Intravenous, (p.o.) Per os 
 
 
Year of Record 2004 2005 2010 2012 2013 
Isolated strain  DSY4454 DSY4452  DSY4588 
Symptoms/intervention 
- Aortic valve 
replacement for 
stenosis 
- C. albicans 
prosthetic valve 
endocarditis 
- C. albicans 
prosthetic valve 
endocarditis 
- C. albicans 
prosthetic valve 
endocarditis 
 
- Valvuloplasty 
 
- Abscess resection 
between aortic and 
mitral valve 
- C. albicans 
prosthetic valve 
endocarditis 
 
- Aortic valve 
replacement 
(homograft) 
Treatments 
 1) AMB1 (5 
mg/kg/day IV2) for 4 
weeks 
 
2) Suppressive 
therapy with FLC1 
(200 mg/day p.o.2) 
1) CSP1 (70 mg/day 
IV) for 3 months 
 
2) Suppressive 
therapy with FLC 
(200 mg/day p.o.) 
1) CSP 70 mg/day for 
1 week IV 
 
2) CSP 50 mg/day for 
5 weeks IV c 
1) AMB (5 
mg/kg/day IV) for 5 
weeks + 5FC1 
(25mg/kg/day IV) for 
2 weeks 
 
2) CSP 100 mg/day IV 
for 6 weeks 
 
3) Suppressive 
therapy with CSP 
3x/week (200-200-
250 mg IV) 
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The strains were subjected to RNA extraction in conditions identical to SC5314 and RNAseq analysis 
was carried out. The data were treated and analyzed in a manner similar to SC5314 and expression 
changes were extracted by pairwise comparison between conditions with and without FLC. The data 
were filtered for significance (FDR ≤ 0.05) and for expression change (≥ 2-fold) between drug-exposed 
and non-exposed conditions (Supplementary File 5). Data are summarized in Table 19.  
Table 19: Genes regulated by FLC in the clinical strains. 
Isolate 
FLC upregulated 
genes 
FLC downregulated 
genes 
DSY4454 484 579 
DSY4452 370 471 
DSY4588 451 262 
 
The FLC-regulated genes from the clinical strains DSY4452, DSY4454 and DSY4588 were also subjected 
to GSEA as was performed for SC5314. These data are summarized in Figure 42. 
When looking at FLC-upregulated genes, the GSEA data of the clinical isolates contained in common 
clusters of nodes related to the calcineurin pathway (CALCINEURIN”, “CNA_CRZ1” and “CNA 20 
min_up”). Strikingly, these nodes were connected to those originating from FLC-exposed conditions 
(“FLUCONAZOLE_UP”, “KETCONAZOLE_UP”, “FLC3H_UP”) and from nodes of transcription factors 
controlling sterol homeostasis (“UPC2_UP”). These networks, containing genes positively regulated by 
FLC, were also associated with a node comprising genes upregulated by UPC2 with a gain of function 
mutation (“UPC2_G648D_UP”) [86]. This underlines the importance of this transcription factor in azole 
response. Taken together, these data suggest that the calcineurin pathway is connected to the 
response of C. albicans to FLC and this confirms the observations made above in SC5314. 
When looking at clusters matching with down-regulated genes, a central node assembling list of genes 
with transcription factor (TF) binding sites could be identified (“NDT80_BIOFILM_TF”) which in some 
cases was itself connected to other nodes of the same type (“BRG1_TF”, “BRC1_TF”, 
“EFG1_BIOFILM_TF”, “TEC1_BIOFILM_TF”, “WOR1_TF”). The data of these gene lists originates from a 
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study that identified a hub of transcription factors controlling biofilm formation [87]. The connections 
between these nodes suggest that most genes down-regulated by FLC are controlled by these 
transcription factors and indicates that biofilm formation is affected by the presence of FLC. One can 
observe the occurrence of nodes of FLC-downregulated genes containing data of hyphal-regulated 
genes. Since biofilm formation is closely associated with hyphal formation [88], the data of the present 
work are consistent with this assumption.  
In the data of the clinical strains, other interesting nodes related to drug resistance, were found in the 
cluster of down-regulated genes. For example, the nodes “TAC1-DN”, “MRR1_TF” and BENOMYL_UP” 
were connected with each other and the remaining clusters of down-regulated genes (data from 
DSY4452). The node “TAC1-DN” assembles data of genes downregulated by the absence of TAC1 in C. 
albicans. Since TAC1 is a major transcription factor in drug-induced response [89], it can be expected 
that several regulated genes will be controlled by this factor. This is reflected by the occurrence of FLC-
downregulated genes in this specific node. The node “MRR1_TF” and “BENOMYL_UP” include genes 
with binding sites of the TF Mrr1 [90] and genes upregulated by the presence of benomyl [91], 
respectively. MRR1 is another TF playing an important role in drug response in C. albicans and 
especially in the response to benomyl [90]. Interestingly, the data presented here show that FLC 
regulates genes in the opposite way compared to benomyl. Therefore, since MRR1 is positively 
controlling benomyl-induced genes, it not surprising that FLC-downregulated genes can be found in 
the node “MRR1_TF”.
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Figure 42: GSEA enrichment map of FLC regulated genes in clinical isolates DSY4454 (A), DSY4452 (B) and DSY4588 (C). Analysis parameters were as follows: norm, meandiv; scoring_scheme, weighted; set_min, 
15; nperm, 1000; set_max, 500. GSEA results were uploaded into Cytoscape 3.0 with the following parameters: P value cutoff, 0.01; FDR q value, 0.05. Red nodes represent enriched gene lists in upregulated genes 
from the GSEA. Blue nodes represent enriched gene lists in downregulated genes from the GSEA. Nodes are connected by edges when overlaps exist between nodes. The size of nodes reflects the total number of 
genes that are connected by edges to neighboring nodes. Edge thickness reflects the level of confidence between nodes. 
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In order to identity potential mediators of tolerance in the set of clinical strains, the expression of 
which could vary between wild type (DSY4454) and FLC-tolerant isolates (DSY4452 and DSY4588), the 
ratios of FLC-regulated genes were determined between pairs of isolates. Expression ratios were first 
calculated between DSY4452 and DSY4454 and between DSY4588 and DSY4454 (Supplementary file 
9). Significant fold-changes were selected between these conditions (p-values ≤ 0.05) and the data 
were filtered with a 2-fold change as a cut-off. The expression ratio between DSY4452 and DSY4454 
was changed by more than 1.5-fold for 41 genes. Interestingly, 12 out these 41 genes were regulated 
by calcineurin and/or CRZ1. Moreover, the expression ratios of these 41 genes between DSY4588 and 
DSY4454 were above the 1.5-fold threshold. These results suggest a conservation of the FLC response 
between the tolerant strains DSY4452 and DSY4588 as compared to DSY4454. Intriguingly, most of the 
ratios of the 41 above-mentioned genes between DSY4454 and SC5314, both of which could be 
considered as “wild type” in term of FLC tolerance, were below the 1.5-fold threshold. Taken together, 
the data presented here suggest that the expression of genes that are known to be calcineurin- and/or 
CRZ1-dependent is increased in the FLC-tolerant clinical strains and this indicates that the calcineurin 
pathway is modified by still uncharacterized factors in these strains. 
 
Conclusions 
In this work, we addressed the transcript profiling of several isolates in the presence of FLC, some of 
which exhibit FLC tolerance. The major difference in these experiments as compared to similar 
published results was that the incubation conditions were mimicking standard susceptibility assays 
performed under EUCAST recommendations. In these conditions, the first investigated isolate was 
SC53145 and showed a typical drug-induced transcriptional response. In addition, we showed here 
that FLC induced a response that included several calcineurin-dependent genes. Such a response 
profile has not yet been clearly demonstrated in published profiling studies. Such an association 
strongly suggests that FLC recruits the calcineurin pathway, which was already showed to be critical 
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for survival of C. albicans exposed to FLC [44]. The same relationship could be established in the clinical 
isolates when inspecting their response to FLC.  
The clinical isolates used here were related to each other, which was expected to reduce 
transcriptional noise that can arise from strains exhibiting different genetic backgrounds. In these 
sequential isolates, DSY4454 was the first recovered isolate from a patient suffering from endocarditis. 
DSY4454 exhibited relative low TI as compared to the other isolates (DSY4452 and DSY4588). The 
patient had been treated for several years with FLC until blood cultures were positive for DSY4452 and 
DSY4588 about 7 and 9 years after the isolation of DSY4454. It is likely that the duration of FLC 
treatment along these years selected for isolates with genome modifications favoring, among other 
phenotypes, the development of azole tolerance. Our data revealed that several genes of the 
calcineurin pathway were upregulated as compared to the initial isolate as well as SC5314. Currently 
the genetic basis for this modification is unknown. In the transcript profiling, CRZ1 was upregulated in 
the tolerant isolates. As mentioned earlier in this work, CRZ1 overexpression mediated by an artificial 
regulatable promoter is enough to induce FLC tolerance in C. albicans. CRZ1 expression changes could 
therefore be taken as a candidate marker for azole tolerance. How CRZ1 overexpression mediates 
azole tolerance is still unknown. CRZ1 needs to localize into the nucleus to target genes and this process 
is known to involve phosphorylation/dephosphorylation steps [44]. CRZ1 overexpression could change 
the protein homeostasis and perturb the ratio between phosphorylation/dephosphorylation states, 
which will result in the upregulation of target genes. No detailed information currently exists on CRZ1 
target genes that could ultimately be responsible for azole tolerance. As mentioned earlier, 
identification of CRZ1 target genes that could mediate azole tolerance needs to be systematically 
performed. Another approach that could lead to resolve the molecular basis of azole tolerance in the 
clinical isolates could consist of comparative genomics. Such an approach could be undertaken in order 
to reveal nucleotide changes between the isolates and thus to identity the molecular basis behind the 
occurrence of FLC tolerance. This type of approach may be rendered difficult due to the likely genome 
divergence that evolved during the years of persistence of the strains in the host. Preliminary data 
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from the isolates’ whole genome sequencing support this hypothesis. In conclusion, even if the present 
results converge to the involvement of the calcineurin pathway in the development of azole tolerance, 
additional studies are needed to resolve the molecular details behind this phenomenon. 
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General discussion and future perspectives: 
C. albicans is a major human pathogen and can develop resistance to antifungal drugs leading to 
therapeutic failures. Antifungal tolerance, characterized by an increased survival in presence of drug 
without acquiring mutations leading to resistance, is also thought to be involved at least in part of 
these therapeutic failures. Antifungal tolerance has mainly been described for the fungistatic drug 
fluconazole (FLC). However, mechanisms behind FLC tolerance have remained little understood, 
mainly due to a lack of clear definition and approaches to identify and quantify tolerance. The work 
described in this thesis contributed to better define FLC tolerance and to give novel insights behind 
this phenomenon. 
 
Defining FLC tolerance 
First, a clearer definition of FLC tolerance as well as a tolerance index (TI) and tolerance thresholds, 
allowing tolerance quantification, were established and used to better identify tolerant clinical 
isolates. Using the standard antifungal susceptibility assays protocols proposed by EUCAST and CLSI, 
tolerance was defined as a residual growth between 20 and 80 % of a drug-free control above the 
clinical breakpoint of FLC. By establishing the TI as the residual growth at a fixed antifungal 
concentration, this allowed an easy way to assess tolerance in large strains collection in so-called 
tolerance assays, as showed with the 182 strains used here. The upper threshold of tolerance (TI = 0.8) 
was also further confirmed as most isolates above this threshold were exhibiting known mutations 
linked to FLC resistance. The lower threshold of tolerance (TI = 0.2) was established on a more empirical 
basis but was useful to distinguish between wild type and tolerant isolates. The method and definition 
developed here gave, in addition to the method based on disk diffusion assay developed by Gerstein 
et al. [51] and applied by Rosenberg et al. [52, 94], an alternative to better understand tolerance and 
identify mechanisms responsible for this phenotype. However, our methods may be more efficient for 
large scale tolerance screenings and may be more easily implemented as a routine laboratory method 
as it only used a microplate reader. In addition, culture in liquid and in RPMI medium might better 
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reflect the environmental conditions of the host, as opposed to static growth on solid phases. This 
method can also be used to assess tolerance to other antifungal drugs in C. albicans but also in other 
pathogenic fungi. 
 
Discovery of novel FLC tolerance mediators 
Using the definition and TI established in the first part of this work, the transcription factors CRZ1 and 
GZF3 were identified in a pool enrichment approach using a collection of doxycycline (Dox)-dependent 
overexpression strains with each a specific barcode and an overexpressed gene. A third gene, encoding 
the plasma membrane protein Yck2, was also observed to increase tolerance when overexpressed but 
with less effect than CRZ1 and GZF3. This gene was not further investigated in the current study but 
remains of interest since its ortholog in S. cerevisiae is critical for the trafficking of Pdr5. This protein is 
functionally similar to the multidrug transporter Cdr1 of C. albicans. CDR1 is already known to be 
involved in acquired FLC resistance [32]. YCK2-induced FLC tolerance may lead to stabilized localization 
of Cdr1 in the plasma membrane, thus resulting in a decreased intracellular FLC concentration.  
CRZ1 was already known to be part of the calcineurin pathway which was reported as involved in FLC 
tolerance. When calcineurin is activated, it dephosphorylates its downstream targets, including Crz1, 
which in turn will translocate into the nucleus. The identification of CRZ1 in this work therefore 
consolidated our approach and highlighted the crucial role of the calcineurin pathway in FLC tolerance. 
On the other hand, little is known from GZF3 in C. albicans. Most information about GZF3 originate 
from the works of Homann et al. and Noble et al. [58, 71], where they linked the absence of GZF3 with 
abnormal growth on Spider medium and decreased competitive fitness in mice, but also with an 
increased susceptibility to heat, FLC, lithium chloride, copper and rapamycin [58, 71]. GZF3 ortholog in 
S. cerevisiae is involved in nitrogen homeostasis but was never linked to any antifungal drug response. 
In the present study, GZF3 was shown for the first time to be linked to Crz1 activity and, more 
interestingly, to be situated downstream of this transcription factor. Indeed, using overexpression of 
each factor in CRZ1 and GZF3 deletion mutants, it was observed that CRZ1 overexpression was enough 
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to promote tolerance, even in absence of GZF3. However, it seems that the effect of GZF3 
overexpression on tolerance needs the presence of at least a single CRZ1 allele. This highlight that, 
somehow, Crz1 regulates GZF3 expression either directly via binding to the GZF3 promoter, or 
indirectly via regulation of intermediate factors. These factors can either regulates GZF3 expression or 
be cofactors of Gzf3 necessary for its activity in the nucleus. Further characterization of the link 
between both factors will reinforce the knowledge on FLC tolerance. More importantly, the present 
study highlighted the role played by both CRZ1 and GZF3 in the FLC tolerance of clinical isolates. Their 
deletions resulted in decreased FLC tolerance, but did not impact the FLC susceptibility, thus showing 
that the cellular processes controlling these phenotypes can be separated.  
 
Next steps in understanding of FLC tolerance  
It is important to note here that only approximatively 1/10th of C. albicans ORFome was covered by the 
overexpression collection used for the identification of tolerance mediators. In addition, the collection 
used was enriched in genes encoding for transcription factors, protein involved in DNA 
replication/repair/recombination, protein kinases/phosphatases and cell wall proteins. Due to the 
limited representation the C. albicans ORFome, only a fraction of potential FLC tolerance mediators 
could be therefore identified. In order to perform a more comprehensive analysis of potential FLC 
tolerance mediators, it will be necessary to include, in the future, an overexpression collection 
representing the whole C. albicans ORFome. 
With regards to the involvement of CRZ1 in tolerance, the next step will be to further characterize its 
role on FLC tolerance in clinical isolates. Crz1 needs to be dephosphorylated by calcineurin to 
translocate into the nucleus and binds to promoters of targets genes. It is possible that, in FLC-tolerant 
clinical isolates, Crz1 is constitutively dephosphorylated due to calcineurin in an activate state, thus 
resulting in increased Crz1 nuclear localization and transcription of target genes. It could be possible 
to tag Crz1 with a fluorescent marker to observe its cellular localization upon FLC treatment as 
compared to a drug-free control. As it was shown that CRZ1 overexpression increased tolerance, a first 
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approach would be to address Crz1 localization in the overexpression system used here. To avoid 
problems with correct localization and/or function of the tagged protein, construction of both N- and 
C- terminal tagged Crz1 would be necessary. 
As both CRZ1 and GZF3 encodes transcription factors, they are indirect mediators of FLC tolerance. It 
is thus of primary interest to identify their targets genes since they might be direct effectors of FLC 
tolerance. In addition, this would reveal other pathways involved in increased FLC tolerance. An 
elegant approach to identify these target genes would be to perform chromatin immunoprecipitation 
sequencing (ChIP-Seq), using the CRZ1 and GZF3 overexpression strains used in this study in order to 
directly identify their DNA binding sites. Another approach would be comparative transcriptomic 
analyses in presence and absence of Dox. However, in this case, it would be more convenient to 
construct a Dox-free overexpression system rather than the one used in this study, in order to avoid 
observing a transcriptomic imprint of the adjunction of Dox and FeCl3. The construction of constitutive 
CRZ1 and GZF3 overexpression strains under the control of a strong constitutive promoter (e.g. ACT1 
or TDH3 promoters) would not only be useful for such transcriptomic comparisons, but also to develop 
“tolerant laboratory strains” which could then be used to assess the effect of tolerance in a mice 
infection model, and also for the identification and characterization of negative mediators of FLC 
tolerance. 
 
Transcriptomic imprints of FLC response in tolerant clinical isolates 
In the last part of this work, we demonstrated, using a transcriptomic approach, for the first time to 
our knowledge, the imprint of the FLC response in conditions similar to the EUCAST’s standard 
antifungal susceptibility assay protocol. Using the WT strain SC5314, we were able to demonstrate that 
FLC seems to recruit the calcineurin pathway. This pathway is already known to be essential for C. 
albicans survival in presence of the drug [89]. The recruitment of this pathway was also confirmed 
using genetically related tolerant clinical isolates that were isolated from the same patient over a time 
lapse of about 9 years. These sequential isolates were known to show an increased tolerance over 
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time, with the initial DSY4454 isolate considered as having a “wild-type” susceptibility profile and the 
following DSY4452 and DSY4588 isolates characterized by a clear increased of FLC tolerance. 
Interestingly, several genes of the calcineurin pathway, including CRZ1, were overexpressed in these 
clinical isolates as compared to the reference strain SC5314, in the presence of FLC. This 
overexpression could at least partially explain the increased FLC tolerance in these clinical isolates. 
Indeed, members of the calcineurin pathway were clearly overexpressed in presence of FLC in the two 
tolerant isolates DSY4452 and DSY4588 in comparison to their parental “wild type” isolate DSY4454 
and the SC5314 control strain. The next step will be to investigate the differentially expressed genes 
between the tolerant clinical isolates and the SC5314 strain. Overexpressing or deleting such genes in 
the SC5314 susceptible strain (for putative positive mediators) or in tolerant clinical isolates (for 
putative negative mediators) will confirm their role in the increased tolerance to FLC and give new 
insights of the mechanisms behind this phenotype. In complement to this transcriptomic approach, 
genome data mining could be implemented in the future to help deciphering the molecular basis of 
FLC tolerance in these isolates. Likely candidate genes could be in the calcineurin pathway for 
examples. In agreement with this hypothesis, a study published by Hill et al. reported that the 
calcineurin subunit A (CNA1/CMP1) exhibited a truncation in a C. albicans FLC-resistant isolate [93]. 
CNA1 truncations were already known to increase FLC tolerance to high levels through hyperactivation 
of calcineurin [44]. Therefore, it is possible that such mutations could be found in clinical isolates as 
those used in this study. 
To conclude, this study, focusing on FLC tolerance and its mechanisms, allowed a better understanding 
of C. albicans response to FLC. The identification of mediators of FLC tolerance, specific to C. albicans, 
might potentially serve as novel drug targets. By targeting such mediators in co-treatment with FLC, 
activity of FLC in C. albicans may be potentiated, or may convert FLC to a fungicidal drug as already 
observed with the inhibition of the calcineurin pathway by cyclosporin A [66]. These new treatment 
strategies may broaden the range of treatment options and help to decrease treatment failures caused 
by C. albicans infections.  
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